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Chapter 1 11
General introduction
Obesity, metabolic syndrome and type 2 diabetes mellitus are multifactorial conditions, 
that have detrimental effects on both individual’s health perspectives and functional out-
come as well as governmental health care expenditures. It is therefore important to gain 
more insight into the magnitude, etiology and complications of these diseases.
1.1 OBESITY
The term overweight refers to a body mass index between 25 and 30, whereas obesity 
is defined as a body mass index of 30 and over. Due to an overabundance of food and 
sedentary lifestyles in both developed and developing countries the worldwide incidence 
and prevalence of obesity is rising (1,2). In the United States for example, the overall 
prevalence of obesity has increased from 13.4% in 1960 to 30.9% in 1999 and 37.7% 
for the year 2013 (3). Obesity is associated with insulin resistance (4–6), lipid disorders 
(7–10), hypertension (7,11,12) and cardiovascular disease (13,14). These conditions are 
therefore becoming increasingly more common and so are their long-term complications 
with associated morbidity and mortality (15–20). Global efforts are needed to deflect the 
widespread epidemic of obesity in order to reduce their burden on quality of life, mortality 
and health care expenditures.
1.2 METABOLIC SYNDROME
The metabolic syndrome is a constellation of risk factors known for their association with 
type 2 diabetes mellitus and cardiovascular disease and consists of obesity, hyperglyce-
mia, dyslipidemia and hypertension (21–24). In 1988 the term was first introduced as a 
pathophysiological entity with insulin resistance as a common denominator (5). However, 
in time it became mainly used to cluster and predict cardiovascular disease and type 2 
diabetes mellitus. As a predictor, a number of issues have arisen. There are a number of 
definitions with different cut-off values for its components (25–27), which may have led 
to heterogeneity in the results of prediction and risk association studies. In addition, the 
added value of metabolic syndrome as a disease entity on top of its individual components 
in terms of risk association with type 2 diabetes, cardiovascular disease and mortality has 
been questioned since its introduction (28–31).
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1.3 TYPE 2 DIABETES
Type 2 diabetes is a metabolic condition characterized by insulin resistance and insuf-
ficient beta-cell capacity resulting in a dysregulation of glucose metabolism (32,33). A 
short-term complication of type 2 diabetes mellitus is hyperglycemia. However, the main 
burden of the disease comes from its long-term complications such as retinopathy (34–36), 
nephropathy (37), neuropathy (38–41) and macrovascular disease (12, 42–44). Because 
of the increased prevalence of obesity, the prevalence of type 2 diabetes also continues 
to rise worldwide (19). Currently, an estimated 1 in 11 adults or 415 million individuals 
worldwide have diabetes (19). A low estimate of health care expenditures on diabetes in 
2014 was USD 612 billion, which is 11% of global health expenditures (45). Although there 
has been a tremendous amount of research devoted to the role of genetic, biochemical 
and environmental factors in type 2 diabetes and its vascular complications, much is still 
unknown on exact pathophysiological disease mechanisms. A staggering 55% global 
increase in prevalence of diabetes by the year 2040 emphasizes the need to improve treat-
ment options and preventive strategies.
1.4 RISK FACTORS FOR TYPE 2 DIABETES AND ITS COMPLICATIONS
Type 2 diabetes is a multifactorial disease with impaired insulin secretion and insulin 
resistance as its main pathophysiological components (32,33,46). Both genetic and en-
vironmental factors influence disease-risk which makes it more difficult to determine the 
exact cause of type 2 diabetes in each individual patient. Known risk factors for type 2 
diabetes are obesity, a family history of diabetes, ethnicity and lifestyle factors, such as 
exercise, sleep duration and smoking (47–53). Type 2 diabetes morbidity and mortality 
are mainly due to its macro- and microvascular complications (42,54–58). Glycaemia is 
associated with the risk of cardiovascular disease and microvascular complications in 
T2DM (42,59,60). However also other metabolic derangements associated with type 2 
diabetes and obesity are important risk factors for the occurrence of complications, such 
as hypertension and dyslipidemia.
It is well known that treatment of blood pressure and dyslipidemia reduces the risk on 
vascular complications in both primary and secondary prevention in the general popula-
tion (61,62). Treatment and prevention strategies in type 2 diabetes focus on aggressive 
reduction of dyslipidemia and hypertension with successful results in the reduction of 
vascular disease risk (63–65). By strict glycemic control, the risk of microvascular disease 
can also be reduced substantially (59,66). However, interventions applying more strict 
glycemic control were unsuccessful or showed adverse effects (67,68) in the reduction 
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of macrovascular disease. The relation between glycemic control and prevention of 
macrovascular events therefore remains incompletely understood. Also, despite optimal 
treatment efforts for all vascular risk factors, a substantial residual risk of macro- and 
microvascular complications remains.
Diabetes care in the Netherlands is organized in primary care and outpatient clinics. In the 
outpatient clinic setting, the more complex patients are situated and care is performed 
by internal medicine consultants. The primary care is performed by general practitioners 
and consists of more elderly patients with a relatively large proportion on oral treatment 
and diets. It is important to gain more insight into characteristics and effect of organizing 
diabetes care this way.
Apart from environmental factors that play a major role in the development of type 2 dia-
betes, there is clear evidence for genetic susceptibility (47). The genetic risk component of 
type 2 diabetes is polygenic, which means many genes with small effects are involved . Up 
to now, a total of 128 signals at 113 loci have been independently associated with type 2 
diabetes (69–71). However, only 5 to 20 % of the attributional predisposition to T2DM can 
be explained by these genetic variants (70,72).
1.5 PREDIABETES, LIFETIME RISK AND PREVENTION
An important condition for preventive efforts to become successful is the ability to iden-
tify individuals at high risk to develop a disease. Individuals with an impaired glucose 
homeostasis below the threshold of diabetes are at high risk to develop diabetes. This 
prediabetes state emerges long before a diagnosis of diabetes is made (33), and can there-
fore be used to identify individuals to apply preventive efforts to. Pharmacological and 
lifestyle interventions have proven their preventive capacity for diabetes when applied 
to individuals with prediabetes (73–76). However, two definitions of prediabetes, by the 
American Diabetes Association (ADA) and World Health Organisation (WHO), exist (77,78). 
A substantial difference in these definitions is the lower threshold of the glycemic index 
by the ADA definition. This may change the balance of sensitivity to identify individuals at 
risk versus overtreatment of false positive identified individuals that will never progress 
to diabetes. Therefore, it is important to investigate the consequences of this difference 
in definition for the relation between prediabetes and progression to diabetes. In order 
to obtain successful individual disease management and preventive effects, clear com-
munication of risks and treatment goals from clinician to patient is key. Non-transparent 
relative risk estimates have less persuasive power when compared to absolute disease 
risks (79–82). Better patient disease awareness improves therapy adherence. Lifetime 
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risks provide a clear message to patients, clinicians and policy makers by providing cu-
mulative risks of developing a disease during an individual’s remaining lifespan. There 
are some reports on life time risks of type 2 diabetes in the US and Australia, however 
these are based on simulated data. Therefore there is a clear need for real-life prospective 
population-based cohort follow-up, high-quality data on impaired glucose metabolism, its 
treatment and complications to gain more insight in to the development and progression 
of the disease. More importantly, by providing patients and physicians with lifetime risk 
estimates of diabetes and prediabetes, a clear communication tool in the doctor’s office 
is provided to persuade patients to adhere to their therapy and create self-awareness in 
disease management.
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Aims and scope
The aim of this thesis is to investigate the clinical value of the metabolic syndrome, to 
assess the lifetime risk of diabetes and prediabetes in the Netherlands and to examine the 
prevalence of vascular complications in the Dutch diabetes patient population. Secondly, 
we investigated association of biochemical markers and genetic variants with risk of type 
2 diabetes.
In Part II (Chapter 3), we study the clinical value of the metabolic syndrome by comparing 
three commonly applied definitions, study their prevalence in the Dutch population and 
investigate the associations of the definitions and their added value above their individual 
components with cardiometabolic diseases.
In part III (chapter 4 and 5) we study the burden of type 2 diabetes in the Netherlands 
in a unique and large prospective population-based study in Ommoord, Rotterdam with 
accurate data on glucose and thus prediabetes and diabetes onset. Through calculation of 
cumulative risks in all person-years of follow-up, we provide lifetime risk estimates which 
help to elucidate an individual’s diabetes risk based on age and body mass index. (chapter 
4) Furthermore, by comparing the different definitions of prediabetes in this population 
with respect to lifetime risk in both women and men (chapter 5), we uncover strengths and 
weaknesses of both definitions from a WHO and ADA perspective.
In part IV, (chapter 6,7 and 8) we present a diabetes population from The Netherlands in 
which we evaluated the presence of micro- and macrovascular complications and the 
prevalence of type 2 diabetes-associated risk factors and genetic risk alleles (chapter 
6). Furthermore, in chapter 7, we present a candidate-gene approach study in which we 
find a genetic variant in SLC6A20, (involved in proline metabolism) to be associated with 
type 2 diabetes in both a European as well as a Chinese population. In chapter 8, we find 
ADAMTS13 to be a novel risk marker for type 2 diabetes (chapter 8)
Finally, in part V, in chapter 9, I will summarize the main findings of this thesis, method-
ological issues, their implication for clinical practice and future research directions.

PART II
Metabolic syndrome in modern society: 
definitions and predictive ability
Chapter 3
The clinical value of metabolic syndrome and risks of cardiometabolic events and 
mortality in the elderly: the Rotterdam Study.
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ABSTRACT
Introduction: To evaluate the clinical value of metabolic syndrome based on different 
definitions (American Heart Association/National Heart, Lung and Blood Institute (AHA/
NHLBI), International Diabetes Federation (IDF) and European Group for the study of 
Insulin Resistance (EGIR)) in middle-aged and elderly populations.
Methods: We studied 8,643 participants from the Rotterdam Study (1990-2012; mean 
age 62.7; 57.6% female), a large prospective population-based study with predominantly 
elderly participants. We performed cox-proportional hazards models for different defini-
tions, triads within definitions and each separate component for the risk of incident type 2 
diabetes mellitus, coronary heart disease, stroke, cardiovascular- and all-cause mortality.
Results: In our population of 8,643 subjects, metabolic syndrome was highly prevalent 
(prevalence between 19.4% and 42.4%). Metabolic syndrome in general was associated 
with incident type 2 diabetes mellitus (median follow-up of 6.8 years, hazard ratios 3.13 to 
3.78). The associations with coronary heart disease (median follow-up of 7.2 years, hazard 
ratios 1.08 to 1.32), stroke (median follow-up of 7.7 years, hazard ratios 0.98 to 1.32), 
cardiovascular mortality (median follow-up of 8.2 years, ratios 0.95 to 1.29) and all-cause 
mortality (median follow-up of 8.7 years, hazard ratios 1.05 to 1.10) were weaker. AHA/
NHLBI- and IDF-definitions showed similar associations with clinical endpoints compared 
to the EGIR, which was only significantly associated with incident type 2 diabetes mel-
litus. All significant associations disappeared after correcting metabolic syndrome for its 
individual components.
Conclusions: Large variability exists between and within definitions of the metabolic syn-
drome with respect to risk of clinical events and mortality. In a relatively old population 
the metabolic syndrome did not show an additional predictive value on top of its indi-
vidual components. So, besides as a manner of easy identification of high-risk patients, 
the metabolic syndrome does not seem to add any predictive value for clinical practice.
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BACKGROUND
The metabolic syndrome (MetS) is a combination of risk factors for type 2 diabetes mel-
litus and cardiovascular disease (CVD). Although MetS was designed to cluster and predict 
risk for type 2 diabetes mellitus and CVD, controversy remains on its usefulness in clinical 
practice. This is due to the fact that it is still not fully clear whether MetS has an added 
value to the prediction of diabetes, cardiovascular disease and mortality above the effect 
of its individual components [1-6].
There are a number of different definitions according to which MetS can be defined which 
may have led to heterogeneity. The currently applied definitions have substantial differ-
ences in the predefined components and cut-off values [7-10]. Furthermore, most studies 
on the association between MetS and cardiovascular disease, mortality and diabetes 
have been performed in middle-aged populations [11-15], while the associations of MetS 
with type 2 diabetes mellitus, CVD and mortality and the added value of MetS above its 
individual components in elderly populations has received less attention and has led to 
inconsistent results [2-5, 16-19].
Therefore, the aim of our study was to determine the clinical value of MetS in a large 
prospective Dutch predominantly elderly population comparing three commonly applied 
definitions. We investigated the associations of the definitions, their exact composition 
and the added predictive value above their individual components with risk of type 2 
diabetes mellitus, coronary heart disease (CHD), stroke, cardiovascular - and all-cause 
mortality.
METHODS
Study Population
Analyses were performed in the Rotterdam Study, an ongoing prospective population-
based cohort study in Rotterdam, The Netherlands. In 1989, all residents aged 55 years 
or older in a well-defined district of Rotterdam were invited to participate in the original 
cohort (RS-I). A total of 7,983 (78.1%) agreed to participate in the follow-up study. The 
study was extended in 2000 with a cohort of individuals who had reached age 55 or 
moved into the study area after the initial cohort (n=3,011). In 2006, a third cohort of 3,932 
participants aged 45 years or older was enrolled, bringing the total study size to 14,926 
individuals. There were no eligibility criteria to enter the Rotterdam Study cohorts except 
the minimum age and residential area. A more detailed description of the methods of the 
Rotterdam Study can be found elsewhere [20,21].
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Participants are being monitored for type 2 diabetes mellitus, CHD, stroke and mortality 
by continuous linkage to files from general practitioners in the study area, information 
from medical specialists and discharge reports after hospitalization. All information was 
obtained through trained research employees and reviewed by two independent medical 
doctors, supervised by a specialist in each separate medical field.
The Rotterdam Study has been approved by the medical ethics committee according to 
the Population Study Act Rotterdam Study, executed by the Ministry of Health, Welfare and 
Sports of the Netherlands. Written informed consent was obtained from all participants.
Population for analysis
A total of 14,926 participants were included in three subsequent cohorts in the Rotter-
dam Study. From the first cohort entering the study in 1990 (n=7,983) we used data from 
their third examination (n=4,797, 1997-1999) because of the availability of fasting blood 
samples. Furthermore, we used data from participants of the second (n=3,011, 2000-2001) 
and third cohort (n=3,932, 2006-2008).
From the 11,740 participants mentioned above, 10,599 went to the research center for 
blood sampling and anthropometric measurements. Only fasting participants were 
included in the study (n=9,819) Subsequently, we excluded 1,176 prevalent cases of type 
2 diabetes mellitus resulting in a population for analysis of n=8,643. For each given end-
point, prevalent cases of that endpoint where excluded. An average of 1.7% had missing 
data on MetS-components. These were imputed by using the multiple imputation method 
described by Sterne et al. [22].
Definitions of MetS
MetS was defined according to 3 definitions (supplemental table S1): 1) as stated by the 
American Heart Association/National Heart, Lung and Blood Institute (AHA/NHLBI) [8], 
which was later used without adjustments in the consensus definition of IDF and AHA/
NHLBI in 2009 [10], 2) according to the International Diabetes Federation (IDF) [9]and 3) ac-
cording to the European Group for the study of Insulin Resistance (EGIR) [7]. A diagnosis of 
MetS according to AHA/NHLBI-criteria consists of at least 3 of the following components: 
(1) waist circumference > 102 cm for males or > 88 cm for females; (2) HDL-cholesterol 
<1.03 mmol/l for males or HDL-cholesterol <1.29 mmol/l for females, (3) triglycerides ≥ 1.7 
mmol/l, (4) systolic blood pressure ≥ 130 mm Hg or diastolic blood pressure ≥ 85 mm Hg 
or antihypertensive treatment; and (5) fasting glucose of ≥ 5.6 mmol/l or drug treatment 
for elevated glucose.
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According to IDF-criteria, a diagnosis of MetS includes the component of central obesity 
(COB) as defined by waist circumference ≥ 94 cm for males or waist circumference ≥80 cm 
for females. If BMI is > 30 kg/m2, central obesity is assumed and waist circumference does 
not need to be measured. Central obesity is the central component in the definition of 
MetS according to IDF. In addition to central obesity, two of the following four components 
should be present: (1) raised triglycerides ≥ 1.7 mmol/l, (2) HDL-cholesterol < 1.03 mmol/l 
for males or HDL-cholesterol < 1.29 mmol/l for females, (3) systolic blood pressure ≥ 130 
mm Hg or diastolic blood pressure ≥ 85 mm Hg or treatment of hypertension, (4) raised 
fasting plasma glucose ≥ 5.6 mmol/l or previously diagnosed type 2 diabetes mellitus. Ac-
cording to EGIR-criteria, the upper quartile of fasting insulin in a non-diabetes population 
is required together with two of the following components: (1) hyperglycemia ≥ 6.1 mmol/l 
but not having diabetes, (2) systolic blood pressure ≥ 140 mm Hg or diastolic blood pres-
sure ≥ 90 mm Hg or treatment of hypertension, (3) dyslipidemia as defined by triglycerides 
>2.0 mmol/l or HDL-C <1.0 mmol/l, (4) central obesity as defined by a waist circumference 
≥94 cm for males or waist circumference ≥80 cm for females.
Components and triads
According to the AHA/NHLBI-, IDF- and EGIR-criteria we defined MetS at baseline. Triads 
where defined as the simultaneous combination within a participant of any 3 different 
components of the MetS that would guarantee a diagnosis of MetS (a participant could 
have >1 triad at the same time).
Definition of type 2 diabetes mellitus
Incident type 2 diabetes mellitus was defined in accordance with the guidelines of the 
American Diabetes Association [23,24] and World Health Organization (WHO) [25] as a (1) 
fasting glucose level ≥ 7.0 mmol/L or (2) a non-fasting glucose level ≥ 11.1 mmol/L or (3) 
treatment with oral glucose-lowering medication or insulin, and (4) diagnosis of diabetes 
as registered by a general practitioner or medical specialist. Prevalent cases of diabetes 
were diagnosed at baseline by a (1) non-fasting or post-load glucose level (after oral glu-
cose tolerance test) ≥ 11.1 mmol/L or (2) treatment with oral glucose-lowering medication 
or insulin, and (3) diagnosis as registered by a general practitioner.
Definition of CHD
Incident CHD was defined as (1) myocardial revascularization (as a proxy for significant 
coronary artery disease), (2) Myocardial Infarction (MI, fatal and nonfatal) and (3) fatal 
CHD. Specific details on definitions in each categories in the Rotterdam Study can be 
found elsewhere [26].
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Definition of stroke
Stroke was defined according to WHO-criteria as a syndrome of rapidly developing clinical 
signs of focal (or global) disturbance of cerebral function, with symptoms lasting 24 hours 
or longer or leading to death, with no apparent cause other than of vascular origin [27]. 
History of stroke at baseline was assessed during the baseline interview and verified by 
review of medical records. A more profound description on methods of data collection for 
stroke can be found elsewhere [28].
Definition of cardiovascular mortality and all-cause mortality
Cardiovascular mortality was classified as mortality as a consequence of (1) CHD, (2) cere-
brovascular disease, (3) atherosclerotic disease other than CHD or cerebrovascular disease 
(including ruptured abdominal aortic aneurysm, peripheral vascular disease, and visceral 
vascular disease) and (4) other cardiovascular disease. Specific details on definitions in 
each categories and methods of data collection of cardiac outcomes in the Rotterdam 
Study can be found elsewhere [26]. With respect to all-cause mortality, information was 
obtained on a weekly basis from the central registry of the municipality in Rotterdam and 
through general practitioners working in the study area.
Statistical Analysis
Normally distributed continuous variables were expressed as mean ± standard deviation 
(SD). Continuous variables that were not normally distributed were log-transformed for 
the analysis and are expressed as a median with interquartile range. Age- and sex-adjusted 
logistic regression and chi-square tests were used to compare baseline characteristics of 
MetS and non-MetS participants. Cox proportional hazards models corrected for age, sex 
and ethnicity served to analyze the associated hazard ratio of MetS and incident type 2 
diabetes mellitus, CHD, stroke, cardiovascular- and all-cause mortality. All models were 
initially adjusted for age, sex and ethnicity. Ethnicity did not have a significant effect in 
any of the models and was therefore left out. To investigate whether the metabolic syn-
drome as a syndrome captures more of the risk for clinical endpoints than the individual 
components, we subsequently corrected the hazard ratios of MetS for each individual 
component. We imputed missing values by using the multiple imputation method, which 
has been proven to be a reliable method [22]. Participants with prevalent or unknown 
disease status were excluded from analyses on type 2 diabetes mellitus, CHD and stroke. 
Participants with prevalent or unknown stroke and/or CHD status were excluded from the 
analyses on cardiovascular mortality. For the analysis on incident diabetes we performed 
sensitivity analyses in which we excluded participants with impaired fasting glucose levels 
(fasting glucose ≥ 5.6 mmol/l). All analyses were adjusted for age, sex and ethnicity. All 
analyses were performed with SPSS version 21.0 (SPSS, Chicago, IL, USA) and a 2-sided ɑ 
smaller than 0.05 was used to claim statistical significance.
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RESULTS
Baseline characteristics
Baseline characteristics are shown in table 1. The overall mean age at baseline was 62.7 
years. Participants were more often female (57.6% vs. 42.4%). Between definitions, the 
mean age of the participants having MetS ranged from 64.2 years (AHA/NHLBI) to 62.1 
years (EGIR). From our study population, 97.8% were of Caucasian descent. Other baseline 
characteristics are being displayed in table 1.
Table 1: Baseline characteristics of population diagnosed with MetS according to different definitions.
Characteristic AHA/NHLBI IDF EGIR Total population
Participants having MetS (n,%) 3055 (35.3) 3646 (42.2) 1680 (19.4) 8643
Age, y 64.2 (58.8-72.5)* 64.0 (58.8-72.6)* 62.1 (57.1-70.8) 62.7 (57.6-71.2)
Female sex (n, %) 1790 (58.6) 2090 (57.3) 919 (54.7)* 4983 (57.7)
Body Mass Index (kg/m2) 29.3 ± 4.1* 28.9 ± 3.9* 30.3 ± 4.3* 27.0 ± 4.1
Waist-circumference, cm 100.0 ± 10.8* 98.9 ± 10.5* 102.0 ± 11.2* 92.8 ± 11.8
Systolic Blood pressure, mmHg 145.6 ± 19.0* 145.3 ± 19.1* 144.1 ± 18.9* 138.3 ± 20.8
Diastolic Blood pressure, mmHg 81.4 ± 11.4* 81.3 ± 11.4* 82.6 ± 11.7* 78.8 ± 11.4
Total cholesterol, mmol/L 5.8 ± 1.1* 5.8 ± 1.1* 5.7 ± 1.1 5.8 ± 1.0
HDL cholesterol, mmol/L 1.2 (1.0-1.4)* 1.2 (1.0-1.4)* 1.2 (1.0-1.4)* 1.4 (1.1-1.7)
Triglycerides, mmol/L 1.8 (1.4-2.3)* 1.7 (1.3-2.2)* 1.8 (1.3-2.4)* 1.3 (1.0-1.8)
Insulin, pmol/L 92 (67-129)* 88 (64-123)* 131 (111-166)* 69 (49-97)
Glucose, mg/L 5.8 (5.4-6.1)* 5.7 (4.5-6.1)* 5.8 (5.4-6.2)* 5.4 (1.1-1.7)
CRP, mg/mL 2.2 (1.0-4.4)* 2.0 (0.9-4.1)* 2.2 (1.0-4.6)* 1.5 (0.6-3.3)
Hypertension treatment (n, %) 1045 (34.2)* 1197 (32.8)* 92 (41.2)* 1873 (21.7()
Antidiabetic treatment (n, %) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Lipid treatment (n, %) 563 (18.4)* 630 (17.3)* 353 (21.0)* 1255 (14.5)
Current smoking (n, %) 287 (9.4) 329 (9.0)* 114 (6.8)* 813 (9.4)
Caucasian descent (n, %) 2732 (98.2) 3255 (98.1) 1482 (96.9) 7655 (97.8)
Prevalent type 2 diabetes (n, %) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0%)
Prevalent CHD (n, %) 218 (7.1)* 249 (6.8)* 121 (7.2)* 518 (6.0)
Prevalent Stroke (n, %) 95 (3.1)* 107 (3.0)* 54 (3.2)* 196 (2.3)
Continuous data are mean ± SD when normally distributed. Otherwise median with interquartile range. 
AHA/NHLBI, American heart association / national heart, lung, and blood institute; IDF, International Diabe-
tes Federation; EGIR, European Group for the study of Insulin Resistance; MetS, metabolic syndrome; HDL, 
High-Density Lipoprotein; CRP, C-reactive Protein; CHD, coronary heart disease. *, Significant difference be-
tween MetS and non-MetS after correction for age and sex (P<0.05).
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Prevalence of MetS
At baseline, a total of 4,118 participants (47.6%) were diagnosed with MetS according to ei-
ther definition. The concordance of diagnoses using AHA/NHLBI, IDF and EGIR-definitions 
is displayed in Figure 1. Thirty-five percent had a diagnosis according to AHA/NHLBI, 42.2% 
according to IDF, and 19.4% according to EGIR (table 2).
Prevalence of components and triads of MetS
Table 2 shows the prevalence of components and triads in each definition of MetS.
A combination of hyperglycemia, high blood pressure and central obesity was the most 
frequent triad within a diagnosis of MetS according to AHA/NHLBI and IDF. In the EGIR-
definition, high blood pressure and central obesity together with hyperinsulinemia were 
most frequently prevalent in MetS-diagnosed participants.
Risk of incident type 2 diabetes mellitus
During a median follow-up of 6.8 years 768 individuals developed type 2 diabetes mellitus. 
MetS was significantly associated with the risk of type 2 diabetes mellitus regardless of 
the definition chosen (table 3) in Cox proportional hazards models. Ethnicity did not have 
a significant effect and was therefore left out of the model. The cox proportional hazard 
ratio (HR) was 3.78 (95%CI 3.24-4.41) for AHA/NHLBI-definition, 3.53 (95%CI 3.01-4.14) for 
IDF definition, and 3.13 (95%CI 2.69-3.64) for EGIR-definition. The risk of type 2 diabetes 
mellitus was highly variable dependent on the composition of diagnosis (supplemental 
table S2). In MetS according to AHA/NHLBI, a combination of GLYC-HDL-WC (HR 6.75; 
95%CI 5.53-8.25) was associated with the highest risk of type 2 diabetes mellitus. In MetS 
according to IDF, a combination of COB-HDL-GLYC (HR 6.07; 95%CI 5.01-7.35) was associ-
ated with the highest risk of type 2 diabetes mellitus. For EGIR-diagnosis, the highest risk 
of type 2 diabetes mellitus was associated with a combination of INS-DYSL-GLYC (HR 7.35; 
95%CI 5.92-9.13). After correction for sex, age and individual components none of the 
Figure 1. Concordance and disparity in diagnosis of metabolic syndrome according to different definitions.
AHA/NHLBI, American heart association / national heart, lung, and blood institute; IDF, International Diabe-
tes Federation; EGIR, European Group for the study of Insulin Resistance
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MetS-definitions itself was significantly associated with the risk of type 2 diabetes mellitus 
(table 4). The results were similar in a sensitivity analysis in which all participants with 
impaired fasting glucose levels (fasting glucose ≥ 5.6 mmol/l) were excluded from the cox 
regression modelling (supplementary table S7).
Table 2: Prevalence of components / triads at RS-I-3 within diagnosis of MetS
AHA/NHLBI IDF EGIR
Metabolic Syndrome Metabolic Syndrome Metabolic Syndrome
3055 (35.3%) 3646 (42.2%) 1680 (19.4%)
Components within diagnosis Components within diagnosis Components within diagnosis
BP 2810 (92.0%) COB 3646 (100%) INS 1680 (100%)
WC 2319 (75.9%) BP 3302 (90.6%) WC 1627 (96.8%)
GLYC 2140 (70.0%) GLYC 2489 (68.3%) BP 1347 (80.2%)
HDL 1688 (55.3%) HDL 1750 (48.0%) DYSL 864 (51.4%)
TRIG 1849 (60.5%) TRIG 1896 (52.0%) GLYC 577 (34.3%)
Triads within diagnosis Triads within diagnosis Triads within diagnosis
GLYC-BP-WC 1469 (48.1%) COB-GLYC-BP 2265 (62.1%) INS-WC-BP 1302 (77.5%)
BP-TRIG-WC 1075 (35.2%) COB-HDL-BP 1474 (40.4%) INS-WC-DYSL 821 (48.9%)
GLYC-BP-TRIG 1004 (32.9%) COB-TRIG-BP 1620 (44.4%) INS-BP-DYSL 611 (36.4%)
BP-HDL-WC 984 (32.2%) COB-TRIG-HDL 1074 (29.5%) INS-WC-GLYC 549 (32.7%)
BP-TRIG-HDL 970 (31.8%) COB-TRIG-GLYC 1067 (29.3%) INS-BP-GLYC 431 (25.7%)
GLYC-BP-HDL 838 (27.4%) COB-HDL-GLYC 926 (25.4%) INS-DYSL-GLYC 278 (16.5%)
GLYC-TRIG-WC 728 (23.8%)
TRIG-HDL-WC 710 (23.2%)
GLYC-HDL-WC 627 (20.5%)
GLYC-TRIG-HDL 633 (20.7%)
AHA/NHLBI, American heart association / national heart, lung, and blood institute; IDF, International Dia-
betes Federation; EGIR,
European Group for the study of Insulin Resistance. GLYC, hyperglycemia; BP, hypertension; TRIG, hypertri-
glyceridemia; HDL, low HDL-cholesterol;
WC, increased waist circumference; COB, central obesity; DYSL dyslipidemia; INS, highest quartile of fasting 
Insulin not having type 2 diabetes;
Table 3: Metabolic syndrome and hazard ratios for incident clinical endpoints.
Outcome Events in population AHA/NHLBI IDF EGIR
Type 2 diabetes mellitus 765/8567 3.78 (3.24-4.41)* 3.53 (3.01-4.14)* 3.13 (2.69-3.64)*
Coronary heart disease 544/7864 1.32 (1.11-1.56)* 1.38 (1.16-1.63)* 1.08 (0.87-1.35)
Stroke 458/8304 1.29 (1.07-1.56)* 1.32 (1.10-1.59)* 0.98 (0.77-1.25)
Cardiovascular mortality 418/7724 1.21 (0.99-1.47) 1.29 (1.05-1.57)* 0.95 (0.73-1.23)
All-cause mortality 2244/8586 1.10 (1.01-1.20)* 1.09 (1.01-1.19)* 1.05 (0.94-1.17)
Data are presented as hazard ratios with 95% confidence intervals. All analysis corrected for age and sex. * = 
statistically significant. AHA/NHLBI, American heart association / national heart, lung, and blood institute; 
IDF, International Diabetes Federation; EGIR, European group for the study of Insulin Resistance.
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Risk of incident CHD
During a median follow-up of 7.2 years in which 544 individuals developed CHD, MetS 
as defined by AHA/NHLBI (HR 1.32; 95%CI 1.11-1.56) and IDF (HR 1.38; 95%CI 1.16-1.63 
P<0.001) were significantly associated with the risk of CHD (table 3). In our population, 
the EGIR definition was not associated with the risk of incident CHD. In MetS according to 
AHA/NHLBI, a combination of BP-TRIG-WC (HR 1.77; 95%CI 1.41-2.23) was associated with 
the highest risk of CHD (supplemental table S3). In MetS according to IDF, a combination of 
COB-TRIG-BP (HR 1.76; 95%CI 1.44-2.15) was associated with the highest risk of CHD. For 
Table 4: MetS according to different diagnosis and hazard ratios for incident clinical endpoints corrected 
for individual components.
AHA/NHLBI IDF EGIR
Type 2 diabetes 
mellitus
MetS 1.19 (0.90-1.58)
GLYC 4.01 (3.30-4.87)*
HDL 1.48 (1.24-1.76)*
WC 1.48 (1.23-1.78)*
BP 1.28 (1.04-1.58)*
TRIG 1.24 (1.04-1.49)*
MetS 1.11 (0.82-1.49)
GLYC 4.20 (3.45-5.12)*
HDL 1.52 (1.29-1.80)*
BP 1.34 (1.08-1.65)*
COB 1.33 (0.99-1.78)
TRIG 1.32 (1.12-1.55)*
MetS 0.91 (0.56-1.49)
GLYC 5.12 (4.38-5.98)*
DYSL 1.64 (1.40-1.92)*
WC 1.33 (1.08-1.64)*
INSUL 1.54 (0.98-2.44)
BP 1.39 (1.18-1.64)*
Coronary Heart 
Disease
MetS 0.73 (0.53-1.01)
BP 1.67 (1.31-2.14)*
TRIG 1.48 (1.18-1.85)*
WC 1.38 (1.11-1.71)*
HDL 1.34 (1.07-1.68)*
GLYC 0.94 (0.77-1.15)
MetS 1.18 (0.86-1.58)
BP 1.53 (1.20-1.95)*
TRIG 1.29 (1.04-1.59)*
HDL 1.17 (0.95-1.44)
COB 0.99 (0.76-1.28)
GLYC 0.82 (0.67-1.01)
MetS 1.00 (0.55-1.81)
BP 1.50 (1.23-1.82)*
DYSL 1.36 (1.12-1.67)*
WC 1.10 (0.90-1.35)
GLYC 0.93 (0.74-1.18)
INSUL 0.87 (0.50-1.52)
Stroke MetS 1.09 (0.76-1.58)
BP 1.44 (1.10-1.89)*
HDL 1.36 (1.06-1.75)*
WC 1.06 (0.83-1.34)
GLYC 0.98 (0.78-1.22)
TRIG 0.84 (0.65-1.10)
MetS 1.12 (0.80-1.56)
BP 1.42 (1.08-1.86)*
HDL 1.35 (1.07-1.71)*
COB 1.11 (0.83-1.48)
GLYC 0.96 (0.76-1.21)
TRIG 0.84 (0.66-1.08)
MetS 0.91 (0.46-1.77)
BP 1.44 (1.16-1.79)*
GLYC 1.22 (0.96-1.56)
WC 1.20 (0.95-1.52)
DYSL 1.11 (0.88-1.41)
INSUL 0.87 (0.47-1.61)
Cardiovascular 
mortality
MetS 0.86 (0.58-1.27)
BP 1.47 (1.10-1.97)*
TRIG 1.24 (0.94-1.62)
WC 1.21 (0.94-1.55)
HDL 1.13 (0.86-1.48)
GLYC 1.00 (0.79-1.26)
MetS 1.06 (0.74-1.54)
BP 1.39 (1.04-1.86)*
COB 1.21 (0.89-1.63)
TRIG 1.14 (0.89-1.47)
HDL 1.05 (0.81-1.35)
GLYC 0.92 (0.71-1.18)
MetS 0.79 (0.40-1.57)
BP 1.35 (1.07-1.69)*
WC 1.30 (1.01-1.67)*
GLYC 1.14 (0.88-1.47)
DYSL 1 .07 (0.84-1.37)
INS 1.00 (0.54-1.86)
All-cause mortality MetS 0.97 (0.82-1.14)
HDL 1.25 (1.11-1.41)*
BP 1.09 (0.97-1.22)
WC 1.02 (0.92-1.13)
GLYC 1.00 (0.90-1.10)
TRIG 0.97 (0.86-1.10)
MetS 0.98 (0.85-1.14)
HDL 1.24 (1.11-1.39)*
BP 1.08 (0.97-1.22)
COB 1.05 (0.93-1.18)
GLYC 0.99 (0.89-1.10)
TRIG 0.96 (0.86-1.08)
MetS 0.81 (0.62-1.05)
INSUL 1.18 (0.93-1.50)
DYSL 1.15 (1.03-1.27)*
GLYC 1.11 (0.99-1.24)
BP 1.10 (1.00-1.21)*
WC 1.04 (0.94-1.15)
Data are presented as hazard ratios with 95% confidence intervals. All analysis corrected for age and sex. * = 
statistically significant. AHA/NHLBI, American heart association / national heart, lung, and blood institute; 
IDF, International Diabetes Federation; EGIR, European group for the study of Insulin Resistance; GLYC, hy-
perglycemia; BP, hypertension; TRIG, hypertriglyceridemia; HDL, low HDL-cholesterol; WC, increased waist 
circumference; COB, central obesity; DYSL dyslipidemia; INS, highest quartile of fasting Insulin not having 
type 2 diabetes.
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EGIR-diagnosis, the highest risk of CHD was associated with a combination of INS-BP-DYSL 
(HR 1.26; 95%CI 0.29-1.72). After correction for age, sex and individual components none 
of the MetS-definitions were significantly associated with CHD (table 4).
Risk of incident stroke
During a median follow-up of 7.7 years in which 458 participants suffered from incident 
stroke, MetS according to AHA/NHLBI (HR 1.29; 95%CI 1.07-1.56) and IDF (HR 1.32; 95%CI 
1.10-1.59) showed a significantly increased risk of stroke (table 3a). No association of 
the EGIR definition and incident stroke was found. In MetS according to AHA/NHLBI, a 
combination of GLYC-HDL-WC (HR 1.75; 95%CI 1.31-2.34) was associated with the highest 
risk of stroke (supplemental table S4). In MetS according to IDF, a combination of COB-
HDL-GLYC (HR 1.62; 95%CI 1.26-2.10) was associated with the highest risk of stroke. For 
EGIR-diagnosis, the highest risk of stroke was associated with a combination of INS-BP-
DYSL (HR 1.02; 95%CI 0.70-1.49). After correction for age, sex and individual components 
none of the MetS-definitions were significantly associated with stroke (table 4).
Risk of cardiovascular mortality
During a median follow-up of 8.2 years in which 418 cardiovascular mortalities occurred, 
only the IDF-diagnosis was associated with significantly increased risk of cardiovascular 
mortality (HR 1.29; 95%CI 1.05-1.57; P=0.01) (table 3). Within each definition, a large vari-
ability in hazard ratios for cardiovascular mortality was found (supplemental table S5). In 
MetS according to AHA/NHLBI, a combination of BP-TRIG-WC (HR 1.48 (95%CI 1.13-1.94)) 
was associated with the highest risk of cardiovascular mortality. In MetS according to 
IDF, a combination of COB-TRIG-BP (HR 1.45 (95%CI 1.13-1.85)) was associated with the 
highest risk of cardiovascular mortality. Neither the EGIR diagnosis nor its triads were 
significantly associated with cardiovascular mortality. After adjustments for age, sex and 
individual components none of the MetS definitions were significantly associated with 
cardiovascular mortality (table 4).
Risk of all-cause mortality
During a median follow-up of 8.7 years in which 2,244 participants deceased, MetS ac-
cording to AHA/NHLBI (HR 1.10 (1.01-1.20) P =0.03) and IDF (HR 1.09 (95%CI 1.01-1.19) P 
= 0.03) were associated with all-cause mortality. There was variability within definition 
as displayed by their triads (supplemental table S6). In MetS according to AHA/NHLBI, a 
combination of TRIG-HDL-WC (HR 1.24 (95%CI 1.07-1.45)) was associated with the highest 
risk of all-cause mortality. In MetS according to IDF, a combination of COB-HDL-GLYC (HR 
1.18 (95%CI 1.04-1.34)) was associated with the highest risk of all-cause mortality. After 
adjustments for age, sex and individual components none of the diagnoses showed a 
significantly increased risk of all-cause mortality (table 4).
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DISCUSSION
In our large predominantly elderly prospective population-based study, we show there is 
large variability between and within the definitions of MetS with respect to prevalence- 
and risk estimates for important cardiovascular and metabolic clinical endpoints. In addi-
tion, we confirm that MetS does not have an additional value in the risk estimation of type 
2 diabetes mellitus, CHD, stroke and mortality on top of its individual components.
MetS is a highly prevalent condition in our Dutch population. This is in line with previous 
reports on MetS in middle-aged and elderly populations in the United States and Europe 
that reported equal or higher prevalence estimates [29-31]. We diagnosed the MetS 
according to the definitions of AHA/NHLBI, IDF and EGIR. The IDF-definition diagnosed 
the largest proportion of our population with MetS, followed by AHA/NHLBI and EGIR 
respectively, which is similar to previous studies [5, 32, 33]. This can be explained by the 
lower IDF cut-off points for waist circumference and BMI, resulting in more individuals that 
meet the central obesity-criterium. The EGIR-diagnosis selects an upper quartile of fasting 
insulin and excludes prevalent diabetes, resulting in a lower prevalence compared to the 
other definitions.
In our population, MetS is a strong risk factor for type 2 diabetes mellitus regardless of the 
definition chosen. This has already been found by several study groups in predominantly 
middle-aged populations of various ethnicities [12, 15, 34, 35]. Sattar et al. also confirmed 
this association in elderly, predominantly male subjects and subjects at risk for cardiovas-
cular disease [19]. However, these studies were partly based on self-reported data and the 
associations were mostly the result of the hyperglycemic component rather than the di-
agnosis of MetS itself. Our findings are in line with this study, since the association of MetS 
with type 2 diabetes mellitus disappears after correcting for its components of which the 
hyperglycemic component constitutes the largest hazard. Our study, being population-
based and with larger and meticulous follow-up, therefore adds to the evidence provided 
by previous studies that MetS does not confer additional risk of type 2 diabetes mellitus 
above the sum of its components, especially fasting glucose [15,19].
MetS is a known risk factor for CVD in middle aged and elderly populations [13, 14, 19, 
36]. We found a relatively weak association of MetS with CVD in concordance with previ-
ous associations reported in literature [19]. Our study adds to previous studies including 
a large meta-analysis [14] that show that MetS does not show additive value to the risk 
associated with the sum of its individual components [1, 2, 4, 5, 36]. Previous studies did 
find an independent associative role of MetS [37] and higher hazard ratios for MetS and 
incident cardiovascular events [38]. However, these studies were done in small numbers 
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of patients at younger age having essential hypertension [37] or being suspected of hav-
ing coronary artery disease [38]. Therefore, those results may not be similar to our study, 
which is a population-based study with predominantly elderly participants. For stroke in 
particular, Kotani et al. found MetS to have a positive association with stroke in women 
in a retrospective cohort [39]. We found MetS to be associated with stroke in the general 
population, but the association disappeared after correcting for the individual MetS com-
ponents.
Although earlier studies on middle-aged younger individuals suggested otherwise [11, 13, 
14, 40], we did not find any significant associations of MetS with all-cause mortality after 
correction for its individual components in any of the definitions. This could very well be an 
effect of the relatively higher age of our population making study subjects equally prone to 
decease due to causes other than cardiometabolic disease, thereby reducing the relative 
effect of MetS. Our findings on all-cause mortality are in line with results obtained from 
patients after coronary artery bypass grafting (CABG) in which survival of MetS patients 
without diabetes resembled their matched background population [41].
Remarkably dyslipidemia and blood pressure were the main contributing factors for car-
diovascular disease and cardiovascular- and all-cause mortality effects of MetS. Although 
these are known as important independent risk factors for coronary heart disease and ath-
erosclerosis [42-47], this finding adds to the evidence that these individual components 
important predictors in CVD [19].
The strengths of this study are the large sample size, population-based design and the 
long-term follow-up. Furthermore, data extraction has been done in a systematic way.
Despite the fact that we have executed this study with great care, we have to address 
some limitations of our study. Participants included in the Rotterdam Study were mainly 
European Caucasians (97.8%). Therefore our results may not apply to other ethnic groups. 
Considering the dynamic changes in European demographic, our results should be 
interpreted accordingly. Unfortunately a small proportion (1.7%) of our population had 
missing data for the definition of MetS. We addressed this by applying a reliable multiple 
imputation method.
In this study, we approach the MetS as a predictive tool to identify patients at high risk for 
cardiometabolic endpoints. However as Tenenbaum and Fisman emphasized [48], MetS 
is still an interesting biological feature of coexistence of components. Research directed 
at the underlying mechanisms of their coexistence could lead to important biological in-
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sights in underlying cardiometabolic disease pathophysiology. These studies are beyond 
the scope of our current epidemiological approach for prediction purposes.
In conclusion, MetS shows high variability in its association with clinical endpoints both 
within and between diagnoses according to different definitions. Also, in a relatively old 
population MetS did not have additional predictive value on top of its components for 
any of the cardiometabolic endpoints. Besides as a manner of easy identification of risk 
patients, MetS does not seem to add any predictive value for clinical practice.
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ABSTRACT
Introduction: Data on lifetime risk of the full spectrum of impaired glucose metabolism 
including prediabetes and the risk to eventually progress to diabetes or start insulin 
therapy are scarce.
Methods: We used data from 10050 participants from the prospective population-based 
Rotterdam Study. Events were diagnosed by use of general practitioners records, hospital 
discharge letters, pharmacy dispensing data and serum fasting glucose measurements at 
the study center visits. Normoglycemia, prediabetes and diabetes were defined accord-
ing to the WHO criteria for fasting glucose (normoglycemia: ≤6.0 mmol/L; prediabetes: 
>6.0mmol/L and <7.0mmol/L; diabetes ≥7.0 mmol/L or use of glucose lowering therapy). 
Lifetime risks were calculated using a modified version of survival analysis adjusted for 
the competing risk of death. In addition, we estimated the lifetime risk of progression 
from prediabetes to overt diabetes and from diabetes free of insulin therapy to insulin 
use. Further, we calculated years lived with healthy glucose metabolism.
Results: During a follow-up of up to 14.7 years, 1148 participants developed prediabetes, 
828 diabetes and 237 started insulin therapy. At the age of 45, the remaining lifetime risk 
(95%CI) was 48.7% (46.2%-51.3%) for prediabetes, 31.3% (29.3%-33.3%) for diabetes and 
9.1% (7.8%-10.3%) for insulin use. The lifetime risk to progress from prediabetes at the age 
of 45 to diabetes was 74.0% (67.6%-80.5%), and 49.1% (38.2%-60.0%) of the individuals 
with overt diabetes at the age of 45 started insulin therapy. The lifetime risks attenuated 
with advancing age but increased with increasing body mass index and waist circumfer-
ence. On average, individuals with severe obesity lived 10 fewer years without glucose 
impairment compared to normal-weight individuals.
Conclusion: Our results highlight the public health burden posed by glycemic disturbanc-
es and demand further investigation into earlier and more effective prevention strategies.
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INTRODUCTION
People with elevated blood glucose levels below the threshold of diabetes, a state referred 
to as prediabetes, have an excess risk of diabetes.[1-3] Today, more than 382 million 
people live with diabetes worldwide and due to the increasing prevalence of prediabetes 
and the rapid conversion of prediabetes to type 2 diabetes, the number is predicted to 
exceed half a billion by 2035.[4] Moreover, many diabetes patients are unable to achieve 
glycemic control goals through diet or oral medications only and ultimately require insulin 
treatment.[5-7] Estimates on the progression from prediabetes to diabetes and ultimately 
insulin therapy are scarce and have been limited to merely annual incidences and absolute 
risks within a restricted time period.[2]
Lifetime risks provide estimation of the cumulative risk of developing a disease during an 
individual’s remaining lifespan and comprise thus a clear message to patients, clinicians 
and policy makers.[8-10] A few reports have simulated the lifetime risk of type 2 diabetes 
in the US and Australia.[10-12] However, estimates using accurate and careful documenta-
tion of elevated blood glucose levels, diabetes diagnosis and diabetes drug use are lack-
ing. Prospective population-based cohort studies with long-term follow-up and detailed 
data on the full spectrum of impaired glucose metabolism including prediabetes, diabetes 
and the eventual need for insulin therapy, permit estimation of the burden of elevated 
blood glucose levels in the context of overall survival.
Hence, we used mortality rates and incidences of the disease during every year of life taking 
into account the competing risk of death to assess the lifetime risks of prediabetes, diabetes 
and insulin use in a large prospective population-based cohort study of individuals aged 45 
years and older. Additionally, we estimated the lifetime risk of individuals with prediabetes 
to eventually develop diabetes and for diabetes patients to ultimately use insulin.
METHODS
Study design and population
This study is embedded within the framework of the Rotterdam Study, a prospective 
cohort study among the community-dwelling population aged 45 years and older in the 
city of Rotterdam, the Netherlands. The study design of the Rotterdam Study has been 
described in detail previously.[13] Briefly, in 1990 all inhabitants of a well-defined district 
of Rotterdam were invited, of whom 7983 agreed to participate (78.1%). The study was 
extended in 2000 with a second cohort of individuals who had reached the age of 55 or 
moved into the study area after 1990 (n=3011). In 2006, a third cohort was enrolled includ-
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ing inhabitants aged 45 years and older (n=3932), bringing the total study size to 14926 
individuals. There were no eligibility criteria to enter the Rotterdam study cohorts except 
the minimum age and residential area based on ZIP codes. We used the third center visit 
(1997–1999, n=4216) of the first cohort and the first visit of the second and third cohorts 
as baseline (2000–2001 and 2006–2008, respectively) for the current analysis. To ascertain 
the absence of prediabetes or diabetes by means of serum glucose measurement and 
use of blood glucose lowering medication, we excluded 1369 individuals without a valid 
baseline glucose measurement. Next, for the calculation of the lifetime risk of prediabetes, 
we only included individuals that were normoglycemic at study baseline (n=7462). To cal-
culate the lifetime risk of diabetes, we only included individuals that were free of diabetes 
at study baseline (n=8844). Further, to calculate the lifetime risk of insulin use, we only 
included individuals that were free of insulin use at study baseline (n=9887). Selection of 
the individuals for the analyses can be found in Figure 1. The individuals with prediabetes 
(n=1382) were used to study progression from prediabetes to diabetes and individuals 
with diabetes without insulin treatment (n=1043) were used to study the progression from 
diabetes to insulin use.
The Rotterdam Study has been approved by the medical ethics committee according to the 
Population Screening Act: Rotterdam Study, executed by the Ministry of Health, Welfare 
and Sports of the Netherlands. All participants in the present analysis provided written 
informed consent to participate and to obtain information from their treating physicians.
Ascertainment of prediabetes and type 2 diabetes
The participants were followed from the date of baseline center visit onwards. At baseline 
and during follow-up, cases of prediabetes and type 2 diabetes were ascertained through 
active follow-up using general practitioners’ records (including laboratory glucose mea-
surements), hospital discharge letters and serum glucose measurements from Rotterdam 
Study visits which take place approximately every four years.[14] Diabetes, prediabetes 
and normoglycemia were defined according to the recent WHO guidelines.[15] Normogly-
cemia was defined as a fasting blood glucose level ≤6.0 mmol/L; prediabetes was defined 
as a fasting blood glucose >6.0 mmol/L and <7.0 mmol/L or a non-fasting blood glucose 
>7.7 mmol/L and <11.1 mmol/L (when fasting samples were unavailable); type 2 diabetes 
was defined as a fasting blood glucose ≥7.0 mmol/L, a non-fasting blood glucose ≥11.1 
mmol/L (when fasting samples were unavailable), or the use of blood glucose lowering 
medication. Information regarding the use of blood glucose lowering medication was de-
rived from both structured home interviews and linkage to pharmacy dispensing records.
[14] At baseline, more than 95% of the Rotterdam Study population was covered by the 
pharmacies in the study area. All potential events of prediabetes and type 2 diabetes were 
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independently adjudicated by two study physicians. In case of disagreement, consensus 
was sought with an endocrinologist. Follow-up data was complete until January 1st 2012.
Statistical analysis
Baseline characteristics were compared between normoglycemic individuals, individuals 
with prediabetes and individuals with type 2 diabetes using linear regression models, 
Kruskal-Wallis tests for continuous data, and 2 tests for categorical data.
Remaining lifetime risks at different ages were calculated for prediabetes, diabetes and 
insulin use. We used a modified version of survival analysis to take the competing event of 
death into account for the calculation of the absolute lifetime risk (see appendix page 3 for 
statistical details). Lifetime risk estimates were calculated at index ages 45, 55, 65, 75, and 
85 years for men and women combined and separately. The lifetime risk estimates reflect 
the remaining risk at the index age to the age of last observation (107 years in our study). 
In addition, to compare lifetime risks at the index ages with absolute risks in a shorter 
time period, we also calculated 10-year risks for prediabetes, diabetes and insulin use at 
all index ages.
Next, we calculated the lifetime risk of diabetes only in individuals with prediabetes in 
order to obtain an estimate of the lifetime risk to progress from prediabetes to diabetes. 
Figure 1. Participants Selection.
Participants without insulin treatment 
were used for the lifetime risk of insu-
lin dependency, participants without 
diabetes for the lifetime risk of diabetes 
and participants with normal glucose 
levels for the lifetime risk of prediabetes. 
Progression from prediabetes to diabe-
tes was assessed in the individuals with 
prediabetes and the progression from 
diabetes to insulin dependency in the 
individuals with diabetes without use of 
insulin treatment.
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Similarly, we calculated the lifetime risk of insulin use in individuals with diabetes free of 
insulin therapy to study what percentage of individuals with diabetes will eventually start 
insulin therapy.
In order to analyze the effect of anthropometric measures on the lifetime risk of prediabe-
tes, diabetes and insulin use, we computed lifetime risks at the age of 45 stratified by BMI 
and waist circumference. The individuals were stratified into four categories of BMI (<25 
kg/m2, 25-30 kg/m2, 30-35 kg/m2, and >35 kg/m2) and three categories of waist circumfer-
ence based on the WHO classification scheme (for men: <94 cm, 94-101 cm and ≥102 cm; 
for women: <80 cm, 80-87 cm and ≥88 cm).[16]
To study the delay in onset of prediabetes, diabetes and insulin use we examined the 
difference in mean disease-free survival among BMI and waist circumference strata. As 
censoring precludes estimation of the mean survival time, we used Irwin’s restricted 
mean survival to calculate the mean disease-free survival and overall mean survival.[17] 
Irwin’s restricted mean survival is the mean of the survival time up to a point in time and 
mathematically is the area under the survival curve up to the selected point in time. As 
data from individuals aged older than 100 was limited, we set the restriction time point to 
100 years of age.
All data were analyzed using the IBM SPSS Statistics version 21.0.0.1 (IBM Corp, Somers, 
NY, USA) and R version 2.1 with the ‘etm’ and ‘survival’ libraries.[18,19]
RESULTS
Baseline population characteristics
The mean (SD) age of the population was 65.2 (9.8) and women made up the majority 
of the study population (56.5%). Of the 10050 participants at baseline, 7462 (74.2%) had 
normoglycemia, 1382 (13.8%) had prediabetes, and 1206 (12.0%) had diabetes (Table 1). 
Prevalences of prediabetes and type 2 diabetes increased with advancing age in both men 
and women and were higher in men compared to women (appendix page 7). Individuals 
with prediabetes and diabetes had higher BMI and unfavorable lipid profile compared to 
normal glycemic individuals. Furthermore, people with diabetes had a higher prevalence 
of stroke, coronary heart disease and were more often smokers compared to normoglyce-
mic individuals.
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Lifetime risk of prediabetes, diabetes and insulin use
During 56230 person-years of follow-up in normoglycemic individuals, 1148 individuals 
developed prediabetes and 1343 died (incidence rate per 1000 person-years (IR): 20.4 
(95%CI 19.3 to 21.6); mortality rate per 1000 person-years (MR): 23.9, 95%CI 22.7 to 25.2). 
We observed 828 cases of diabetes during 69639 person-years of follow-up in non-diabetic 
individuals and 1709 deaths (IR: 11.9, 95%CI 11.1 to 12.7; MR: 24.5, 95%CI 23.4 to 25.7). 
Among non-insulin users, 237 incident cases of insulin use were observed during 80832 
person-years of follow-up (IR: 3.4, 95%CI 3.0 to 3.9) and 2183 individuals died (MR: 27.0, 
95%CI 25.9 to 28.1). The remaining lifetime risk for a 45-year old individual to develop pre-
diabetes was 48.7% (95%CI 46.2 to 51.3), whereas the lifetime risks of diabetes and insulin 
use were 31.3% (95%CI 29.3 to 33.3) and 9.1% (95%CI 7.8 to 10.3), respectively (Table 2). 
The cumulative incidences function subsequent to 45 years of age, are depicted in Figure 
Table 1: Baseline characteristics of participants by prevalent glycemic state.
Characteristics Normal glucose
(n = 7462)
Prediabetes
(n = 1382)
Diabetes
(n = 1206)
P-value
Women (n, %) 4411 (59.1) 692 (51.0) 582 (47.7) <0.001
Age (y) 64.4 ± 9.8 66.6 ± 9.4 67.5 ± 9.6 <0.001
Waist circumference (cm) 90 ± 11 96 ± 12 101 ± 12 <0.001
Body mass index (kg/m2) 26.3 ± 3.8 27.9 ± 4.2 29.4 ± 4.8 <0.001
Total cholesterol (mmol/L) 5.7 ± 1.0 5.8 ± 1.0 5.4 ± 1.1 <0.001
HDL cholesterol (mmol/L) 1.4 (1.2-1.7) 1.3 (1.1-1.5) 1.2 (1.0-1.4) <0.001
Triglycerides (mmol/L)† 1.3 (1.0-1.7) 1.5 (1.1-2.1) 1.7 (1.2-2.3) <0.001
non HDL cholesterol (mmol/L) 4.3 ± 1.0 4.4 ± 1.0 4.2 ± 1.1 <0.001
LDL cholesterol (mmol/L) 3.7 ± 0.9 3.6 ± 0.9 3.4 ± 0.9 <0.001
Insulin (pmol/L)† 66 (47-93) 93 (64-133) 110 (73-177) <0.001
Glucose (mmol/L)† 5.3 (5.0-5.6) 6.3 (6.1-6.5) 7.7 (7.0-9.5) <0.001
eGFR (mL/min/1.73 m2) 81 ± 17 80 ± 18 83 ± 22 <0.001
C-reactive protein (mg/L) 1.4 (0.6-3.1) 2.0 (0.9-4.2) 2.5 (1.1-4.9) <0.001
Systolic blood pressure (mmHg) 137 ± 21 145 ± 21 147 ± 22 <0.001
Diastolic blood pressure (mmHg) 78 ± 11 81 ± 12 79 ± 12 <0.001
Hypertension (n, %) 3448 (46.7) 873 (64.0) 875 (73.3) <0.001
History of stroke (n, %) 178 (2.4) 35 (2.5) 77 (6.4) <0.001
History of CHD (n, %) 422 (5.8) 110 (8.1) 164 (13.8) <0.001
Use of blood pressure lowering drugs (n, %) 1408 (19.6) 437 (32.8) 474 (40.5) <0.001
Use of lipid lowering agents (n, %) 1043 (14.4) 239 (17.8) 1178 (27.4) <0.001
Current smoking (n, %) 707 (9.5) 144 (10.4) 147 (12.3) 0.001
Former smoking (n, %) 2769 (37.4) 553 (40.2) 480 (40.1) 0.001
Values are mean ± standard deviation or median (interquartile range) for characteristics with skewed dis-
tributions. eGFR denotes estimated glomerular filtration rate, HDL high-density-lipoprotein, and CHD coro-
nary heart disease. †Only fasting samples.
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1. Lifetime risks of prediabetes, diabetes and insulin use subsequent to increasing ages 
attenuated. Compared to the lifetime risks, the 10-year risks of prediabetes, diabetes 
and insulin use were lower at all index ages. The remaining lifetime risks did not differ by 
gender irrespective of age (appendix page 8-9). With adjustment for the competing risk 
of death, the lifetime risks were lower as compared to the unadjusted risk derived from 
Kaplan-Meier estimates (appendix page 4).
Progression to diabetes and insulin use
In 1382 individuals with prediabetes we observed 425 incident cases of diabetes, whilst 257 
died without diabetes (IR: 43.0, 95%CI 39.2 to 47.2; MR: 26.0, 95%CI 23.0 to 29.3). The lifetime 
risk for individuals that experience prediabetes at 45 years of age to progress to diabetes 
was 74.0% (95%CI 67.6 to 80.5). Further, among 1043 individuals with diabetes, we observed 
183 incident cases of insulin use, whilst 302 died without ever using insulin treatment (IR: 
24.0, 95%CI 20.8 to 27.7; MR: 39.7, 95%CI 35.5 to 44.3). The lifetime risk for individuals with 
diabetes at the age of 45 to start insulin therapy was 49.1% (95%CI 38.2 to 60.0).
Stratification by BMI and waist circumference
Stratification by BMI revealed that people with normal weight at the age of 45 have a 
significantly lower prediabetes lifetime risk compared to overweight and obese individu-
als (Table 3). Stratification by waist circumference revealed similar effects on the lifetime 
risks of prediabetes. In accordance with the lifetime risks for prediabetes, lifetime risks for 
diabetes and insulin use were higher with increasing BMI and waist circumference. The 
cumulative incidences by BMI strata as a function of age, for 45 year olds, are depicted 
in Figure 2. When we stratified individuals within the BMI strata by waist circumference 
Table 2: Remaining lifetime and 10-year risks of prediabetes, diabetes and insulin use.
Age, years N Lifetime risk 
prediabetes (95%CI)
N Lifetime risk 
diabetes (95%CI)
N Lifetime risk insulin 
use (95%CI)
45 Lifetime
 10-year
7462
1233
48.7% (46.2-51.3)
8.4% (5.4-11.4)
8844
1344
31.3% (29.3-33.3)
3.4% (2.1-4.8)
9887
1400
9.1% (7.8-10.3)
0.5% (0.0-1.0)
55 Lifetime
 10-year
6939
3788
44.5% (42.5-46.6)
13.2% (11.4-15.0)
8291
4456
29.2% (2..4-31.0)
7.0% (5.8-8.3)
9329
4914
8.8% (7.6-10.0) 
2.2% (1.4-3.0)
65 Lifetime
 10-year
5109
3901
37.6% (35.6-39.5)
19.3% (17.7-20.9)
6257
4754
24.8% (2..1-26.5)
11.2% (10.0-12.3)
7179
5414
7.0% (6.0-7.9)
3.0% (2.4-3.6)
75 Lifetime
 10-year
3073
2885
25.8% (23.7-28.0)
19.1% (17.3-20.9)
3850
3618
17.4% (15.7-19.1)
12.2% (10.9-13.6)
4547
4273
4.7% (3.8-5.6)
2.6% (2.0-3.2)
85 Lifetime
 10-year
1072
1060
13.1% (10.4-15.7)
11.9% (9.5-14.4)
1405
1390
8.9% (6.9-10.9)
8.2% (6.4-10.0)
1725
1707
3.3% (2.2-4.4)
3.3% (2.2-4.4)
The lifetime risk of prediabetes is for individuals with normal glucose levels at the index age, lifetime risk of 
diabetes for individuals without diabetes at the index age and the lifetime risk of insulin use for individuals 
free of insulin use at the index age.
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categories, we observed an increasing risk of diabetes with increasing waist, except in the 
lowest BMI category (appendix page 10).
The lifetime risk to progress from prediabetes to diabetes was also substantially lower 
for individuals with a normal weight compared to overweight and obese individuals. 
However, the risk to start insulin therapy in individuals with diabetes did not differ sub-
stantially between strata of BMI (Table 4).
Table 3: Lifetime risk at the age of 45 for prediabetes, diabetes and insulin use by body mass index 
and waist circumference strata.
BMI
(kg/m2)
N Lifetime risk 
prediabetes 
(95%CI) P
-v
a
lu
e N Lifetime risk 
diabetes 
(95%CI) P
-v
a
lu
e N Lifetime risk 
Insulin use 
(95%CI) P
-v
a
lu
e
< 25 2686 36.9% (33.1-40.6) 2955 18.8% (15.8-21.7) 3124 4.6% (3.0-6.2)
25-30 3452 52.1% (48.0-56.2) <0.001 4132 33.1% (30.2-36.0) <0.001 4598 9.6% (7.7-11.5) <0.001
30-35 1013 60.2% (54.1-66.2) 0.02 1324 43.9% (38.6-49.2) <0.001 1613 14.2% (10.5-17.9) 0.01
> 35 240 71.3% (60.5-82.0) 0.04 352 56.6% (46.7-66.6) 0.01 462 17.1% (9.9-24.2) 0.24
Waist circumference
Small 2127 37.5% (33.2-41.7) 2329 19.5% (16.0-23.1) 2449 4.5% (2.8-6.3)
Medium 2220 46.6% (41.1-52.2) 0.005 2589 25.1% (21.6-28.6) 0.01 2815 6.5% (4.4-8.5) 0.08
Large 2801 57.8% (54.2-61.5) <0.001 3553 41.8% (38.5-45.0) <0.001 4205 12.6% (10.5-14.8) <0.001
*Waist circumference categories small, medium and large represent the WHO classification scheme (for 
men: <94 cm, 94-102 cm and ≥102; for women: <80 cm, 80-88 cm and ≥88). BMI denotes body mass index. 
P-values are for the comparison with the lower BMI or waist category.
The lifetime risks are subsequent to the age of 45.
Table 4: Lifetime Risk to Develop Diabetes in Individuals with Prediabetes at the Age of 45 and the 
Lifetime Risk to Use Insulin in Individuals aged 45 with Diabetes but Free of Insulin Use, Stratified by 
Body Mass Index and Waist Circumference.
BMI (kg/m2) N Prediabetes to 
diabetes (95%CI)
P-value N Non-insulin 
dependent diabetes 
to insulin use (95%CI)
P-value
< 25.0 269 35.9% (18.4-53.4) 169 58.6% (34.2-83.1)
25 – 30 680 76.3% (68.9-83.7) <0.0001 466 57.5% (45.2-69.9) 0.47
30 – 35 311 87.7% (79.4-96.0) 0.02 289 25.0% (0.0-60.1) 0.04
> 35 112 80.9% (65.9-95.9) 0.22 110 46.4% (28.6-64.1) 0.14
Waist circumference
Small 202 49.8% (28.6-70.9) 120 43.0% (24.4-61.7)
Medium 369 70.0% (56.4-83.7) 0.06 226 55.9% (38.6-73.2) 0.16
Large 752 78.8% (70.4-87.1) 0.14 652 45.0% (29.0-61.0) 0.18
*Waist circumference categories small, medium and large represent the WHO classification scheme (for 
men: <94 cm, 94-102 cm and ≥102; for women: <80 cm, 80-88 cm and ≥88). P-values are for the comparison 
with the lower BMI or waist category.
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Diabetes-free survival
Remaining life years free of prediabetes, diabetes and insulin use from the age of 45 by sex, 
BMI and waist circumference strata are depicted in appendix page 5-6. Overall, years lived with 
normal glucose metabolism diminished with increasing levels of obesity. Also, individuals with 
higher BMI experienced more years lived with diabetes. For example, the average age of onset 
of prediabetes in men with normal weight was more than 10 years later compared to men with 
a BMI >35 kg/m2. On average, insulin therapy is only used in a short time period at the end of life.
DISCUSSION
The lifetime risk of prediabetes for an individual aged 45 is one in two, and one in three 
individuals aged 45 will develop diabetes. The vast majority of individuals that have pre-
diabetes at age 45 will eventually progress to diabetes and one in two diabetes patients 
aged 45 will start insulin therapy. Furthermore, obesity substantially affects the risk to 
progress from prediabetes to diabetes and compresses the years lived with normal glu-
cose metabolism.
Individuals with prediabetes have an increased risk of diabetes, cardiovascular disease, 
cancer and mortality.[20-22] Despite the high prevalence of prediabetes, estimates of 
what proportion of the population will eventually present with prediabetes have not 
been previously published. Evidence regarding the preventive effects of both lifestyle and 
pharmacological interventions on the progression of prediabetes to diabetes increases.
[23-25] Lifetime risk estimates may indicate the proportion of individuals for whom early 
intervention would be applicable. We observed that half of our population will sooner 
or later present with prediabetes and may qualify for potential interventions during their 
lifespan.
In contrast to diabetes, prediabetes is a more fluctuating health state. The lifetime risk 
estimates of prediabetes in the current study should be interpreted as ever experiencing 
a serum glucose in the prediabetes range. However, individuals diagnosed with predia-
betes could return to normoglycaemia. In the Diabetes Prevention Program (DPP), 19% 
of the placebo group returned to normoglycemia within 10 year.[26] In the pioglitazone 
for diabetes prevention study, 28% returned to normoglycemia in the placebo arm dur-
ing a median follow-up of 2.4 years. These estimates are based on a limited time period 
and longer follow-up may result in different estimates. Our lifetime estimates show that 
3 in 4 individuals with a glucose level in the prediabetes range at the age of 45 progress 
to diabetes. These estimates provide a better long-term perspective of individuals who 
ever meet prediabetes criteria, irrespective whether an individual remains prediabetes or 
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returns to normoglycemia in the following years. This is in agreement with the American 
Diabetes Association expert panel suggesting that 70% of the individuals with prediabetes 
progress to diabetes.[2] The higher prevalence of obesity in the US raises the concern of 
even higher progression rates compared to the estimates from our European population.
A previous report simulated the lifetime risk of diabetes in a US population based on 
questionnaire data for the adjudication of diabetes which does not comprise undiagnosed 
diabetes.[11] As the prevalence of undiagnosed diabetes is more than 25%,[27] the risk 
estimates in the US study are likely to be underestimated. Furthermore, an Australian 
study estimated the lifetime risk of diabetes using two cross-sectional examinations 
(diabetes defined based on fasting plasma glucose (≥7.0 mmol/L) and 2hr plasma glucose 
(≥11.1 mmol/L)) with a short time interval (5 years) in a population with a large number of 
dropouts (39%) and without active follow.[12] Instead, we used active follow-up data and 
fasting glucose measurements as an objective and comprehensive assessment of diabetes 
diagnosis enabling us to provide accurate estimates of the entire spectrum of impaired 
glucose metabolism.
We observed a substantial impact of obesity on the remaining lifetime risk of prediabetes, 
diabetes and insulin use, which is in line with a previous report.[28] Also, obesity increased 
the risk to progress from prediabetes to diabetes. This is in agreement with the observa-
tion in the placebo group of the DPP in which obese individuals had a higher risk to prog-
ress to diabetes (9 vs 14 cases/100 person-years).[23] Furthermore, obesity compressed 
the survival with normal glucose metabolism and influenced the time lived within each 
glycemic state underscoring the importance of weight management.
We estimate that one in two patients with diabetes eventually start insulin treatment. 
Together, the lifetime risk of diabetes and insulin use show the burden of pharmacologi-
cal treatment of diabetes in our Western population. Despite the consensus statements 
from the ADA and the European Association for the Study of Diabetes in 2006[29] and 
2009,[30] physicians consider a variety of non-standardized factors to initiate glucose 
lowering treatment.[31] Therefore, our lifetime risks of insulin use may not reflect country 
and population-specific prescription behaviors. Furthermore, recent developments in 
diabetes care include the initiation of insulin therapy for beta-cell preservation, which has 
not been common practice in the calendar time period of our study. The lifetime risk of 
9.1% in non-insulin users at the age of 45 may therefore be an underestimation of the risk 
of insulin use in current diabetes clinical care.
The strength of our study is the comprehensive assessment of incident diabetes diagnosis 
through use of blood glucose lowering treatment using medical records from hospitals 
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and general practitioners, standardized blood glucose measurements at the repeated 
study center visits, and electronic linkage with the pharmacy dispensing records in the 
study area. Also, we used data from a prospective population-based cohort study with 
long-term follow-up and adjusted the lifetime risks for the competing risk of death to 
avoid overestimation. We need to address some limitations. First, we calculated remain-
ing lifetime risks at the age of 45 because we did not have data for individuals younger 
than 45. Nevertheless, the cumulative incidence of type 2 diabetes before the age of 45 is 
low.[10,11] Also, for estimating the lifetime risk in BMI and waist circumference strata, we 
used anthropometric data at older ages than 45 as not all individuals entered the study 
at age 45. This could have led to the misclassification of individuals across the different 
categories as BMI and waist circumference could have changed with age. Third, we used 
data from an completely unselected sample of the general Dutch population with high 
participation rates (72.0%).[13] However, all studies requiring active participation are to 
some extent subject to the “healthy volunteer effect” and this generally leads to slight 
underestimations of absolute risk estimates at short term follow-up. However, this under-
estimation attenuates at long-term follow-up.[32] Last, the vast majority of the Rotterdam 
Study participants are white (97%) and we therefore present lifetime risks for individuals 
from European ancestry.
Half of the general population will sooner or later develop prediabetes defined as fasting 
glucose >6.0 mmol/L. Up to three in four of those with prediabetes aged 45 will progress to 
diabetes and one in two diabetics aged 45 eventually starts insulin therapy. These lifetime 
risks demonstrate the burden of impaired glucose metabolism on our society and demand 
earlier and more effective prevention strategies.
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SUPPLEMENTAL MATERIAL
Statistical analysis lifetime risk
We used data from individuals at each age during follow-up that they attained free of the 
disease (i.e. prediabetes, diabetes or insulin therapy).[1,2] Individuals who reached to age 
j free of the disease at some point during follow-up constituted the population at risk for 
any age j (risk set, Rj). If an individual developed the disease, died or was censored at age 
j, he or she was removed from the risk set for age j+1 and older. If an individual entered 
the study at age j+1, he or she was added to the risk set for age j+1.[3] For the lifetime 
risk at 45, for instance, hazards (hj), age-specific incidences (fj), cumulative incidences (Fj), 
and survival probabilities (Sj) were calculated according to the standard Kaplan-Meier 
methods for each age j (assuming F44 = 0 and S44 = 1):
hj = ej / Rj (ej = # of events at age j)
f j = hj × Sj – 1
Fj = ji = 45fi
Sj = 1 – Fj
It should be noted that Fj is the cumulative incidence of the disease (prediabetes, diabetes 
or insulin therapy) which applies to individuals who survive through age j-1. This cumula-
tive incidence does not take into account the competing risk of death from another cause. 
This means that individuals that decease count as withdrawals and are assumed to have 
the same risk of the disease compared to the individuals that are alive at censoring. How-
ever, individuals who die before age j have a zero future risk of the disease. This competing 
risk of death will result in overestimation of the lifetime risk.[4] Therefore, we used a sepa-
rate survival function (Uj) with death included as an event alongside prediabetes, diabetes 
or insulin therapy to adjust for the competing risk of death. The adjusted incidence and 
true lifetime risk was calculated as follows:
fj* = hj × Uj – 1
Fj* = ji = 45fi*
Sj* = 1– Fj*
We used similar methods to calculate lifetime risks at the starting age 55, 65, 75 and 85. 
We set the FT-1 and UT-1 to 0 for every index age T and used the original hazard (hj) to cal-
culate Uj for j T. The analysis methods for prediabetes, diabetes and insulin dependency 
were similar. Furthermore, we calculated the lifetime risks stratified by body mass index 
and waist circumference. Finally, we calculated the lifetime risk of diabetes conditional on 
the presence of prediabetes to study the progression from prediabetes to overt diabetes. 
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Similarly, we studied the lifetime risk of insulin therapy conditional on the presence of 
diabetes (without insulin therapy) to study the progression from insulin-free diabetes to 
diabetes with insulin therapy.
Figure S1. Kaplan-Meier Estimate Compared to Competing-Risk Estimate of Lifetime Risk of Type 2 
Diabetes.
Comparison of the cumulative incidence of type 2 diabetes adjusted for the competing risk of death (Cu-
mulative Incidence estimates) with the Kaplan-Meier estimate of the lifetime risk of type 2 diabetes (unad-
justed for the competing risk of death) in men (n = 3741) and women (n = 5103) aged 45.
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Figure S2. Survival free of prediabetes, diabetes and insulin use after the age of 45 by body mass 
index strata.
The blue bars represent the prediabetes-free survival in men and women with normal glucose levels at the 
age of 45. The red bars represents the diabetes-free survival in men and women without diabetes at the age 
of 45. Finally, the green bars represent the insulin-free survival in men and women that do not use insulin 
at the age of 45. All analyses are stratified by body mass index and adjusted for the competing risk of death.
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Figure S3. Survival free of prediabetes, diabetes and insulin use after the age of 45 by waist circumfer-
ence strata.
The blue bars represent the prediabetes-free survival in men and women with normal glucose levels at 
the age of 45. The red bars represents the diabetes-free survival in men and women without diabetes at 
the age of 45. Finally, the green bars represent the insulin-free survival in men and women that do not use 
insulin at the age of 45. All analyses are stratified by waist circumference and adjusted for the competing 
risk of death.
70 PART III
Type 2 diabetes mellitus: Lifetime risk and disease course 
Table S1: Prevalence of Prediabetes and Diabetes at Baseline by Sex and Age (n = 10050).
Age (years)
Men (n = 4368) Women (n = 5682)
Total N (cases) Prevalence (95%CI) Total N (cases) Prevalence (95%CI)
Prediabetes
45-55 622 (58) 0.09 (0.07-0.12) 795 (43) 0.05 (0.04-0.07)
55-65 1824 (318) 0.17 (0.16-0.19) 2311 (279) 0.12 (0.11-0.13)
65-75 1243 (198) 0.16 (0.14-0.18) 1453 (191) 0.13 (0.11-0.15)
75-85 596 (105) 0.18 (0.15-0.21) 928 (146) 0.16 (0.13-0.18)
>85 83 (11) 0.13 (0.07-0.23) 195 (33) 0.17 (0.12-0.23)
Diabetes
45-55 622 (43) 0.07 (0.05-0.10) 795 (40) 0.05 (0.04-0.07)
55-65 1824 (254) 0.14 (0.13-0.16) 2311 (206) 0.09 (0.08-0.10)
65-75 1243 (195) 0.16 (0.14-0.18) 1453 (169) 0.12 (0.10-0.13)
75-85 596 (118) 0.20 (0.17-0.23) 928 (135) 0.15 (0.12-0.17)
>85 83 (17) 0.20 (0.13-0.31) 195 (29) 0.15 (0.11-0.21)
CI denotes confidence interval.
Table S2: Remaining Lifetime Risk of Prediabetes, Type 2 Diabetes and Insulin Dependent Type 2 Dia-
betes in Men by Categories of Age, Body Mass Index, and Waist Circumference.
Age (years) N
Lifetime risk 
prediabetes (95%CI)
N
Lifetime risk 
diabetes (95%CI)
N
Lifetime risk insulin 
use (95%CI)
45 3051 48.4% (44.1-52.6) 3741 30.5% (27.5-33.5) 4282 10.7% (8.7-12.7)
55 2835 42.6% (39.5-45.8) 3505 28.1% (25.4-30.7) 4045 10.3% (8.4-12.2)
65 2070 35.1% (32.2-38.1) 2619 24.1% (21.6-26.6) 3085 7.8% (6.3-9.3)
75 1228 24.5% (21.2-27.7) 1557 16.0% (13.4-18.6) 1887 5.3% (3.9-6.8)
85 346 12.9% (8.2-17.5) 463 8.3% (4.9-11.8) 584 4.0% (2.0-6.0)
BMI (kg/m2)
< 25 1047 37.5% (31.6-43.3) 1174 19.6% (15.3-23.9) 1273 6.9% (3.5-10.3)
25-30 1596 51.2% (43.6-58.8) 1979 31.5% (27.3-35.7) 2254 11.1% (8.3-13.8)
30-35 346 58.4% (49.1-67.8) 492 42.0% (33.7-50.3) 614 16.5% (10.3-22.7)
>35 41 72.4% (48.6-96.2) 69 59.7% (38.4-81.0) 110 16.8% (3.8-29.8)
Waist circumference
Small 1129 40.2% (34.3-46.1) 1266 21.8% (17.0-26.6) 1357 5.0% (2.6-7.4)
Medium 1005 52.1% (41.6-62.6) 1237 29.0% (23.5-34.6) 1392 9.6% (6.2-12.9)
Large 797 53.4% (46.7-60.1) 1087 39.4% (33.8-44.9) 1359 15.3% (11.2-19.3)
*Waist circumference categories small, medium and large represent the WHO classification scheme (for 
men: <94 cm, 94-102 cm and ≥102 cm). BMI denotes body mass index. The lifetime risk of prediabetes is 
for individuals with normal glucose levels at the index age, lifetime risk of diabetes for individuals without 
diabetes at the index age and the lifetime risk of insulin use for individuals free of insulin use at the index 
age. For BMI and waist circumference, the lifetime risks are subsequent-the age of 45.
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Table S3: Remaining Lifetime Risk of Prediabetes, Type 2 Diabetes and Insulin Dependent Type 2 Dia-
betes in Women by Categories of Age, Body Mass Index, and Waist Circumference.
Age (years) N
Lifetime risk 
prediabetes (95%CI)
N
Lifetime risk diabetes 
(95%CI)
N
Lifetime risk insulin 
use (95%CI)
45 4411 49.1% (46.1-52.0) 5103 31.9% (29.3-34.6) 5605 7.8% (6.2-9.3)
55 4104 46.1% (43.4-48.8) 4786 30.1% (27.7-32.5) 5284 7.5% (6.1-9.0)
65 3039 39.4% (36.8-42.1) 3638 25.3% (23.1-27.6) 4094 6.3% (5.0-7.6)
75 1845 26.8% (24.0-29.6) 2293 18.5% (16.2-20.7) 2660 4.2% (3.0-5.3)
85 726 13.2% (10.0-16.4) 942 9.2% (6.8-11.6) 1141 2.9% (1.6-4.2)
BMI (kg/m2)
< 25 1639 36.6% (31.6-41.5) 1781 18.0% (14.0-22.0) 1851 3.2% (1.6-4.8)
25-30 1856 53.5% (49.3-57.7) 2153 34.8% (30.7-38.8) 2344 8.0% (5.4-10.7)
30-35 667 61.3% (42.8-69.8) 832 43.4% (36.7-50.1) 999 13.0% (8.3-17.6)
>35 199 71.0% (58.4-83.6) 283 55.9% (44.6-67.3) 352 16.1% (7.8-24.4)
Waist circumference
Small 998 33.9% (27.8-39.9) 1063 16.0% (10.8-21.1) 1092 4.1% (1.3-7.0)
Medium 1215 42.4% (36.8-48.0) 1352 21.6% (17.1-26.1) 1423 2.9% (0.8-5.0)
Large 2004 59.7% (55.4-64.1) 2466 42.8% (38.8-46.8) 2846 11.4% (8.8-13.9)
*Waist circumference categories small, medium and large represent the WHO classification scheme (for 
women: <80 cm, 80-88 cm and ≥88 cm). BMI denotes body mass index. The lifetime risk of prediabetes is 
for individuals with normal glucose levels at the index age, lifetime risk of diabetes for individuals without 
diabetes at the index age and the lifetime risk of insulin use for individuals free of insulin use at the index 
age. For BMI and waist circumference, the lifetime risks are subsequent-the age of 45.
Table S4: Remaining Lifetime Risk of Diabetes at Age 45 by Body Mass Index and Waist Circumference.
Waist circumference
Body mass index (kg/m2)
<25 25-30 30-35 >35
Small 18.4% (14.3-22.5) 22.8% (15.9-29.8) N/A N/A
Medium 18.5% (13.5-23.5) 28.5% (23.9-33.2) 27.6% (10.2-44.9) N/A
Large 17.7% (10.5-24.9) 39.0% (34.6-43.4) 44.6% (39.0-50.1) 57.1% (46.8-67.3)
* Waist circumference categories small, medium and large represent the WHO classification scheme (for 
men: <94 cm, 94-102 cm and ≥102 cm; for women: <80 cm, 80-88 cm and ≥88 cm).
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ABSTRACT
Introduction: Type 2 diabetes is a major healthcare problem. Glucose-, lipid-, and blood 
pressure-lowering strategies decrease the risk of micro- and macrovascular complications. 
However, a substantial residual risk remains. To unravel the etiology of type 2 diabetes 
and its complications, large-scale, well-phenotyped studies with prospective follow-up 
are needed. This is the goal of the DiaGene study. In this manuscript, we describe the 
design and baseline characteristics of the study.
Methods: The DiaGene study is a multi-centre, prospective, extensively phenotyped type 
2 diabetes cohort study with concurrent inclusion of diabetes-free individuals at baseline 
as controls in the city of Eindhoven, The Netherlands. We collected anthropometry, 
laboratory measurements, DNA material, and detailed information on medication usage, 
family history, lifestyle and past medical history. Furthermore, we assessed the prevalence 
and incidence of retinopathy, nephropathy, neuropathy, and diabetic feet in cases. Using 
logistic regression models, we analyzed the association of 11 well known genetic risk vari-
ants with type 2 diabetes in our study.
Results: In total, 1886 patients with type 2 diabetes and 854 controls were included. Cases 
had worse anthropometric and metabolic profiles than controls. Patients in outpatient 
clinics had higher prevalence of macrovascular (41.9% vs. 34.8%; P=0.002) and microvas-
cular disease (63.8% vs. 20.7%) compared to patients from primary care. With the excep-
tion of the genetic variant in KCNJ11, all type 2 diabetes susceptibility variants had higher 
allele frequencies in subjects with type 2 diabetes than in controls.
Conclusions: In our study population, considerable rates of macrovascular and micro-
vascular complications are present despite treatment. These prevalence rates are compa-
rable to other type 2 diabetes populations. While planning genomics, we describe that 11 
well-known type 2 diabetes genetic risk variants (in TCF7L2, PPARG-P12A, KCNJ11, FTO, 
IGF2BP2, DUSP9, CENTD2, THADA, HHEX, CDKAL1, KCNQ1) showed similar associations 
compared to literature. This study is well-suited for multiple omics analyses to further 
elucidate disease pathophysiology. Our overall goal is to increase the understanding of 
the underlying mechanisms of type 2 diabetes and its complications for developing new 
prediction, prevention, and treatment strategies.
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BACKGROUND
Type 2 diabetes mellitus (T2DM) is a complex metabolic disease characterized by over-
weight, insulin resistance and beta-cell dysfunction [1-3]. Because of ageing and the rising 
prevalence of obesity, the incidence and prevalence of T2DM are increasing [4-7]. T2DM 
accounts for a large proportion of present and future health care expenditure in Western 
societies [5, 7, 8]. People affected by T2DM have an increased risk of cardiovascular events 
[9-13], and a poor prognosis after these events [14, 15]. In addition, T2DM gives rise to 
microvascular complications such as retinopathy, nephropathy and neuropathy [16-19]. 
We have collected a new large cohort of individuals with and without T2DM with prospec-
tive follow-up in the Netherlands: the DiaGene study.
The care for T2DM in the Netherlands is organized in primary care by general practitioners 
and at hospital-based outpatient clinics by medical specialists. This systematic care is 
based on local and international treatment guidelines aiming to reduce morbidity and 
mortality through optimal treatment of hyperglycemia and associated metabolic com-
plications, such as dyslipidemia, vascular dysfunction and high blood pressure [20, 21]. 
Treatment of these components has proven to reduce the risk of cardiovascular morbidity 
and mortality in T2DM [22-30]. However, a substantial residual risk remains. Improving 
knowledge on genetic, biochemical and environmental (lifestyle and anthropometric) 
determinants of T2DM and its micro– and macrovascular complications can have large 
implications for prevention, treatment and prognosis of T2DM [22, 23, 31]. Through high 
throughput sequencing, about 80 common genetic variants associated with T2DM have 
been discovered [31, 32]. These common variants only explain 5-10% of the overall pre-
disposition of T2DM [33]. There clearly is a need to expand these analyses to additional 
populations.
In this paper, we present the DiaGene Study, a new, multicenter T2DM cohort study 
collected in the Netherlands in both primary and secondary care. The main purpose of 
the DiaGene Study is to study the analyses of genetic, biochemical and environmental 
determinants of T2DM and its complications. Here we describe the characteristics of our 
population, the prevalence of complications and future perspectives.
METHODS
Study design
The DiaGene-study is a multicenter cohort study that was coordinated by the vascular 
section of internal medicine of the Erasmus Medical Center and the Diabetes subunit 
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of the Máxima Medical Center, and collected in the city of Eindhoven, The Netherlands. 
Eindhoven is a medium-sized city with 170,668 adult (> 21 years) inhabitants in 2011. 
Both hospitals in Eindhoven participated in the DiaGene study: Catherina Hospital and 
Máxima Medical Center. In addition, the local Primary Care Diagnostic Centre participated. 
Hence, virtually all diabetes patients in Eindhoven were approached for inclusion through 
this population-based approach. Between 2006 and 2011, physicians at all three centers 
included a total of 2,065 patients with T2DM. Of these, 179 patients were excluded from 
analysis. Reasons for exclusion where: no diabetes (n=1), Type 1 diabetes (n=30), Maturity-
Onset Diabetes of the Young (n=4), Latent auto-immune diabetes in adults (n=3), double 
inclusion (n=77), post-pancreatitis diabetes (n=3), refusal during study period (n=2) and 
missing written informed consent (n=59); resulting in a total of 1,886 patients in the study 
population.
The control group consisted of two groups: 1. subjects recruited via advertisement in local 
newspapers, and 2. subjects that where included through invitation of friends and self-
reported unrelated family members of participating patients. Inclusion criteria for controls 
was age 55 years or older. Exclusion criteria were the presence of any kind of diabetes, 
use of metformin or Cushing’s disease. Subjects who were approached had at least 7 days 
of decision-time to fully reflect on research goals and methods using physician-provided 
information, before giving their written informed consent. Eventually, 904 diabetes-free 
subjects participated as controls. Of these, 50 were excluded from all analyses based 
on missing written informed consent (n=14), double inclusion (n=17), and suspected or 
confirmed diagnosis of diabetes (n=19), resulting in a total of 854 controls included in 
the final population. This study was approved by the Medical Ethics Committees of the 
Erasmus MC, Catherina Hospital and Máxima Medical Center. Written informed consent 
was obtained from all participants.
Definition of T2DM
Information on the diagnosis of T2DM was retrieved from the patient’s medical records. 
In accordance with American Diabetes Association – and World Health Organization – 
guidelines [34, 35], diabetes was defined as a fasting plasma glucose ≥ 7.0 mmol/L and/
or a non-fasting plasma glucose level ≥ 11.1 mmol/l measured at least at 2 separate time 
points, treatment with oral glucose-lowering medication or insulin, and/or the diagnosis 
of T2DM as registered by a medical specialist. Persons with the diagnosis of type 1 diabetes 
(as derived from medical records and patient-questionnaires) or other types of diabetes 
mellitus were excluded from the study. Control subjects with fasting glucose ≥ 7.0 mmol/L 
or glycated hemoglobin (HbA1c ) ≥ 47.5mmol/mol were excluded. Information on T2DM 
status was checked by two investigators. If they did not reach consensus, the participant’s 
treating physician was consulted.
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Medical and family history
Each participant filled out an extensive questionnaire on their medical history (history 
of diabetes, metabolic disease, vascular disease, medication use and intoxications) and 
ethnicity of their parents (Supplement 1). We classified a participant to be Caucasian if 
both parents were reported to be Caucasian. Furthermore, the participant’s family his-
tory regarding diabetes and cardiovascular disease and medication usage was recorded 
through the questionnaire.
Sample collection
A 20cc Ethylene diamine tetra acetic (EDTA) fasting blood sample was taken from all par-
ticipants. Samples were centrifuged (3000rpm; 1800G for 15 minutes at 4°C). Directly after 
centrifugation, the plasma and the buffy coat were separated and stored (at -80°C) for DNA 
analysis and future measurements.
Diabetes and complications of diabetes
Data on body mass index (BMI) (kg/m2) and blood pressure (mmHg) were extracted from 
medical records at inclusion. Similarly, laboratory results were extracted around time of 
inclusion and contained fasting glucose, glycated hemoglobin (HbA1c), total cholesterol, 
low-density lipoprotein cholesterol (LDL-cholesterol), high-density lipoprotein-choles-
terol (HDL-cholesterol), triglycerides, creatinin and urinary albumin/creatinine-ratio. The 
majority of measurements were collected within 6 months prior to or after the actual 
date of inclusion. To estimate kidney function, the estimated glomerular filtration rate 
was calculated with the Modification of Diet in Renal Disease-formula. Information on the 
presence of cardiovascular disease in the patients treated in the hospital-based outpatient 
clinics was retrieved from their medical records. Cardiovascular disease comprised myo-
cardial infarction, percutaneous coronary intervention / coronary arterial bypass graft 
(PCI/CABG), cerebrovascular accident, transient ischemic attack and peripheral arterial 
disease. PCI/CABG was defined as any invasive intervention to treat coronary arterial dis-
ease (PCI, CABG). Peripheral arterial disease was defined as an ankle-brachial index below 
0.80 or below 0.90 with typical complaints, any intervention to treat peripheral arterial 
disease (supervised exercise training, stenting, bypass and percutaneous transluminal 
angioplasty, or the self-reported presence of intermittent claudication. Information on 
cardiovascular disease in patients from primary care and diabetes-free controls was based 
on self-reporting.
Microvascular complications were subdivided into retinopathy, nephropathy and neu-
ropathy. Diabetic foot was additionally assessed. Retinopathy was scored according to 
the report of an ophthalmologist as absent or present and classified as non-proliferative, 
proliferative, or retinopathy treated with photo coagulation or intra-vitreal injections. 
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Neuropathy was defined by a podotherapist, neurologist or the patients’ treating physi-
cian. Nephropathy was defined present when micro-albuminuria (Albumin/creatinin-ratio 
(ACR)≥2.5 for men or ≥3.5 for women) was present at two of three consecutive measure-
ments, or when high micro-albuminuria or macro-albuminuria was present at one 
measurement (ACR≥12.5 for men or ≥17.5 for women). Diabetic foot was established by a 
podotherapist or physician according to the SIMM’s classification [36]. All information on 
laboratory data, macrovascular, and microvascular events in case and control subjects at 
baseline that was retrieved from medical records was separately checked by two inves-
tigators. When they did not reach consensus, the participant’s physician was consulted.
Genotyping
DNA was isolated using the Invisorb® Blood Universal Kit from Stratec Molecular (Berlin, Ger-
many). Eleven well-known T2DM genetic risk variants were genotyped: TCF7L2(rs7903146), 
PPARG-P12A(rs1801282) , DUSP9(rs594532), CENTD2(rs1552224), THADA(rs7578597), 
HHEX(rs1111875), CDKAL1(rs7754840) and KCNQ1(rs231362)which had previously been 
genotyped for replication in DIAGRAM [37], and KCNJ11(rs5219), IGF2BP2(rs4402960) and 
FTO(rs8050136). These risk variants were chosen because of their relatively large effect 
sizes on T2DM risk in previous studies [32, 37-42]. Genotyping was performed with TaqMan 
allelic discrimination assays, designed and optimized by Applied Biosystems (Foster City, 
CA, USA). Reactions were performed on the Taqman Prism 7900 HT platform.
Follow-up data
Currently, we are finalizing the first collection of prospective follow-up in our study popu-
lation. This encompasses all anthropometric and laboratory measurements and data on 
metabolic, microvascular and macrovascular complications of T2DM and enables us to 
perform prospective analyses.
Statistical analysis
Continuous variables are expressed as median with interquartile range unless otherwise 
specified. Comparisons between groups were performed with Mann-Whitney U tests for 
continuous and X2-tests for categorical data. Deviation from the Hardy-Weinberg equilibri-
um was assessed by X2-testing. Associations of the genotypes with T2DM were tested using 
logistic regression models. We have calculated interaction effects of odds ratios for T2D to 
compare our results with previous genetic studies according to the method of Altman et al 
[43]. All models were adjusted for age and sex. Additionally, models were adjusted for cen-
ter of inclusion as a categorical covariate. Cases and controls of non-Caucasian ethnicity 
were excluded from the genetic analyses. P-values smaller than 0.05 were considered to 
be statistically significant. Statistical analysis was performed with SPSS-software version 
22.0 (SPSS, Chicago, IL, USA).
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RESULTS
General characteristics
The most relevant general characteristics of the cohort are displayed in Table 1. A total 
of 1886 patients with T2DM and 854 diabetes-free controls were included. Of all anthro-
pometric measurements, 90.6% and 96.1% were performed within 6 and 12 months of 
inclusion, respectively. Of laboratory data, 81.8% and 93.2% were measured within 6 and 
12 months of inclusion, respectively. The cases and controls were of similar age. When 
compared to controls, cases had higher BMI (29.5 (Interquartile range (IQR) 26.4-32.7) 
vs. 25.5 (IQR 23.3-27.7) kg/m2 ; P<0.001), higher HbA1c (50.8 (IQR 43.7-57.9) vs. 37.7 (IQR 
36.1-39.3) mmol/mol; P<0.001), higher creatinin (78 (IQR 66-91) vs. 72 (IQR 63-81) umol/L; 
P<0.001), higher triglycerides (1.4 (IQR 0.9-1.9) vs 1.2 (IQR 0.9-1.5) mmol/L; P<0.001), 
lower HDL-cholesterol (1.1 (IQR 0.9-1.3) vs 1.4 (IQR 1.2-1.6) mmol/L; P<0.001) and lower 
LDL-cholesterol (2.4 (0.8) vs. 3.6 (0.9) mmol/L; P<0.001). A larger proportion of cases had 
reduced estimated glomerular filtration rate (19.7% vs. 4.7%, P<0.001) and prevalent 
macrovascular disease (38.0% vs 8.3%, P<0.001) compared to diabetes-free controls. 
More cases had a first-degree relative with T2DM compared to controls (64.4% vs 33.3%, 
P<0.001). More baseline characteristics can be found in Table 1.
Primary care versus hospital-based outpatient clinic
Table 2 shows baseline characteristics of patients with T2DM in primary care and hospital-
based outpatient clinic. Patients with T2DM from the outpatient clinic had longer median 
duration of diabetes compared to primary care (12.5 (IQR 7.2-17.8) vs. 4.6 (IQR 1.2-7.9) 
years; P<0.001) while they were diagnosed at a younger age (50.8 (10.8) vs. 58.4 (11.3) years, 
P<0.001). At the outpatient clinic, participants had higher BMI (30.2 (IQR 26.8-33.7) vs. 29.0 
(IQR 26.0-32.0) kg/m2; P<0.001), HDL-cholesterol (1.2 (IQR 1.0-1.4) vs.1.1 (IQR 0.9-1.3); 
P<0.002), HbA1c (56.3 (IQR 48.1-64.5) vs. 48.6 (43.7-53.6) mmol/mol; P<0.001) and higher 
creatinin (81 (67-95) vs. 76 (64-88) umol/L; P<0.001). Total cholesterol (4.3 (0.9) vs 4.2 (0.9); 
P=0.04) and LDL-cholesterol (2.6 (0.8) vs. 2.3 (0.8); P<0.001) was higher in primary care 
patients. A larger proportion of patients with T2DM at the outpatient clinic had reduced 
estimated glomerular filtration rate (25.5% vs. 15.2%, P<0.001), macrovascular disease 
(41.9% vs. 34.8%; P=0.002) and microvascular disease (63.8% vs. 20.7%) compared to 
patients with T2DM from primary care. We could not retrieve reliable data on neuropathy 
nor diabetic foot in primary care population. More patients from the outpatient clinic had 
a first-degree relative with T2DM compared to controls (64.4% vs. 33.3%, P<0.001).
Genetics
Table 3 shows the associations of 11 well-established genetic T2DM variants in our study 
population. Hardy-Weinberg’s equilibrium was met for all variants. With the exception 
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Table 1: General baseline characteristics of participants with and without T2DM
Cases Controls p-value
Number of participants 1886 854
Female sex, n (%) 874 (46.4) 511 (59.8) <0.001
Age, yr, median (IQR) 65.7 (58.5-72.9) 64.9 (60.4-69.4) 0.72
Age of onset diabetes, yr, median (IQR) 55 (47-63) N/A N/A
Duration of diabetes, yr, median (IQR) 8.1 (2.8-13.5) N/A N/A
BMI, kg/m2, median (IQR) 29.5 (26.4-32.7) 25.5 (23.3-27.7) <0.001
HbA1c, mmol/mol, median (IQR) 50.8 (43.7-57.9) 37.7 (36.1-39.3) <0.001
Diabetes treatment, % (n / n-available / n-missing)
No glucose-lowering medication
Oral glucose-lowering agent
Insulin
19.2 (340 / 1772 / 114)
64.3 (1140 /1773 / 113)
32.3 (572 / 1772 / 114)
N/A
N/A
N/A
N/A
N/A
N/A
Systolic blood pressure, mmHg, median (IQR) 140 (129-151) 137 (124-150) <0.001
Diastolic blood pressure, mmHg, median (IQR) 78 (71-85) 82 (76-89) <0.001
Total Cholesterol, mmol/L, median (IQR) 4.2 (3.6-4.8) 5.6 (4.9-6.2) <0.001
Triglycerides, mmol/L, median (IQR) 1.4 (0.9-2.0) 1.2 (0.9-1.5) <0.001
HDL-cholesterol, mmol/L, median (IQR) 1.1 (0.9-1.3) 1.4 (1.2-1.6) <0.001
LDL-cholesterol, mmol/L, median (IQR) 2.3 (1.8-2.8) 3.5 (2.9-4.1) <0.001
Creatinin, μmol/L, median (IQR) 78 (66-91) 72 (63-81) <0.001
eGFR < 60ml/min, % (n / n-available / n-missing) 21.2 (372 / 1756 / 130) 5.0 (40 / 795 / 59) <0.001
Cardiovascular disease, % (n / n-available / n-missing)
Any macrovascular disease
Ischemic heart disease
Ischemic brain disease
Peripheral arterial disease
38.0 (660 / 1738 / 148)
28.0 (497 / 1778 / 108)
12.0 (211 / 1757 / 129)
10.8 (193 / 1783 / 103)
8.3 (68 / 824 / 30)
4.9 (41 / 842 / 12)
1.4 (12 / 840 / 14)
2.2 (18 / 823 / 31)
<0.001
<0.001
<0.001
<0.001
Microvascular diabetes complications, % (n / n-available / n-missing)
Any microvascular disease
Diabetic retinopathy
Diabetic nephropathy
34.3 (561 / 1637 / 249)
17.3 (308 / 1778 / 108)
23.0 (387 / 1684 / 202)
N/A
N/A
N/A
N/A
N/A
N/A
Family history, % (n / n-available / n-missing)
First-degree relative with T2DM
First-degree relative with CVD
Any relative with early-onset CVD
64.4 (1104 / 1714 / 172)
68.3 (1086 / 1590 / 296)
45.0 (780 / 1732 / 154)
33.3 (269 / 809 / 45)
68.7 (519 / 755 / 99)
41.5 (342 / 825 29)
<0.001
0.87
0.09
Descent:
Caucasian descent, % (n / n-available / n-missing)
Age of death father, yr, median (IQR)
Age of death mother, yr, median (IQR)
91.9 (1613 / 1755)
73 (65-82)
78 (70-86)
96.1 (810 / 843 / 11)
75 (67-84)
81 (73-89)
<0.001
<0.001
<0.001
Table 1 shows baseline characteristics of participants from the DiaGene Study. BMI, body mass index; CVD, 
cardiovascular disease; eGFR, estimated glomerular filtration rate calculated with the Modification of Diet 
in Renal Disease-formula; IQR, interquartile range; n-total, total number of participants for whom informa-
tion was available; T2DM, type 2 diabetes mellitus; Yr, year.
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Table 2: general baseline characteristics of participants in primary care and hospital-based outpatient 
clinic at inclusion.
Primary Care Outpatient clinic p-value
Number of participants 1056 830
Female sex, n (%) 494 (46.8) 380 (45.9) 0.71
Age, yr, median (IQR) 65.5 (58.1-72.9) 65.9 (58.9-72.9) 0.66
Age of onset diabetes, yr, median (IQR) 59 (51-67) 51 (44-59) <0.001
Duration of diabetes, yr, median (IQR) 4.5 (1.2-7.9) 12.5 (7.2-17.8) <0.001
BMI, kg/m2, median (IQR) 29.0 (26.0-32.0) 30.2 (26.8-33.7) <0.001
HbA1c, mmol/mol, median (IQR) 48.6 (43.7-53.6) 56.3 (48.1-64.5) <0.001
Diabetes treatment, % (n / n-available / n-missing)
No medication
Oral glucose-lowering agents
Insulin
24.7 (248 / 1004 / 52)
72.9 (732 / 1004 / 52)
8.6 (86 / 1004 / 52)
12.0 (92 / 768 / 62)
53.1 (408 / 768 / 62)
63.3 (486 / 768 / 62)
<0.001
<0.001
<0.001
Systolic blood pressure, mmHg, median (IQR) 146 (133-159) 134 (126-143) <0.001
Diastolic blood pressure, mmHg, median (IQR) 79 (72-86) 75 (70-80) <0.001
Total Cholesterol, mmol/L, median (IQR) 4.2 (3.6-4.9) 4.1 (3.6-4.6) 0.047
Triglycerides, mmol/L, median (IQR) 1.4 (0.9-1.9) 1.5 (1.0-2.0) 0.104
HDL-cholesterol, mmol/L, median (IQR) 1.1 (0.9-1.3) 1.2 (1.0-1.4) 0.002
LDL-cholesterol, mmol/L, median (IQR) 2.5 (2.0-3.1) 2.1 (1.7-2.6) <0.001
Creatinin, μmol/L, median (IQR) 76 (64-88) 81 (67-95) <0.001
eGFR < 60ml/min % (n / n available/ n-missing) 16.4 (160/978/78) 27.2 (212/778/52) <0.001
Cardiovascular disease, % (n / n-available/ n-missing)
Any macrovascular disease
Ischemic heart disease
Ischemic brain disease
Peripheral arterial disease
34.8 (335 / 963 / 93)
25.2 (252 / 1000 / 56)
12.7 (124 / 973 / 83)
9.2 (88 / 958 / 98)
41.9 (325 / 775 / 55)
31.5 (245/ 778 / 52)
11.1 (87 / 784 / 46)
12.7 (105 / 825 / 5)
0.002
0.004
0.302
0.018
Microvascular diabetes complications, % (n / n-available / n-missing)
Any microvascular disease
Diabetic retinopathy
Diabetic nephropathy
Neuropathy
20.7 (172 / 830 / 226)
6.1 (59 / 962 / 94)
15.4 (134 / 868 / 188)
Unknown
48.2 (389 / 807 / 23)
30.5 (249 / 816 / 15)
31.0 (253 / 816 / 15)
31.2 (238 / 762 / 68)
<0.001
<0.001
<0.001
N/A
Family history, % (n / n-available / n-missing)
First-degree relative with T2DM
First-degree relative with CVD
Any relative with early-onset CVD
61.4 (586 / 955 / 101)
67.6 (608 / 899 / 157)
45.0 (436 / 968 / 88)
68.2 (518 / 759 / 71)
69.2 (478 / 691 / 139)
45.0 (344 / 764 / 66)
0.003
0.712
1.0
Descent
Caucasian descent, % (n / n-available / n-missing)
Age of death father, yr, median (IQR)
Age of death mother, yr, median (IQR)
90.3 (892 / 988 / 132 )
73 (65-82)
79 (72-87)
94.0 (721 / 767 / 63)
73 (65-82)
77 (69-85)
0.005
0.728
0.055
Table 2 shows baseline characteristics of participants from the DiaGene Study in both primary care and 
hospital-based outpatient clinic. BMI, body mass index; CVD, cardiovascular disease; eGFR, estimated glo-
merular filtration rate calculated with the Modification of Diet in Renal Disease-formula; HDL, high-density 
lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; n-total, total number of participants for 
whom information was available; T2DM, type 2 diabetes mellitus; Yr, year.
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of the variant in KCNJ11, all T2DM susceptibility variants had higher allele frequencies 
in cases with T2DM than in controls. TCF7L2 showed the highest odds ratio for prevalent 
T2DM (OR 1.37 (95%CI 1.17, 1.60; P<0.001). These results were unaffected by additional 
correction for center of inclusion. After calculation of interaction effects, the associations 
of all genetic variants except for KCNJ11 did not significantly differ from the large scale 
meta-analyses of Morris et al. [44].
DISCUSSION
In this manuscript, we present the baseline characteristics and future perspectives of the 
DiaGene study, a new multi-centre cohort study with prospective follow-up on biochemi-
cal and genetic determinants of T2DM and its complications. We show that the population 
is representing both primary and secondary care and that despite treatment, considerable 
rates of macrovascular and microvascular complications are present. To further elucidate 
determinants of T2DM and its complications, multi-layer omics and prospective analyses 
will be of great value. Our study offers excellent opportunities to perform these analyses.
In the Netherlands, primary care practices are led by general practitioners, who are eas-
ily accessible and offer essential family medicine. Outpatient clinics of hospitals provide 
specialized care and require referral by the general practitioner for reimbursement by 
insurance companies. Therefore, complex and more severely affected patients will be 
referred to the hospital-based outpatient clinics. This is reflected in the higher prevalence 
of micro- and macrovascular complications at the outpatient clinics in our population.
The risk of microvascular disease can be reduced substantially by glycemic control and 
general measures to prevent cardiovascular disease such as lifestyle, blood pressure and 
lipid optimization [22, 23, 25]. Rates of microvascular disease in our study at baseline were 
17.3%, 23.0% and 31% for retinopathy, nephropathy and neuropathy, respectively. This in-
cidence of retinopathy in T2DM is comparable to a report from the Dutch National Institute 
for Public Health and the Environment [45] and in line with a worldwide meta-analyses 
for diabetes with a duration of less than 10 years [46], but higher than in a screening 
study for T2DM from the Netherlands [47]. In the latter study, the duration of T2DM was 
short and this probably explains the difference. For nephropathy, our rate is slightly lower 
than in the United Kingdom Prospective Diabetes Study (25%), also probably because 
of shorter follow-up [16]. Our primary care population appeared to have lower rates of 
nephropathy compared to studies on prevalent diabetes and newly diagnosed diabetes 
in patients of general practitioners in the Netherlands [47, 48]. Although the single urinary 
measurement-based prevalence rates in the latter could be an explanation for this dis-
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crepancy. The percentage of patients with T2DM and neuropathy in our population (31%) 
is lower compared to a prospective study (50%) with 25 years of follow-up from diagnosis 
[19] and comparable to a cross-sectional study on peripheral neuropathy in the United 
Kingdom [49].
The risk of macrovascular disease in T2DM can be successfully reduced by applying lifestyle 
interventions, lipid lowering therapies and antihypertensive treatment. The relationship 
with glycemic control is more complex. Even though glycemic control epidemiologically is 
strongly related to cardiovascular disease in T2DM, interventions applying strict glycemic 
control were unsuccessful [22, 50] or even showed adverse effects [51]. Macrovascular 
disease rates in our population with T2DM is comparable to previous reports in the Neth-
erlands [45, 52], but lower than in an interview-based study in diabetes patients in the 
USA [53]. Our population is on average 5 years older than the patients in this American 
study, and also contains a significant proportion of patients from outpatient clinics having 
further progressed disease.
T2DM and its complications are multifactorial in their pathophysiology’s. Genetics, epi-
genetics, biological mechanisms and environmental factors are probably interacting at 
multiple levels. Therefore a pathway-based approach in well-defined cohorts is needed, 
supported by full use of information technology. High throughput research has been 
mainly focused on genome wide genetic associations. This has elucidated interesting as-
sociations. Yet the results only explain disease susceptibility to a small extent [31, 33]. We 
are planning to perform genome-wide association analysis in the near future. The qual-
ity control of this future genomic work will include analyses of the genetic-based ethnic 
background to definitively determine population sub-structures. Here, we restricted our 
analyses of well-known genetic T2DM risk variants to the sub-group of self-reported Cau-
casians. These DNA polymorphisms showed similar associations in our mainly Caucasian 
population as in previous extensive meta-analyses: most genetic variants had similar 
direction of their associations as earlier reported and for TCF7L2, THADA, KCNQ1 and 
CDKAL1 this was significant [32, 44, 54]. KCNJ11 and CENTD2 showed a slight but not sta-
tistically significant opposite association to what has previously described, with estimates 
close to 1 and confidence intervals embracing the estimates from literature [32]. Except 
for KCNJ11, all genetic variants had non-significant interaction effects for odds ratios of 
T2DM-risk variants compared to the latest meta-analysis [44]. The significant difference 
for KCNJ11 can be an effect of population-specific variance, differences in environmental 
factors, age or interactions of these factors with the genetic variant [44].
To study the aetiology of T2DM and its complications we need well phenotyped cohorts 
with prospective follow-up. Our population has these characteristics. We therefore plan to 
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analyse several omics layers for their associations with T2DM and its complications. We are 
currently measuring total N-glycomics with matrix-assisted laser desorption-ionization-
time of flight (MALDI-TOF), -Fourier transform ion cyclotron resonance mass spectrometry 
(MALDI-FTICR) [55] and IgG-glycomics with ultra-performance liquid chromatography 
[56]. In the near future, we aim to include lipidomics, with a focus on lipoprotein(a), me-
tabolomics, and proteomics. Also we plan to perform genomics using the Illumina chip, 
for mendelian randomization and multilayer interaction analyses. The overall goal being 
to elucidate new pathophysiological pathways for prediction, prevention and treatment 
of T2DM.
Although we have performed our study with precision, we need to consider a number 
of limitations. A large majority of our population is of self-reported Caucasian ethnicity, 
which limits extending conclusions from our analyses to non-Caucasian populations. 
However, it also makes our analyses less vulnerable to genetic population stratification 
bias. Self-reported Caucasian mono-ethnicity in two generations results in a very lim-
ited risk of misclassifying genetic admixtures [57, 58]. In addition, a small proportion of 
diabetes-free subjects where recruited by asking T2DM subjects to invite unrelated family 
members and friends. Hence, absence of family ties was self-reported, with a small pos-
sibility of hidden relatedness. In the near future, we will perform genome-wide association 
analysis, which will allow us to perform formal quality control and accurately account for 
hidden relatedness and genetic population stratification bias [59]. Another limitation of 
this study was our inability to retrieve information on neuropathy in primary care setting. 
Conclusions on neuropathy are therefore restricted to the secondary care setting. We have 
made extensive efforts to optimise the reliability of our data by having two independent 
investigators collect the data and reach consensus. This means we did have to rely on 
common clinical practice and adequate record keeping in primary and secondary care. For 
macrovascular events in primary care we had to rely on self-reported data. For validation, 
we have therefore checked self-reported myocardial infarction data from hospital-based 
participants and found that in only 6.0% of participants with self-reported myocardial 
infarction this diagnosis was not confirmed in hospital data. These events have therefore 
been scored as missing. Underestimation of the incidence of myocardial infarction based 
on hospital discharge data has however been described before [60]. And although the 
questionnaire on lifestyle, medication, clinical events and family history was straight-
forward and easy to use, it is not an externally validated questionnaire. At last, our prelimi-
nary genetic results had approximately 10% missing values. We are currently collecting 
additional samples from the participants whose DNA was not available at the time of the 
current genetic analysis to improve our genetic analysis. Further strengths of our study are 
the meticulous hands-on medical file review for each patient by two separate physicians, 
which produced high-quality data that enable us to research both T2DM itself as well as 
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its complications in great detail. Currently, we are finalizing the first collection prospec-
tive follow up on all T2DM complications. The prospective cohort setting with concurrent 
inclusion of diabetes-free individuals at baseline, will allow us to perform cross-sectional 
and prospective end-point analyses to study aetiology and progression of type 2 diabetes 
and its complications.
CONCLUSION
In conclusion, this manuscript describes the design and baseline characteristics of the 
DiaGene Study, a large multi-centre prospective follow-up cohort study on environmental, 
biochemical and genetic risk factors of T2DM and related vascular complications. By study-
ing both clinical and complex biochemical parameters with a current focus on glycomics, 
genomics and lipidomics, the DiaGene Study aims to contribute to the pathophysiological 
understanding of T2DM and all its vascular complications in a prospective case-control 
setting.
Chapter 6 111
Introduction of the DiaGene Study
REFERENCES
 1. Kahn CR: Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 
1994, 43(8):1066-1084.
 2. Stumvoll M, Goldstein BJ, van Haeften TW: Type 2 diabetes: pathogenesis and treatment. Lancet 
2008, 371(9631):2153-2156.
 3. Samuel VT, Shulman GI: The pathogenesis of insulin resistance: integrating signaling pathways and 
substrate flux. J Clin Invest 2016, 126(1):12-22.
 4. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB: Diabetes in Asia: epidemiology, risk 
factors, and pathophysiology. JAMA 2009, 301(20):2129-2140.
 5. da Rocha Fernandes J, Ogurtsova K, Linnenkamp U, Guariguata L, Seuring T, Zhang P, Cavan D, 
Makaroff LE: IDF Diabetes Atlas estimates of 2014 global health expenditures on diabetes. Diabetes 
Res Clin Pract 2016, 117:48-54.
 6. Flegal KM, Carroll MD, Ogden CL, Curtin LR: Prevalence and trends in obesity among US adults, 
1999-2008. JAMA 2010, 303(3):235-241.
 7. Narayan KM, Boyle JP, Geiss LS, Saaddine JB, Thompson TJ: Impact of recent increase in incidence 
on future diabetes burden: U.S., 2005-2050. Diabetes Care 2006, 29(9):2114-2116.
 8. Herman WH: The Global Burden of Diabetes: An Overview. In: Diabetes Mellitus in Developing Coun-
tries and Underserved Communities. edn. Edited by Dagogo-Jack S. Cham: Springer International 
Publishing; 2017: 1-5.
 9. Almdal T, Scharling H, Jensen JS, Vestergaard H: The independent effect of type 2 diabetes mellitus 
on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women 
with 20 years of follow-up. Arch Intern Med 2004, 164(13):1422-1426.
 10. Emerging Risk Factors C, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, 
Ingelsson E, Lawlor DA, Selvin E et al: Diabetes mellitus, fasting blood glucose concentration, and 
risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010, 
375(9733):2215-2222.
 11. Kannel WB, McGee DL: Diabetes and glucose tolerance as risk factors for cardiovascular disease: the 
Framingham study. Diabetes Care 1979, 2(2):120-126.
 12. Schramm TK, Gislason GH, Kober L, Rasmussen S, Rasmussen JN, Abildstrom SZ, Hansen ML, Folke 
F, Buch P, Madsen M et al: Diabetes patients requiring glucose-lowering therapy and nondiabetics 
with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 mil-
lion people. Circulation 2008, 117(15):1945-1954.
 13. Tancredi M, Rosengren A, Svensson AM, Kosiborod M, Pivodic A, Gudbjornsdottir S, Wedel H, Cle-
ments M, Dahlqvist S, Lind M: Excess Mortality among Persons with Type 2 Diabetes. N Engl J Med 
2015, 373(18):1720-1732.
 14. Ashfaq S, Ghazzal Z, Douglas JS, Morris DC, Veledar E, Weintraub WS: Impact of diabetes on five-year 
outcomes after vein graft interventions performed prior to the drug-eluting stent era. J Invasive 
Cardiol 2006, 18(3):100-105.
 15. Chun BY, Dobson AJ, Heller RF: The impact of diabetes on survival among patients with first myocar-
dial infarction. Diabetes Care 1997, 20(5):704-708.
112 PART IV
Type 2 diabetes mellitus: Risk factors and complications 
 16. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, Ukpds G: Development and 
progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study 
(UKPDS 64). Kidney Int 2003, 63(1):225-232.
 17. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL: The Wisconsin epidemiologic study of diabetic 
retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more 
years. Arch Ophthalmol 1984, 102(4):527-532.
 18. Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M: Natural history of periph-
eral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995, 
333(2):89-94.
 19. Pirart J: [Diabetes mellitus and its degenerative complications: a prospective study of 4,400 pa-
tients observed between 1947 and 1973 (author’s transl)] Diabete et complications degeneratives 
presentation d’une etude prospective portant sur 4400 cas observes entre 1947 et 1973. (Premiere 
partie). Diabete Metab 1977, 3(2):97-107.
 20. Standards of Medical Care in Diabetes-2016: Summary of Revisions. Diabetes Care 2016, 39 Suppl 
1:S4-5.
 21. Sluiter A vWH, Arntzenius A, Bots A, Dijkhorst-Oei L, van der Does F, Palmen J, Potter van Loon BJ, 
Schaper N, van Balen J: Dutch National Transmural Agreement (LTA) on type 2 diabetes mellitus. 
Dutch national society of general practitioners 2012, 55(1):S1-S12.
 22. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional 
treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective 
Diabetes Study (UKPDS) Group. Lancet 1998, 352(9131):837-853.
 23. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 
diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998, 317(7160):703-713.
 24. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, 
Mackness MI, Charlton-Menys V, Fuller JH et al: Primary prevention of cardiovascular disease with 
atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicen-
tre randomised placebo-controlled trial. Lancet 2004, 364(9435):685-696.
 25. Heart Protection Study Collaborative G: MRC/BHF Heart Protection Study of cholesterol lowering 
with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 
2002, 360(9326):7-22.
 26. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, Woodward M, MacMahon S, Blood 
Pressure Lowering Treatment Trialists C: Effects of different blood pressure-lowering regimens on 
major cardiovascular events in individuals with and without diabetes mellitus: results of prospec-
tively designed overviews of randomized trials. Arch Intern Med 2005, 165(12):1410-1419.
 27. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW: Achievement of goals in U.S. 
diabetes care, 1999-2010. N Engl J Med 2013, 368(17):1613-1624.
 28. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose 
control in type 2 diabetes. N Engl J Med 2008, 359(15):1577-1589.
 29. Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, Woodward M, MacMahon S, Turnbull F, Hillis GS 
et al: Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated 
systematic review and meta-analysis. Lancet 2016, 387(10017):435-443.
Chapter 6 113
Introduction of the DiaGene Study
 30. Ziaeian B, Dinkler J, Guo Y, Watson K: The 2013 ACC/AHA Cholesterol Treatment Guidelines: Ap-
plicability to Patients with Diabetes. Curr Diab Rep 2016, 16(2):13.
 31. Kwak SH, Park KS: Recent progress in genetic and epigenetic research on type 2 diabetes. Exp Mol 
Med 2016, 48:e220.
 32. Billings LK, Florez JC: The genetics of type 2 diabetes: what have we learned from GWAS? Ann N Y 
Acad Sci 2010, 1212:59-77.
 33. McCarthy MI: Genomics, type 2 diabetes, and obesity. N Engl J Med 2010, 363(24):2339-2350.
 34. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complica-
tions. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consulta-
tion. Diabet Med 1998, 15(7):539-553.
 35. American Diabetes A: Diagnosis and classification of diabetes mellitus. Diabetes Care 2011, 34 
Suppl 1:S62-69.
 36. Sims DS, Jr., Cavanagh PR, Ulbrecht JS: Risk factors in the diabetic foot. Recognition and manage-
ment. Phys Ther 1988, 68(12):1887-1902.
 37. Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, Zeggini E, Huth C, Aulchenko 
YS, Thorleifsson G et al: Twelve type 2 diabetes susceptibility loci identified through large-scale 
association analysis. Nature Genetics 2010, 42(7):579-589.
 38. Diabetes Genetics Initiative of Broad Institute of H, Mit LU, Novartis Institutes of BioMedical R, Sax-
ena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, Roix JJ et al: Genome-wide association 
analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007, 316(5829):1331-1336.
 39. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, Erdos MR, Stringham HM, Chines PS, 
Jackson AU et al: A genome-wide association study of type 2 diabetes in Finns detects multiple 
susceptibility variants. Science 2007, 316(5829):1341-1345.
 40. Yasuda K, Miyake K, Horikawa Y, Hara K, Osawa H, Furuta H, Hirota Y, Mori H, Jonsson A, Sato Y et 
al: Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nature Genetics 
2008, 40(9):1092-1097.
 41. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T, de Bakker PI, Abecasis GR, Almgren P, 
Andersen G et al: Meta-analysis of genome-wide association data and large-scale replication identi-
fies additional susceptibility loci for type 2 diabetes. Nature Genetics 2008, 40(5):638-645.
 42. Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, Timpson NJ, Perry JR, Rayner 
NW, Freathy RM et al: Replication of genome-wide association signals in UK samples reveals risk loci 
for type 2 diabetes. Science 2007, 316(5829):1336-1341.
 43. Altman DG, Bland JM: Interaction revisited: the difference between two estimates. BMJ 2003, 
326(7382):219.
 44. Morris AP, Voight BF, Teslovich TM, Ferreira T, Segre AV, Steinthorsdottir V, Strawbridge RJ, Khan 
H, Grallert H, Mahajan A et al: Large-scale association analysis provides insights into the genetic 
architecture and pathophysiology of type 2 diabetes. Nature Genetics 2012, 44(9):981-990.
 45. Dutch National Institute for Public Health and the Environment (RIVM) on Health indicators in 
prevention and Diabetes Care. Governmental report 2006.
 46. Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletcher A, 
Grauslund J et al: Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 
2012, 35(3):556-564.
114 PART IV
Type 2 diabetes mellitus: Risk factors and complications 
 47. Spijkerman AM, Dekker JM, Nijpels G, Adriaanse MC, Kostense PJ, Ruwaard D, Stehouwer CD, Bouter 
LM, Heine RJ: Microvascular complications at time of diagnosis of type 2 diabetes are similar among 
diabetic patients detected by targeted screening and patients newly diagnosed in general practice: 
the hoorn screening study. Diabetes Care 2003, 26(9):2604-2608.
 48. Ubink-Veltmaat LJ, Bilo HJ, Meyboom-de Jong B: [Microalbuminuria in patients with type 2 diabe-
tes mellitus in general practice] Microalbuminurie bij patienten met diabetes mellitus type 2 in de 
huisartspraktijk. Ned Tijdschr Geneeskd 2004, 148(41):2026-2030.
 49. Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH: A multicentre study of the prevalence 
of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 
1993, 36(2):150-154.
 50. Action to Control Cardiovascular Risk in Diabetes Study G, Gerstein HC, Miller ME, Byington RP, Goff 
DC, Jr., Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F et al: Effects of intensive glucose 
lowering in type 2 diabetes. N Engl J Med 2008, 358(24):2545-2559.
 51. Group AC, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, 
Glasziou P et al: Intensive blood glucose control and vascular outcomes in patients with type 2 
diabetes. N Engl J Med 2008, 358(24):2560-2572.
 52. Spijkerman AM, Henry RM, Dekker JM, Nijpels G, Kostense PJ, Kors JA, Ruwaard D, Stehouwer CD, 
Bouter LM, Heine RJ: Prevalence of macrovascular disease amongst type 2 diabetic patients de-
tected by targeted screening and patients newly diagnosed in general practice: the Hoorn Screen-
ing Study. J Intern Med 2004, 256(5):429-436.
 53. Gregg EW, Cheng YJ, Saydah S, Cowie C, Garfield S, Geiss L, Barker L: Trends in death rates among 
U.S. adults with and without diabetes between 1997 and 2006: findings from the National Health 
Interview Survey. Diabetes Care 2012, 35(6):1252-1257.
 54. Fuchsberger C, Flannick J, Teslovich TM, Mahajan A, Agarwala V, Gaulton KJ, Ma C, Fontanillas P, 
Moutsianas L, McCarthy DJ et al: The genetic architecture of type 2 diabetes. Nature 2016.
 55. Wuhrer M: Glycomics using mass spectrometry. Glycoconj J 2013, 30(1):11-22.
 56. Pucic M, Knezevic A, Vidic J, Adamczyk B, Novokmet M, Polasek O, Gornik O, Supraha-Goreta S, 
Wormald MR, Redzic I et al: High throughput isolation and glycosylation analysis of IgG-variability 
and heritability of the IgG glycome in three isolated human populations. Mol Cell Proteomics 2011, 
10(10):M111 010090.
 57. Mersha TB, Abebe T: Self-reported race/ethnicity in the age of genomic research: its potential 
impact on understanding health disparities. Hum Genomics 2015, 9:1.
 58. Sinha M, Larkin EK, Elston RC, Redline S: Self-reported race and genetic admixture. N Engl J Med 
2006, 354(4):421-422.
 59. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D: Principal components analy-
sis corrects for stratification in genome-wide association studies. Nature Genetics 2006, 38(8):904-
909.
 60. Merry AH, Boer JM, Schouten LJ, Feskens EJ, Verschuren WM, Gorgels AP, van den Brandt PA: Valid-
ity of coronary heart diseases and heart failure based on hospital discharge and mortality data in 
the Netherlands using the cardiovascular registry Maastricht cohort study. Eur J Epidemiol 2009, 
24(5):237-247.
Chapter 6 115
Introduction of the DiaGene Study
Supplementary material: Flow chart of the inclusion of cases and controls
DM, diabetes mellitus; MODY, Maturity-Onset Diabetes of the Young; Latent Auto-immune Diabetes of the 
Adult

Chapter 7
A genetic variant in SLC6A20 is associated 
with type 2 diabetes in White European 
and Chinese populations
Yan Ling
Thijs T.W. van Herpt
Mandy van Hoek
Abbas Dehghan
Albert Hofman
Andre G. Uitterlinden
Sunfang Jiang
Aloysius G. Lieverse
Bert Bravenboer
Daru Lu
Cornelia M. van Duijn
Xin Gao
Eric J.G. Sijbrands
Diabetic Medicine 2014 Nov;31(11):1350-6
118 PART IV
Type 2 diabetes mellitus: Risk factors and complications 
ABSTRACT
Introduction: SLC6A20 is a proline transporter and is an essential component of proline 
metabolism. In a recent metabolic study, reduced SLC6A20 activity was found related 
to type 2 diabetes in primates and mice. However, its role in the pathogenesis of type 2 
diabetes in humans is unclear. We investigated whether polymorphisms in SLC6A20 are 
associated with susceptibility to type 2 diabetes.
Methods: In the Rotterdam Study, a prospective, population-based cohort (n=5974), 22 
tagging polymorphisms with minor allele frequencies>0.05 across SLC6A20 were studied. 
Replication studies were performed in an independent Dutch case-control study (Dia-
Gene-Rotterdam Study 2 n=3133), and in a Chinese Han case-control population(n=2279). 
Finally, meta-analysis was performed.
Results: In the Rotterdam Study, the minor alleles of rs13062383, rs10461016 and 
rs2286489 increased risk of type 2 diabetes (HR=1.37 (95%CI 1,15-1,63), HR1,30 (95% CI 
1,09-1,54) and HR 1,20 (95% CI 1,07-1,35, respectively). In DiaGene/Rotterdam Study 2, 
the A allele of rs13062383 increased risk of type 2 diabetes (OR=1.45, 95% CI 1.19–1.76). In 
the Chinese Han study, rs13062383 A allele also increased risk of type 2 diabetes (OR=1.21, 
95% CI 1.03–1.42). Meta-analysis showed a highly significant association of rs13062383 
with type 2 diabetes (OR=1.35, 95% CI 1.21–1.47, p=3.3×10-8).
Conclusions: In conclusion, rs13062383 in SLC6A20 increased the susceptibility to type 2 
diabetes in populations with different genetic backgrounds
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INTRODUCTION
Solute carrier family 6 (SLC6) is one of the largest membrane transporter families in the 
human genome and comprises 20 members. [1] Recently, the SLC6A20 kidney transporter 
was shown have reduced activity in type 2 diabetes in primates and mice.[2] However, the 
role of SLC6A20in relation to type 2 diabetes in humans is unclear.
SLC6A20 is a proline transporter and is an essential component of proline metabolism.
[1] Proline may influence glucose homeostasis through metabolic pathways that involve 
glutamine and arginine, amino acids involved in gluconeogenesis and energy homeosta-
sis.[3,4] Moreover, it has been shown that the well-replicated type 2 diabetes risk gene 
HNF1ɑ, is an important regulator of SLC6A20.[5]
In this study, we hypothesized that variants in the SLC6A20 gene may influence type 2 
diabetes risk. Therefore, we investigated whether variants in the SLC6A20 gene contribute 
to the risk of type 2 diabetes. Our discovery population is a prospective population-based 
study in white Europeans. Significant findings were taken forward to a white European 
and a Chinese replication population.
SUBJECTS AND METHODS
Study population
Details of the original Rotterdam Study (RS1) have been described previously.[6] In brief, 
the Rotterdam Study is an ongoing prospective, population-based, cohort study on 7,983 
inhabitants of a suburb in Rotterdam, designed to investigate determinants of chronic 
diseases in the elderly. Participants were aged 55 years or older. Continuous surveillance 
on major disease outcomes was conducted between these examinations. Information on 
vital status was derived from municipal health authorities.
Replication studies
The first replication study was performed in a combined case-control sample of cases of 
the DiaGene Study, and controls from the second phase of the Rotterdam Study (RS2). The 
DiaGene study is an ongoing collection of population-based cases with type 2 diabetes from 
Eindhoven, the Netherlands, and has been described previously.[7] RS2 refers to persons in 
the Rotterdam Study district that became 55 years since the start of the study or those of 55 
years or over that migrated into the study district. This cohort comprises 3,011 participants 
and started in 1999.[6] Persons without diabetes from the RS2 cohort served as controls in a 
combined case-control sample with the DiaGene study, as described and validated earlier.[7]
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The second replication study included a total of 2279 individuals of Chinese Han ancestry 
who were residents in Shanghai, China, comprising 1118 persons with type 2 diabetes 
and 1161 normoglycaemic controls.[8] The cases were inpatients from the department 
of Endocrinology and Metabolism of Zhongshan hospital, Shanghai, China. Controls were 
people undergoing health examinations in Zhongshan hospital, Shanghai, China. The 
controls were older than 40 years and had fasting glucose below 5.6 mmol/l.
Written informed consent was obtained from all participants and all studies were ap-
proved by the local ethic committees.
Diabetes
In accordance with the guidelines of the World Health Organization and the American 
Diabetes Association[9,10], diabetes was diagnosed as fasting plasma glucose levels ≥7.0 
mmol/l or a non-fasting plasma glucose levels ≥11.0 mmol/l or treatment with antidia-
betic medication (oral medication or insulin) or a diagnosis of diabetes as registered by a 
general practitioner in the Rotterdam Study (RS1 and RS2), in the DiaGene study and in the 
Chinese Han population.
In all populations, type 1 diabetes and other known subtypes of diabetes were excluded 
based on general practitioners and specialists records.
Genotyping
For the first phase of the study, we selected tagging single nucleotide polymorphisms 
(SNPs) with R2=1 and minor allele frequency>0.05 across the region of SLC6A20 (include 
20kb upstream and 10kb downstream of the gene) from HapMap Phase II, using the pair-
wise tagging model in Haploview.[11] Overall, 22 tagging SNPs were chosen and available 
in Illumina 550K genotyping BeadChip version3 in 5974 subjects. (complete list of SNPs in 
Supplementary Table 1)
In RS1 and RS2, participants with proper quality DNA samples were considered for geno-
typing using the Infinium II HumanHap 550K Genotyping BeadChip® version 3 (Illumina, 
San Diego, USA). After quality control genotyped data was available for 5974 individuals in 
RS1 and 2157 individuals in RS2.
In the DiaGene Study, DNA material was available for 1472 cases with type 2 diabetes. Taq-
Man allelic discrimination assays were used for genotyping of significant findings from the 
first phase. The assays were designed and optimized by Applied Biosystems (Foster City, 
CA, USA; http://store.appliedbiosystems.com). Reactions were performed on the Taqman 
Prism 7900HT platform.
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In the Chinese Han population, genotyping was performed by primer extension of multi-
plex products with detection by matrix-assisted laser desorption/ionization time-of-flight 
mass spectroscopy using a MassARRAY platform (MassARRAY Compact Analyzer, Seque-
nom, San Diego, CA, USA).
Statistical analysis
Analyses were performed with SPSS version 12.0.1. Continuous variables are expressed 
as means ± SEM. ANOVA was used for comparisons of continuous variable and chi-square 
tests were used for comparisons of categorical variables between groups. Deviation from 
Hardy–Weinberg equilibrium was assessed using chi-square tests. SNPs that were not in 
Hardy-Weinberg equilibrium were excluded from further analyses. Pairwise linkage dis-
equilibrium (LD) including D’ and r2 were estimated by Haploview4.1.[11]
In RS1, we tested the association of the polymorphisms with type 2 diabetes risk in Cox 
proportional hazards models. Participant with diabetes at baseline were excluded from 
the analyses. (n=631) We used a Bonferroni correction (0.05/19=0.0026) to adjust for 
multiple testing.
In both replication studies, we tested the association of the SNPs with type 2 diabetes 
using logistic regression models. All models were corrected for year of birth and sex. Ad-
ditional models were corrected for BMI.
We performed a meta-analysis to combine the measure of effects from all three studies. 
To have comparable measures of effects, we calculated the ORs for RS1 using a logistic 
regression model, adjusted for the follow-up time. An inverse variance weighting method 
was used to combine the statistical information from the three independent data sets. 
Package “meta” , running under “R”, was used to perform the meta-analysis.[12] We used 
the I2 index to quantify the degree of heterogeneity. The I2 statistic describes the percent-
age of variation across studies that is due to heterogeneity rather than chance.[13,14]
RESULTS
General characteristics
In 5974 genotyped participants of RS1, 10.3% developed diabetes during follow-up. A total 
of 666 individuals were excluded of which 631 had prevalent diabetes at baseline, and 35 
had no available data on their diabetes status. (Mean follow-up time20.6years)
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The DiaGene study- RS2 replication cohort contained 1472 cases and 1661 controls from 
RSII. The Chinese Han replication study comprised 2279 participants of which 1118 were 
type 2 diabetes cases and 1161 were healthy controls. The baseline characteristics of all 
three populations are presented in Table 1.
Discovery analyses
In RS1, 19 genotyped SNPs were in Hardy–Weinberg equilibrium(ꭓ2<2.362, df=1, p>0.12) 
in the total population and in individuals without type 2 diabetes. Three SNPs (rs6770261, 
rs2531747 and rs12488144) deviated from Hardy–Weinberg equilibrium, and were ex-
cluded.
Out of 19 SNPs, 3 were significantly associated with the risk of type 2 diabetes (Table 2). 
The minor alleles of rs13062383, rs10461016 and rs2286489 increased the risk of type 2 
diabetes (HR=1.37, 95% CI 1.15-1.63, p=4.5×10-4; HR=1.30, 95% CI 1.09-1.54, p=0.003; 
HR=1.20, 95% CI 1.07-1.35, p=0.003, respectively). The association of rs13062383 and 
rs2286489 with type 2 diabetes remained significant after additional adjustment for BMI 
(HR=1.34, 95% CI 1.13-1.60, p<9.1×10-4; HR=1.19, 95% CI 1.06-1.35, p=0.004, respectively).
After Bonferroni correction only the association of rs13062383 remained significant and 
was taken forward for replication.
The replication of rs13062383 in white Europeans
Genotyping success rate was 97.9% for rs13062383 in the DiaGene/RS2 replication study 
and was in Hardy–Weinberg equilibrium in the total population and in controls (ꭓ2<2.259, 
df=1, p=0.13). The A allele of rs13062383 increased the risk of type 2 diabetes (OR=1.45, 
95% CI 1.19–1.76, p=0.0001) (Table 2). Additional adjustment for BMI did not change the 
results.
The replication of 13062383 in the Chinese Han population.
Genotyping success rate was 98.5% for rs13062383 in the Chinese Han replication study. 
It was in Hardy–Weinberg equilibrium in the total population and in controls (ꭓ2=0.264, 
df=1, p=0.61). The A allele of rs13062383 increased the risk of type 2 diabetes adjusted for 
year of birth and sex (OR=1.21, 95% CI 1.03–1.42, p=0.02). The association became more 
significant after additional adjustment for BMI (OR=1.26, 95% CI 1.07–1.49, p=0.007) (Table 
2).
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Table 2 Risk of type 2 diabetes by SLC6A20 alleles in the Rotterdam Study, the DiaGene study and the 
Shanghai replication study
Study Allele Non-diabetes 
(%)
Diabetes 
(%)
HR/OR1* 95% CI p value
Rotterdam rs12490575
Study G 85.9 86.6 1 (Ref.)
A 14.1 13.4 0.95 0.80-1.13 0.58
rs17213127
G 95.3 95.4 1 (Ref.)
A 4.7 4.6 1.00 0.75-1.32 0.98
rs13062383
G 89.8 86.4 1 (Ref.)
A 10.2 13.6 1.37 1.15-1.63 4.5 × 10-4
rs4327428
C 89.7 89.4 1 (Ref.)
A 10.3 10.6 1.017 0.84-1.23 0.86
rs17279465
A 56.7 60.2 1 (Ref.)
G 43.3 39.8 0.86 0.76-0.97 0.01
rs10461016
A 89.1 85.9 1 (Ref.)
G 10.9 14.1 1.30 1.09-1.54 0.003
rs2286489
A 62.7 57.8 1 (Ref.)
G 37.3 42.2 1.20 1.07-1.35 0.003
rs13067466
A 82.7 81.2 1 (Ref.)
C 17.3 18.8 1.09 0.93-1.26 0.29
rs2191028
G 61.8 66.1 1 (Ref.)
A 38.2 33.9 0.84 0.74-0.95 0.01
rs2531742
G 61.5 59.9 1 (Ref.)
A 38.5 40.1 1.08 0.95-1.21 0.24
rs2191027
G 69.8 73.3 1 (Ref.)
A 30.2 26.7 0.85 0.74-0.97 0.02
rs2531748
A 66.5 66.1 1 (Ref.)
G 33.5 33.9 1.02 0.90-1.16 0.72
rs720625
Chapter 7 125
A genetic variant in SLC6A20 is associated with type 2 diabetes in White European and Chinese populations
Table 2 Risk of type 2 diabetes by SLC6A20 alleles in the Rotterdam Study, the DiaGene study and the 
Shanghai replication study (continued)
Study Allele Non-diabetes 
(%)
Diabetes 
(%)
HR/OR1* 95% CI p value
A 62.3 63.0 1 (Ref.)
G 37.7 37.0 0.99 0.88-1.12 0.88
rs9843503
A 92.8 93.1 1 (Ref.)
C 7.2 6.9 0.96 0.76-1.22 0.75
rs17078339
A 71.3 71.6 1 (Ref.)
G 28.7 28.4 1.01 0.88-1.15 0.94
rs4299518
A 52.7 56.3 1 (Ref.)
G 47.3 43.7 0.86 0.76-0.97 0.02
rs2531757
C 67.8 66.8 1 (Ref.)
A 32.2 33.2 1.05 0.93-1.20 0.41
rs9848415
G 75.0 76.1 1 (Ref.)
A 25.0 23.9 0.97 0.84-1.11 0.64
rs2159272
A 56.9 57,8 1 (Ref.)
G 43.1 42.2 0.99 0.87-1.11 0.81
DiaGene Rs13062383
Study G 93.6 90.8 1 (Ref.)
A 6.4 9.2 1.45 1.19-1.76 0.0001
Shanghai rs13062383
Replication G 86.2 83.9 1 (Ref.)
Study A 13.8 16.1 1.21 1.03-1.42 0.02
All studies rs13062383
G 1 (Ref.)
A 1.35 1.21 - 1.50 3.3 × 10-8
* Adjusted for year of birth and sex
HR: hazard ratio OR: odds ratio CI: confidence interval
HR for the Rotterdam Study; OR for the replication studies
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Meta-analysis
A heterogeneity test for rs13062383 ORs was performed on the three cohorts, and was 
found to be homogenous (I2 = 7.4%). Meta-analysis was performed using the fixed effects 
model. The combined OR was 1.35 (95% CI 1.21–1.50, p=3.3×10-8).
DISCUSSION
We showed in a large cohort study of white Europeans that individual genetic variants in 
SLC6A20 are associated with risk of type 2 diabetes. One of the variants, rs13062383, repli-
cated in an independent Dutch white European population and a Chinese Han population. 
In the combined analysis of this SNP, the minor allele associated with 35% increased risk 
of type 2 diabetes and this finding was highly significant.
There are a number of pathways through which SLC6A20 may influence type 2 diabetes 
risk. SLC6A20 is an essential component in the metabolism of proline.[1] First, proline is 
synthesized from dietary glutamate and can interconvert with glutamate via the mito-
chondrial pathway involving pyrroline-5-carboxylate.[15,16] Glutamate and glutamine are 
major gluconeogenic precursors in the kidney[4,17] and the small intestine[18], contribut-
ing to at least 50% of the endogenous glucose production in insulinopenic states, such as 
fasting[19] and diabetes[20]. Changes in the metabolism of proline, may therefore affect 
gluconeogenesis in kidney and small intestine. Second, proline is also an important sub-
strate for the synthesis of arginine, the exclusive substrate for the synthesis of nitric oxide 
(NO). Emerging evidence shows that the arginine-NO pathway is involved in the regulation 
of the metabolism of glucose, fatty acids and amino acids in mammals.[3,21] Third, a re-
cent metabolomic study revealed that SLC6A20 kidney expression was reduced in primate 
and mouse models of type 2 diabetes without the presence of damage to the proximale 
tubular architecture secondary to type 2 diabetes.[2] In this study, increased levels of 
glycine betaine, proline, pipecolic acid and glucose were found in urine. Moreover, HNF1 , 
a genome-wide proven risk locus for type 2 diabetes and the causative gene for MODY3, 
has been shown to be a regulator of SLC6A20.[5] Taken together, we think SLC6A20 is a 
promising candidate gene for type 2 diabetes.
Rs13062383 is located in intron 4 of SLC6A20. In a genome-wide association study on urine 
metabolic traits an association between a nonsynonimus functional variant (rs 17279437) 
in SLC6A20 and N-N-dimethylglycine was found in healthy subjects.[22] This variant is 
tagged by rs4327428, which was not associated with T2D in our study. However, it is dif-
ficult to speculate on the exact mechanisms by which variation in the SLC6A20 gene influ-
ences T2D risk and how this relates to the transport of specific imino acids. Rs13062383 
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may be linked to one or more functional variants within the SLC6A20 gene or its regulatory 
regions. The haploblock in which rs13062383 resides contains the 3’UTR of the gene. There 
is evidence showing that 3’UTRs are particularly rich in regulatory elements.[23]
We have studied populations with different genetic backgrounds and found similar effect 
sizes for the associated polymorphism, with no signs of heterogeneity across studies. 
Haploblock plots of SLC6A20 show a similar genetic architecture of the gene in Asians and 
Caucasians. Despite the fact that rs13062383 had a highly significant p-value in our meta-
analysis, the variant has not been related to diabetes risk in large-scale genome-wide 
meta-analyses such as DIAGRAM+, in which RS1 has been a discovery population.[24] A 
regional plot from DIAGRAM+ results does show a modest, non-significant peak in the area 
of the SLC6A20 gene (Supplementary Figure 1. Derived from http://diagram-consortium.
org/downloads.html). Additional age-stratified analyses in our discovery population 
showed a stronger association in the older half of the population (HR 1.42, 95%CI 1.12-
1.79; p=0.004) compared to the younger half (HR 1.20, 95% CI 0.94-1.55, p=0.15) (stratified 
into two equally sized groups with cut off age of 67.7) . Age-stratified analyses in both 
replication cohorts generated similar results.(data not shown) Since the DIAGRAM+ meta-
analyses contain studies with different age-ranges this might explain why this particular 
SNP did not reach significance in DIAGRAM+. This means we must bear in mind that our 
finding may not be generalizable to younger populations. Although association studies 
cannot fully exclude false positive findings, the small p-value reduces the risk of such an 
erroneous observation.
Strengths of our study include a prospective population-based design in the discovery 
analyses with up to 10 years of follow-up, and large sample sizes in the following replica-
tion studies. Moreover, we were able to study the genetic variant in independent popula-
tions with different lifestyles and genetic backgrounds.
Unfortunately, we did not have patient material available to investigate proline and 
other related metabolites in urine in relation to the polymorphism, to study the underlying 
mechanism. This may be an interesting next step for future studies on the subject.
In conclusion, this is the first report describing a highly significant relationship between a 
SLC6A20 polymorphism and type 2 diabetes in white European, as well as Chinese individu-
als. Our finding highlights the proline pathway in glucose homeostasis and susceptibility 
to type 2 diabetes.
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ABSTRACT
Introduction: ADAMTS13 is a protease that breaks down von Willebrand factor (VWF) 
multimers into smaller, less active particles. VWF has been associated with an increased 
risk of incident type 2 diabetes mellitus. Here, we determine the association of ADAMTS13 
activity and VWF antigen with incident diabetes.
Methods: The study included 5,176 participants of the Rotterdam Study, a prospective 
population-based cohort study. Participants were free of diabetes at baseline and fol-
lowed up for more than 20 years. Cox proportional hazards models were used to examine 
the association of ADAMTS13 activity and VWF antigen with incident diabetes.
Results: ADAMTS13 activity was associated with an increased risk of incident diabetes (HR: 
1.17; 95%CI: 1.08 to 1.27) after adjustment for known risk factors and VWF antigen. Al-
though ADAMTS13 activity was positively associated with fasting glucose and insulin, the 
association with incident diabetes did not change when we adjusted for these covariates. 
ADAMTS13 activity was also associated with incident prediabetes after adjustment for 
known risk factors (HR: 1.11; 95%CI: 1.03, 1.19), while VWF antigen was not. VWF antigen 
was associated with incident diabetes, but this association was attenuated when adjusted 
for known risk factors.
Conclusions/interpretation: ADAMTS13 activity appears to be an independent risk factor 
for incident prediabetes and type 2 diabetes. As the association between ADAMTS13 and 
diabetes did not appear to be explained by its cleavage of VWF, ADAMTS13 may have an 
independent role in the development of diabetes.
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INTRODUCTION
ADAMTS13 (A Disintegrin And Metalloprotease with a ThromboSpondin type 1 motif, 
member 13) reduces the activity of von Willebrand factor (VWF) in platelet adhesion and 
aggregation by cleaving prothrombotic VWF multimers [1, 2]. Low ADAMTS13 levels and 
activity are associated with an increased risk of various thrombotic diseases, including 
ischemic stroke and myocardial infarction [3-8], as well as kidney disease [9]. Addition-
ally, low ADAMTS13 activity may contribute to renal and cardiovascular complications of 
diabetes [10-12]. The association of ADAMTS13 with diabetes itself remains unexplored. 
Elevated levels of VWF have been associated with an increased risk of type 2 diabetes 
[13-17] which has been attributed primarily to VWFs role as a marker of endothelial 
dysfunction rather than its role in thrombosis [18]. However, VWF may also be associ-
ated with diabetes through its prothrombotic effect. This would be in line with emerging 
evidence that vascular disease may contribute to the development of diabetes [19]. Low 
ADAMTS13 activity and high VWF levels may exacerbate small vessel disease, which in turn 
may contribute to the development of diabetes [20-22]. If VWF is associated with diabetes 
through its prothrombotic function, then we expect ADAMTS13, with its antithrombotic 
function, to be inversely associated with the risk of diabetes. On the other hand, still little 
is known about the regulation of ADAMTS13 and its role as a marker of other physiological 
processes[23]. We previously showed that type 2 diabetes patients have higher ADAMTS13 
activity than controls [8] [23], which is inconsistent with a mechanism involving VWF’s 
prothrombotic function.
Nevertheless, the association may also reflect a response to diabetes, and studies on inci-
dent diabetes are needed to provide further insight into the direction of this association. 
In this study, we examined whether ADAMTS13 activity or VWF antigen levels associate 
with risk of type 2 diabetes in a large prospective population-based cohort study.
METHODS
Study description and population
The Rotterdam Study is a prospective population-based cohort study initiated in 1990 to 
study the determinants of several chronic diseases in older adults [24]. The first cohort 
(RS-I) includes 7,983 inhabitants of Ommoord, a district of Rotterdam in the Netherlands, 
who were 55 years or older. The first examination took place between 1990 and 1993. The 
third visit, including 4,797 participants, took place between March 1997 and December 
1999, and was used as the baseline in this study. The second cohort (RS-II) established 
between February 2000 and December 2001, includes another 3,011 inhabitants of 
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Ommoord who either reached the age of 55 years after the recruitment phase of RS-I or 
who had migrated into the research area. There were no eligibility criteria to enter the 
Rotterdam Study except age and residential area (postal code). The Rotterdam Study has 
been approved by the Medical Ethics Committee of the Erasmus MC and by the Ministry 
of Health, Welfare and Sport of the Netherlands, implementing the Wet Bevolkingsonder-
zoek: ERGO (Population Studies Act: Rotterdam Study). All included participants provided 
written informed consent to participate in the study and to obtain information from their 
treating physicians.
Ascertainment of prediabetes and diabetes
iabetes, prediabetes and normoglycemia were defined according to the most recent WHO 
guidelines [25]. Prediabetes was defined as a fasting blood glucose between 6.0 mmol/L 
and 7.0 mmol/L or a non-fasting blood glucose between 7.7 mmol/L and 11.1 mmol/L 
(when fasting samples were absent); diabetes was defined as a fasting blood glucose higher 
than 7.0 mmol/L, a non-fasting blood glucose ≥ 11.1 mmol/L (when fasting samples were 
absent), or the use of blood glucose lowering medication. Prevalent and incident diabetes 
and prediabetes were ascertained using records kept by general practitioners, hospital 
discharge letters, pharmacy records, home interviews, and fasting glucose measurements 
performed at our research center during baseline and follow-up visits [26]. Information 
regarding the use of blood glucose lowering medication was derived from both home 
interviews and pharmacy records [26]. A schematic representation of the follow-up design 
is provided in Supplementary Figure 1. At baseline, more than 99% of the Rotterdam 
Study population was covered by the pharmacies in the study area. All potential events of 
prediabetes and diabetes were independently adjudicated by two study physicians, and 
in the case of disagreement consensus was sought with the help of an endocrinologist. 
Follow-up data is completed until January 1st 2012. Flowcharts detailing why prevalent 
cases of diabetes and prediabetes were classified as as such are shown in Supplementary 
Figures 2 and 3 respectively.
ADAMTS13 activity and VWF antigen measurements
Citrated plasma samples were collected at the third visit of RS-I and the baseline ex-
amination of RS-II, and stored at -80°C. Between June and October 2013, we measured 
ADAMTS13 activity using a kinetic assay based on the Fluorescence Resonance Energy 
Transfer Substrate VWF 73 (FRETS-VWF73) assay [27]. Plasma samples were measured 
against a reference curve of serial dilutions of pooled normal human plasma defined to 
have an ADAMTS13 activity of 1 IU/ml, and we express ADAMTS13 activity as a percentage 
of this. The ADAMTS13 activity of 6,258 participants was measured: 3,791 from RS-I, and 
2,467 from RS-II
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Between July and October of 2008, VWF antigen was determined in IU/ml with an in-house 
ELISA using polyclonal rabbit antihuman VWF antibodies (DakoCytomation, Glostrop, 
Denmark) for catching and tagging [28]. The intra-assay coefficient of variation was 5.8% 
and the inter-assay coefficient of variation was 7.8%. VWF antigen was measured in 3,968 
individuals from RS-I, and 2,561 individuals from RS-II.
In total, 5,176 participants with VWF and ADAMTS13 measurements also had a fasting 
glucose measurement and were free of diabetes at baseline, while 4,232 participants were 
free of prediabetes at baseline (Supplementary Figure 2 and 3).
Covariates
BMI was calculated by dividing weight in kilograms by height in meters squared. Infor-
mation on current tobacco smoking was acquired from questionnaires. Lipid-lowering 
(statins, fibrates, and other lipid modifying agents), antihypertensive (diuretics, beta-
blocking agents, ACE-inhibitors, calcium channel blockers), and antithrombotic medica-
tion use was assessed during a structured home interview. Blood pressure was measured 
twice by an oscillometric device after five minutes of rest and the mean was taken as the 
subject’s reading. Serum total cholesterol and HDL-cholesterol levels were determined 
using an automated enzymatic method. Blood glucose levels were measured using the 
glucose hexokinase method (Instruchemie) [29]. Insulin levels were determined by metric 
assay (Biosource Diagnostics, Camarillo, CA). This assay has no cross-reactivity with either 
proinsulin or C-peptide. Serum alanine-aminotransferase (ALAT) levels were measured us-
ing a Merck Diagnostica kit on an Elan Autoanalyzer (Merck, Whitehouse Station, NJ, USA). 
White blood cell count was assessed in citrate plasma with a Coulter Counter T540 (Coulter 
Electronics, Hialeah, Florida, USA). C-reactive protein (CRP) was measured using CRPL3, 
an immunoturbidometric assay (Roche Diagnostics, Indianapolis, IN, USA). Prevalent CHD 
was defined as having a history of myocardial infarction or coronary revascularization 
procedures, as previously described [30].
Statistical Analysis
Statistical analyses were performed in SPSS version 21 (IBM Corp, Armonk, NY, USA) and 
R version 3.1.3 (R Foundation for Statistical Computing, Vienna, Austria). Missing values 
for covariates (<5%) were imputed in SPSS using single imputation based on expectation 
maximization. VWF antigen, HDL cholesterol, CRP, ALAT, and fasting insulin were natural 
log-transformed. We used linear regression models to test the association of ADAMTS13 
activity and VWF antigen with fasting glucose and fasting insulin. Individuals with preva-
lent diabetes were excluded in all analyses.
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The association of ADAMTS13 activity and VWF antigen with incident diabetes was exam-
ined using Cox proportional hazards models. The assumption of proportional hazards 
was met. Three adjustment models were used. Model 1 was adjusted for age, sex, and 
cohort. Model 2 was additionally adjusted for HDL and total cholesterol, lipid-lowering 
medication, BMI, CRP, current smoking, antithrombotic medication, ALAT, white blood cell 
count, systolic blood pressure, antihypertensive medication, and prevalent CHD. Model 3 
was additionally adjusted for fasting glucose and insulin. The assumption of proportional 
hazards was met for all models. In Model 1 ADAMTS13 activity and VWF antigen were tested 
separately, whereas in Models 2 and 3 the analysis of ADAMTS13 activity was adjusted for 
VWF antigen and vice versa. We examined the interaction between ADAMTS13 activity and 
VWF antigen on incident diabetes using a multiplicative interaction term, and adjusting for 
age, sex, and cohort. Results are shown per standard deviation (SD) of VWF antigen levels 
and ADAMTS13 activity. We also tested the association of ADAMTS13 activity quartiles with 
incident diabetes.
To test whether associations with incident diabetes were driven by participants with 
prevalent CHD, or users of lipid-lowering, antihypertensive, and antithrombotic medica-
tion, we excluded participants in each of these subgroups in a sensitivity analysis.
RESULTS
Baseline characteristics are shown in Table 1. In a median follow-up time of 11.2 years 
(interquartile range: 9.8, 12.6), 638 participants out of 5,176 participants that were free 
of diabetes at baseline developed diabetes (incidence rate: 12.4 per 1000 person years). 
As shown in Supplementary Figure 4, 36 of these individuals were diagnosed during 
follow-up because they started with insulin treatment, whereas 278 started using oral 
glucose-lowering medication. Another 324 participants were diagnosed with diabetes 
because of their fasting glucose levels. Of the 4,234 participants without prevalent predia-
betes, 862 developed prediabetes (incidence rate: 21.1 per 1000 person years). As shown 
in Supplementary Figure 5, during follow-up 13 of these individuals started with insulin 
treatment, 118 started taking oral glucose-lowering medication, and 731 were diagnosed 
with prediabetes based on their fasting glucose levels.
Associations of ADAMTS13 activity and VWF antigen with incident diabetes are shown in 
Table 2. ADAMTS13 activity was associated with a 19% increased risk of incident diabetes 
per SD in the age and sex adjusted model (Hazard ratio [HR]: 1.19; 95% confidence inter-
vals [95%CI]: 1.10 to 1.30), and this association remained unchanged when adjusting for 
potential confounders. Participants in the highest quartile of ADAMTS13 activity had a 46% 
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increased risk compared to participants in the lowest quartile (HR: 1.46; 95%CI: 1.15, 1.85). 
VWF antigen was associated with a 12% (HR: 1.12; 95%CI: 1.03 to 1.21) increased risk of 
incident diabetes per SD in the age and sex adjusted model. However, the increased risk 
was attenuated to 6% (HR: 1.06; 95%CI: 0.98 to 1.15) increased risk per SD after adjustment 
for additional covariates, and was 8% (HR: 1.08; 95%CI: 0.99 to 1.17) after further adjust-
ment for fasting glucose and insulin.
Both ADAMTS13 activity and VWF antigen were positively associated with baseline fasting 
insulin, and ADAMTS13 activity was positively associated with baseline fasting glucose 
(Supplementary Table 1). Nevertheless, when we additionally adjusted for fasting glucose 
and insulin, the effect sizes did not change. These associations were robust to the exclusion 
of participants with prevalent CHD at baseline, and the exclusion of users of lipid-lowering, 
antihypertensive, and antithrombotic medication (Supplementary Table 2). There was an 
interaction between ADAMTS13 activity and VWF antigen with incident diabetes (P-value: 
0.01). As shown in Figure 1, the association of ADAMTS13 activity with incident diabetes 
was strongest in the fourth quartile of VWF antigen (HR: 1.49: 95%CI: 1.27 to 1.75).
Table 1: Baseline characteristics of the study population.
Mean (SD) or Percentage
 N = 5,176
Age (years) 69.0 (8.1)
Sex (female) 57.7
Body mass index (kg/m2) 26.7 (3.8)
High-density lipoprotein cholesterol (mmol/L) 1.3 (1.12-1.60)
Total cholesterol (mmol/L) 5.9 (1.0)
Lipid-lowering medication use 11.4
Systolic blood pressure (mmHg) 142.1 (21.0)
Antihypertensive medication use 20.8
Alanine aminotransferase (U/L) 20.0 (16.0-26.0)
Current smoking 12.5
C-reactive protein (mg/L) 21.0 (10.0-44.3)
White blood cell count (109 cells/L) 6.7 (1.9)
Prevalent coronary heart disease 7.3
Prevalent prediabetes 18.2
Fasting glucose (mmol/L) 5.5 (0.5)
Fasting insulin (pmol/L) 71.36 (50.60-100.00)
Antithrombotic medication use 17.4
ADAMTS13 activity (%) 91.0 (17.2)
VWF antigen (IU/ml) 1.3 (0.6)
N=5176 Data are the mean (SD), percentage or median (interquartile range)
140 PART IV
Type 2 diabetes mellitus: Risk factors and complications 
Furthermore, ADAMTS13 activity was also associated with an 11% (HR: 1.11; 95%CI: 1.03 
to 1.19) increased risk of prediabetes per SD in Model 1, and this association was similar 
in Model 2 and 3 (Figure 2). In contrast, VWF antigen was not associated with incident 
prediabetes.
Table 2: Hazard ratios of ADAMTS13 activity on incident type 2 diabetes.
Model 1 Model 2 Model 3
Hazard Ratio
(95%CI)
P-value Hazard Ratio
(95%CI)
P-value Hazard Ratio
(95%CI)
P-value
Continuous (per SD) 1.19 (1.10, 1.30) 0.00003 1.17 (1.08, 1.27) 0.0001 1.17 (1.08, 1.27) 0.00009
Quartile 1 (Ncases: 129) Reference Reference Reference
Quartile 2 (Ncases: 150) 1.12 (0.88, 1.42) 0.4 1.10 (0.87, 1.39) 0.4 1.12 (0.88, 1.41) 0.4
Quartile 3 (Ncases: 168) 1.26 (1.00, 1.59) 0.05 1.31 (1.03, 1.65) 0.03 1.36 (1.08, 1.73) 0.01
Quartile 4 (Ncases: 191) 1.47 (1.16, 1.86) 0.001 1.46 (1.15, 1.85) 0.002 1.48 (1.17, 1.88) 0.001
ADAMTS13, A Disintegrin And Metalloprotease with a ThromboSpondin type 1 motif, member 13. SD, stan-
dard deviation. Ncases, number of incident diabetes cases. Adjustments: Model 1: Adjusted for age, sex, and 
cohort. Model 2: Additionally adjusted for VWF antigen, HDL and total cholesterol, lipid-lowering medi-
cation, body-mass index, CRP, former smoking, current smoking, antithrombotic medication, ALAT, white 
blood cell count, systolic blood pressure, antihypertensive medication, and prevalent CHD. Model 3: Ad-
ditionally adjusted for glucose and insulin levels. HDL cholesterol, CRP, ALAT, and insulin were natural log 
transformed when used
Figure 1: Hazard ratios of ADAMTS13 activity (per SD) for incident type 2 diabetes across quartiles of VWF 
antigen: interaction between ADAMTS13 and VWF. The vertical bars represent the 95% confidence intervals.
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DISCUSSION
In our study, ADAMTS13 activity was associated with an increased risk of incident diabetes, 
even after adjustment for other known risk factors, including VWF antigen, fasting glucose 
and fasting insulin. Furthermore, ADAMTS13 activity was associated with the incidence of 
prediabetes among participants with normoglycemia at baseline. VWF antigen was also 
associated with an increased risk of diabetes, but this association was attenuated after 
adjustment for known risk factors. These results suggest a role for ADAMTS13 in the occur-
rence of type 2 diabetes at an early stage before glucose levels rise.
To our knowledge, the association of ADAMTS13 with diabetes has not previously been 
studied with diabetes as the primary outcome, and we are the first to examine this as-
sociation in a large prospective population-based cohort study. One cross-sectional study 
reported the association between ADAMTS13 and prevalent diabetes [12]. The researchers 
did not observe a statistically significant difference in ADAMTS13 levels between 86 cases 
of diabetes and 26 healthy controls. We previously observed that ADAMTS13 activity is 5% 
higher in participants with prevalent diabetes compared to participants without prevalent 
diabetes [31]. In the current study we excluded participants with prevalent diabetes, and 
instead focused on the risk of future diabetes. The results of this study are therefore largely 
independent from the results of previous cross-sectional study.
Our results for VWF are consistent with previous studies. VWF has been associated with 
incident diabetes in a range of studies [13-17], but in general the association weakened 
Figure 2: Hazard ratios of ADAMTS13 activity and log transformed VWF antigen (per SD) for incident predia-
betes excluding participants with prediabetes at baseline (862 events in 4232 participants). The horizontal 
bars represent the 95% confidence intervals
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after adjustment for confounders and became non-significant. In the Framingham Heart 
Study however, VWF remained significantly associated after adjustment for a wide range of 
potential confounders, including insulin resistance [14]. Similarly, in the Coronary Artery 
Risk Development in Young Adults study, VWF remained associated with insulin resistance 
after multivariable adjustment [32]. VWF is a marker of endothelial dysfunction, and this 
is thought to explain the association between VWF and diabetes [18]. We report an inter-
action between ADAMTS13 activity and VWF, with the largest effect of ADAMTS13 activity 
among participants in the highest quartile of VWF. This interaction suggests that the effect 
of ADAMTS13 is mainly present in individuals with advanced endothelial dysfunction.
The mechanism underlying the association of ADAMTS13 activity with diabetes remains 
unclear. Because the association was robust to the adjustment for baseline fasting glucose 
and insulin, and because ADAMTS13 activity was also associated with incident prediabe-
tes, the possibility of reverse causation is limited. The latter association, for example, 
implies that high ADAMTS13 activity in individuals with healthy glucose metabolism is 
associated with the development the early subclinical stages of type 2 diabetes. However, 
the association between ADAMTS13 activity and diabetes is unlikely to be explained by 
its only robustly identified function as a cleaving protease of VWF, because in that case 
we would expect VWF (prothrombotic) and ADAMTS13 activity (antithrombotic) to be as-
sociated with diabetes in opposite directions. An alternative hypothesis is an additional 
proteolytic functionality of ADAMTS13 beyond VWF cleavage. After an initial interaction 
with globular VWF, ADAMTS13 undergoes a conformational change that increases its abil-
ity to break down VWF [33]. Recent research suggests that the conformational change not 
only increases the ability of ADAMTS13 to break down VWF, but also allows it to break 
down other proteins such as fibrinogen [34]. ADAMTS13 activity, as measured in our study, 
may partly reflect this process. As such, the observed association between ADAMTS13 
activity and incident type 2 diabetes might be explained by the interaction of ADAMTS13 
with one or more currently unknown proteins. Finally, the association could be explained 
by pathways responding to ADAMTS13. For example, there is preliminary evidence that 
ADAMTS13 upregulates the expression of vascular endothelial growth factor, a protein in-
volved in angiogenesis that may contribute to the development of type 2 diabetes [35, 36]. 
ADAMTS13 may similarly activate other pathways that lead to the development of type 2 
diabetes. However, since ADAMTS13 was discovered in 2001 most research has focused 
on its interactions with VWF and its role in thrombotic thrombocytopenic purpura. There-
fore, we believe that further research is required to elucidate other pathways affected by 
ADAMTS13.
We measured ADAMTS13 activity using the FRETS assay, which is based on a synthetic 
peptide spanning the VWF cleavage site [27]. ADAMTS13 antigen is an alternative mea-
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surement, which corresponds to the abundance of ADAMTS13. Future studies should 
investigate whether ADAMTS13 activity or antigen is most strongly associated to diabetes. 
If the association with diabetes is strongest with ADAMTS13 antigen, then the association 
of markers of ADAMTS13 gene expression, synthesis, secretion, and degradation with 
diabetes should be explored. Alternatively, a stronger association with ADAMTS13 activity 
points towards a downstream implication of VWF cleavage, albeit not the decreased activ-
ity of VWF itself.
The strengths of our study include the comprehensive assessment of incident diabetes 
and prediabetes, using medical records, linkage with pharmacies in the study area, and 
standardized blood glucose measurements at each of the follow up visits. Additionally, we 
used data from a well-characterized prospective population-based cohort study, which 
allowed us to correct for a wide range of covariates. We used a long follow up period, and 
adjusted for baseline fasting glucose and insulin to reduce the possibility of reverse causa-
tion. By also examining associations with incident prediabetes, we provide insight into the 
early development of subclinical disease.
The main limitation of our study is that, as in all observational studies, we cannot rule 
out residual confounding. In addition, we included individuals aged 55 years and older 
and effect estimates might not be generalizable to younger ages. A second limitation of 
this study is that we did not measure VWF activity or the ratio of small inactive VWF to 
large active VWF. Such measurements would provide insight into whether the observed 
association is related to the proteolysis of VWF by ADAMTS13.
In conclusion, we identified ADAMTS13 activity as a novel independent marker of incident 
diabetes, associated with both diabetes and prediabetes. Future research is necessary to 
confirm this association and to elucidate the biology underlying this association. Explora-
tion of alternative mechanisms of ADAMTS13 beyond VWF cleavage is warranted as the 
association may not be explained by its antithrombotic function.
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SUPPLEMENTAL MATERIAL
Supplementary Table 1: Cross-sectional association of ADAMTS13 activity and VWF antigen (per SD) with 
fasting glucose and natural log transformed fasting insulin.
ADAMTS13 activity VWF antigen
ꞵ coefficient (95%CI) P-value ꞵ coefficient (95%CI) P-value
Glucose
Model 1 0.03 (0.01, 0.04) 0.001 0.01 (-0.00, 0.03) 0.08
Model 2 0.02 (0.01, 0.04) 0.003 -0.01 (-0.02, 0.01) 0.4
Insulin
Model 1 0.06 (0.04, 0.07) 6×10-15 0.07 (0.05, 0.08) 1×10-19
Model 2 0.05 (0.04, 0.06) 4×10-15 0.03 (0.02, 0.05) 2×10-8
ꞵ coefficient refers to the 1 unit increase in fasting glucose (mmol/L) or insulin (natural log transformed 
pmol/L) per 1 standard deviation increase in VWF antigen or ADAMTS13 activity.
Adjustments: Model 1: Adjusted for age, sex, and cohort. Model 2: Additionally adjusted for HDL and to-
tal cholesterol, lipid-lowering medication, body-mass index, CRP, former smoking, current smoking, an-
tithrombotic medication, ALAT, white blood cell count, systolic blood pressure, antihypertensive medica-
tion, and prevalent CHD. The analysis of VWF antigen was adjusted for ADAMTS13 activity and vice versa. 
HDL cholesterol, CRP, and ALAT were natural log transformed.
Chapter 8 147
ADAMTS13 activity as a novel risk factor for incident type 2 diabetes mellitus
Supplementary Table 2: Association of ADAMTS13 activity and VWF antigen (per SD) with incident diabe-
tes after exclusions based on disease and medication use at baseline*.
ADAMTS13 Activity VWF antigen
Hazard Ratio
(95%CI)
P-value Hazard Ratio
(95%CI)
P-value
Excluding cases of prevalent CHD: 
565 events in 4674 participants
Model 1 1.20 (1.10, 1.30) 0.00007 1.14 (1.05, 1.25) 0.002
Model 2 1.17 (1.07, 1.27) 0.0004 1.09 (1.00, 1.19) 0.06
Model 3 1.18 (1.08, 1.28) 0.0002 1.09 (1.00, 1.20) 0.05
Excluding antithrombotic medication users: 
490 events in 4062 participants
Model 1 1.20 (1.09, 1.32) 0.0001 1.14 (1.04, 1.25) 0.006
Model 2 1.15 (1.05, 1.27) 0.002 1.07 (0.98, 1.18) 0.1
Model 3 1.16 (1.06, 1.27) 0.001 1.09 (0.99, 1.20) 0.08
Excluding lipid-lowering medication users: 
526 events in 4372 participants
Model 1 1.18 (1.08, 1.29) 0.0005 1.12 (1.03, 1.23) 0.01
Model 2 1.15 (1.05, 1.26) 0.002 1.05 (0.96, 1.15) 0.3
Model 3 1.15 (1.05, 1.25) 0.002 1.07 (0.98, 1.17) 0.2
Excluding antihypertensive medication users: 
415 events in 3837 participants
Model 1 1.19 (1.07, 1.32) 0.001 1.12 (1.01, 1.24) 0.03
Model 2 1.20 (1.08, 1.33) 0.0005 1.06 (0.96, 1.18) 0.2
Model 3 1.20 (1.08, 1.33) 0.0005 1.11 (1.00, 1.23) 0.05
*Exclusions were based on non-imputed variables.
Adjustments: Model 1: Adjusted for age, sex, and cohort. Model 2: Additionally adjusted for HDL and total 
cholesterol, lipid-lowering medication, body-mass index, CRP, current smoking, antithrombotic medica-
tion, ALAT, white blood cell count, systolic blood pressure, antihypertensive medication, and prevalent 
CHD. The analysis of VWF antigen was adjusted for ADAMTS13 activity and vice versa. Model 3: Addition-
ally adjusted for glucose and insulin levels. HDL cholesterol, CRP, ALAT, and insulin were natural log trans-
formed when used. 
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Supplementary Figure 1: Schematic representation of the follow-up design.
Supplementary Figure 2: Selection of the study population at baseline for incident diabetes follow-up.
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Supplementary Figure 3: Selection of the study population at baseline for incident prediabetes follow-up.
Supplementary Figure 4: Follow-up of incident diabetes events in the study population.
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Supplementary Figure 5: Follow-up of incident prediabetes events in the study population.
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General discussion
Given the ongoing global epidemic of obesity and obesity-related diseases, research 
on this topic is of vital importance. Both metabolic syndrome and type 2 diabetes are 
obesity-related health conditions. In this thesis, I studied the incidence and prevalence 
of metabolic syndrome, type 2 diabetes, and associated cardiovascular disease and 
mortality. Furthermore, both the prevalence of well-known type 2 diabetes-associated 
risk alleles, a novel hematological substance as a risk marker and a novel candidate gene 
were investigated. Here, I will discuss the findings of my research, methodological issues, 
potential implications for clinical practice and directions for future research.
9.1 MAIN FINDINGS
PART II: METABOLIC SYNDROME IN MODERN SOCIETY: DEFINITIONS AND 
PREDICTIVE ABILITY
Metabolic syndrome is a combination of risk factors for diabetes mellitus and cardiovas-
cular disease that often cluster together. Although considered a useful tool in categorizing 
patients, its added value for prediction of cardiometabolic events above its individual 
components was unclear (1–3), especially since there are several definitions of metabolic 
syndrome (4–7). In part II of this thesis, we have investigated the prevalence and longitu-
dinal hazard ratios for cardiometabolic endpoints of different definitions and components 
of metabolic syndrome in a prospective population-based study.
The clinical value of metabolic syndrome and risks of cardiometabolic events and 
mortality in the elderly: the Rotterdam Study (Chapter 3)
Since the introduction of insulin resistance in type 2 diabetes by Himsworth (8) and the 
postulation of insulin resistance as the underlying cause of dyslipidemia and hyperten-
sion clustered in the ‘insulin resistance syndrome’ by Reaven in 1988 (9), there has been 
much debate on the metabolic syndrome. The debate primarily questions the added value 
of the metabolic syndrome in prediction and treatment of cardiovascular disease and 
diabetes (10). Also, there is still no concluding evidence of a common pathophysiological 
pathway that has been postulated some decades ago. Finally, the numerous definitions of 
metabolic syndrome make it challenging to compare population estimates. In our studies, 
we found metabolic syndrome to be highly prevalent with prevalence estimates of 19.4 
to 42.4%, depending on the definition, in line with previous reports in middle-aged and 
elderly populations in the USA and Europe (11–17). The high variability in prevalence be-
tween the three definitions reflects the inhomogeneity of metabolic syndrome definitions. 
While the EGIR-definition has a more restrictive nature towards the selection of insulin-
resistant non-diabetic patients, the IDF and AHA/NHLBI emphasize obesity. Since the 
prevalence and incidence of obesity are rising, we have found higher prevalence estimate 
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of metabolic syndrome according to these latter definitions. We have investigated each 
definition’s hazard ratio for cardiometabolic disease: metabolic syndrome has a strong, 
mainly hyperglycemia-based, risk associations with incident diabetes and only weak 
associations with cardiovascular disease and mortality. However, after correction for its 
components, none of the definitions remained significantly associated with cardiometa-
bolic endpoints. Which leads us to the following considerations. First, our results add to 
the evidence that metabolic syndrome has no additional value on top of its components 
in risk association for cardiometabolic disease in the general population. This has been 
observed previously (1–3,18,19). In line, single glucose measures were more predictive 
for incident diabetes than a diagnosis of metabolic syndrome (1,20,21). In our study, a 
diagnosis of metabolic syndrome had only a weak association with CVD-events which 
disappeared after correction for its own components. We already knew that metabolic 
syndrome is more related to diabetes than to CVD-events (2) and metabolic syndrome 
is outperformed by risk-assessment tests of the prediction of cardiovascular disease 
(2,20,22–24). This could be a result of weakening by dichotomization since the components 
of metabolic syndrome are continuous variables losing valuable information when forced 
into dichotomous values. It could also be the result of a lack of risk factors for cardio-
vascular disease not included in the definitions of metabolic syndrome like smoking, age 
and low-density lipoprotein (LDL) cholesterol. Our results re-emphasize the limited clini-
cal applicability of metabolic syndrome in risk prediction of cardiovascular disease and 
diabetes. There are also no consequences for treatment when a patient is diagnosed with 
metabolic syndrome. Hypertension, diabetes and dyslipidemia will be treated according 
to the current guidelines (25–29). An effective treatment option to target all components 
at once is improving lifestyle. Fasting blood glucose, blood pressure, waist circumference 
and triglycerides improve simultaneously when reducing body weight (30–32). Lifestyle 
modification should be the primary focus of a physician when faced with each separate 
metabolic entity instead of a therapeutic response on a diagnosis of metabolic syndrome. 
After lifestyle, residual risk for cardiovascular disease needs to be treated with appropriate 
drugs (10).
The metabolic syndrome did not have an additional value in risk prediction and treatment, 
but it may be useful in creating awareness in both physician and patient. Since the compo-
nents are more often found in combination than chance would dictate (33), a physician will 
be triggered to look for other risk factors when faced with one component. Furthermore, 
a diagnosis of metabolic syndrome can provide a physician with a more powerful com-
munication tool in order to make a patient aware, take actions and be more adherent to 
therapy compared to the message of each separate risk factor (34). By clarifying a patient’s 
perceived risk, one can increase chances of participating in lifestyle interventions (35,36).
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Apart from its role in risk prediction and risk communication, the metabolic syndrome can 
be of importance from a pathophysiological perspective. Numerous studies have aimed 
to explain the coherence of cardiovascular risk factors such as insulin resistance, central 
obesity and hypertension. Targeting the initiating events that lead to metabolic syndrome 
can prevent or delay the onset of cardiovascular disease.
Initially, insulin resistance was seen as the underlying cause of metabolic syndrome (9,37). 
The cause of the insulin resistance itself, however, remains to be clarified. One explanation 
was the abdominal fat and oversupply of fatty acids in central obesity. Adipose tissue is 
both metabolically and immunologically active (38), secreting cytokines and adipokines 
(39,40). Due to nutritional excess, adipocytes undergo hypertrophy that can lead to cells 
that outgrow their blood supply (41), leading to inflammation, secretion of cytokines like 
interleukin (IL)-6 and decreased levels of adiponectin and cell stress with increased ROS 
production (42–44). So a state of lipid oversupply in peripheral tissues leads to chronic in-
flammation (45,46), leading to impaired insulin signalling (47–51). In metabolic syndrome, 
increased levels of inflammation have been found in the liver, intestines, and adipose 
depots (52–54). Obese subjects with metabolic syndrome and weight gaining subjects 
have higher levels of oxidative stress biomarkers compared to obese subjects without 
metabolic syndrome and lean subjects (55–58). Treatment of inflammation with salicylate 
leads to improved insulin sensitivity and lipid profiles in prediabetic and type 2 diabetes 
patients (59–61). Another factor that is related to the metabolic syndrome could be related 
to the microbiome. Studies have already shown an association between fecal microbiota 
and type 2 diabetes and obesity (62). Modifying the gut microbiota can be an approach to 
target metabolic syndrome (63).
Both lifestyle modification (31,64,65), gastric bypass (66,67), medication that directly in-
terferes with pro-inflammatory pathways, the microbiome or the relieve of oxidative stress 
could stop or slow down the deteriorating effects of metabolic syndrome. Although the 
metabolic syndrome is not as useful in clinical practice for prediction purposes, through 
pathophysiological research, we can find potentially new therapeutic targets to prevent 
obesity-associated disease.
PART III: TYPE 2 DIABETES MELLITUS: LIFETIME RISK AND DISEASE COURSE
In the year 2035, more than half a billion people worldwide are expected to live with 
diabetes (68). Preventive strategies are very important in averting this epidemic. An ef-
fective risk communication strategy from the physician to the patient in the prevention of 
prediabetes and diabetes is vital. Lifetime risks reflect precise estimates of an individual’s 
risk of developing a disease throughout a lifespan. Patients prefer lifetime risk over 10-
year and 20-year risk estimates and absolute risk over relative risk. The absolute risks are 
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clear and simplistic presentations of risks of disease and projections of long-term benefits 
of preventive measures are possible, which are more likely to affect a patient’s perception 
of effectiveness (69,70). In part III of this thesis, we have assessed lifetime risk of predia-
betes, diabetes and insulin dependency in a prospective, population-based cohort study 
(Chapter 4). Furthermore, we have assessed the effect of applying two different glucose 
cut-off values to define prediabetes on prevalence and lifetime risk estimates to develop 
type 2 diabetes (chapter 5).
Lifetime risk of progression from prediabetes to type 2 diabetes: a prospective 
cohort study (Chapter 4)
A raised blood glucose level just below the threshold for a diagnosis of type 2 diabetes is 
a major risk factor for diabetes (71–73) referred to as prediabetes. Prediabetes increases 
the risk for diabetes but also for cardiovascular disease, cancer and mortality (74–76). 
Previous analysis has shown that patients evolve through a prediabetic state to eventu-
ally become an incident case of diabetes (77). By applying both pharmacological and 
non-pharmacological interventions in prediabetes, patients can lower their diabetes-risk 
(73–76)(71,73,78–83), thus averting a diagnosis of diabetes. Since fasting and post-load 
glucose levels increased linearly no less than 6 years before a diagnosis of diabetes (77), 
screening for prediabetes could be relevant in the prevention of diabetes.
Due to our study, we now know that at age 45, one in three individuals in the Netherlands 
will develop diabetes, one in two will develop prediabetes and that three out of four 
individuals that have glucose ranges in the prediabetes range at age 45 will progress to 
diabetes. Our results came from a large, prospective, community-dwelling population, 
and indicate the magnitude of the health issue we face. We are the first to address life-
time risk of diabetes, prediabetes and progression from prediabetes to diabetes based 
on data retrieved from active prospective follow-up and actual measurements instead of 
cross-sectional data (84) and simulated models based on questionnaires (85). We see a 
resemblance of our percentage of progression from prediabetes to diabetes (70 vs 75%) 
(79–82)(71,73,86) in US-based research, which strengthens our belief in the vast extent of 
this health issue.
Although it is a well-known risk factor for diabetes, we noted a substantial obesity-related 
increase in lifetime risk on prediabetes, diabetes and insulin use. By providing these esti-
mates, including the obesity-relation, the communication between patient and physician 
could be substantially improved. From literature, it is clear that by increasing the impact of 
risk-communication as a physician, therapy-adherence will improve (87). The impact that 
risk communication has on a patient’s behaviour depends on its presentation: absolute 
risk has more impact than relative risk (88). Alternative presentations, such as 30-year risk 
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or lifetime risk have more impact than 10-year risk and are therefore recommended by 
the American Heart Association (89) for young people, as they respond better to these 
estimates (90). The estimates we present here are easy to interpret for both the experts 
and lays and will thereby facilitate clear communication.
Lifetime risk to progress from prediabetes to type 2 diabetes among women and 
men: a comparison between American Diabetes ASsociation and World Health 
Organization diagnostic criteria (Chapter 5)
The American Diabetes Association (ADA) and the World Health Organisation (WHO) de-
fine prediabetes differently (91,92). The ADA definition has a lower threshold of 5.6mmol/L 
for fasting glucose and diagnoses a larger portion of the population with prediabetes 
compared to the WHO’s threshold of 6.1 mmol/L. In our population-based study, 39% of 
all participants and half the elderly had ADA-defined prediabetes, comparable to Vistisen 
2018 (93). These high prevalence estimates raise questions on the definition of predia-
betes since it is used to identify high-risk individuals eligible for interventions to prevent 
diabetes. In studies such as the DPP 19% of prediabetes returned to normoglycemia within 
10 years using lifestyle, medication or both (78), through treatment of pioglitazone 48% 
returned to normoglycemia in 2 to 4 years (94) and metformin showing a risk reduction of 
18% in 15 years after randomization (81,95). However, since up to half our population is 
identified as a high-risk individual, we question the feasibility of ADA-prediabetes screen-
ing and prevention of diabetes. We evaluated this question from two perspectives: 1) the 
prevention of incident diabetes and 2) the prevention of cardiovascular disease.
Lowering the cut-off value of ADA-prediabetes is based on results from progression to 
diabetes among Pima-Indians and a study from the island of Mauritius (96,97). The ADA’s 
motivation for the lower cut-off value was to improve the prediction of diabetes risk (91). 
Indeed, numerous trials and meta-analyses have found diet, exercise and drug-based 
interventions to be successful in reducing the risk of diabetes with 40 to 60% in high-risk 
individuals (79,83,98). In the follow-up studies, it became clear that this was merely a delay 
in the onset of diabetes by two to four years than prevention as such (95,99–101). Recent 
meta-analyses confirm the effectiveness of both diet and physical activity- interventions 
in high-risk individuals in decreasing progression rates of diabetes (80,102,103). However, 
there is no evidence that the effectiveness of prevention strategies increases by lowering 
the glucose cut-off value. Furthermore, results from prevention studies show that ef-
fectiveness is related to the intensity and the length of programs (102,103). Doubling the 
prevalence of high-risk individuals will increase the need for high-intensity prevention 
programs and will put a major burden on the health care budget. In our population, a 
45-year old individual with ADA- prediabetes has a lifetime risk of 51.7% to develop dia-
betes, whereas at age 75 a lifetime risk of 29.4% remains. So at age 45, half the high-risk 
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individuals and at age 75, almost two-thirds will never develop diabetes regardless of a 
costly prevention program.
Although prediabetes is indisputably associated with cardiovascular disease, studies and 
meta-analyses on prevention of prediabetes found no reduction in microvascular (104), 
cardiovascular disease and mortality (80,99,102,105–108). Although there was a 50% 
reduction in retinopathy in the Da Qing study, there was no effect on the incidence of 
nephropathy and neuropathy (109). In the same follow-up study, Zhang reported a 38% 
and 20% reduction in all-cause and cardiovascular mortality, respectively (100). This is 
surprising since the result was only seen in women and the diabetes onset in this study 
was delayed by only 3.6 years. No other trial study has reported similar effects on cardio-
vascular disease and mortality. To explain the results of prediabetes prevention on cardio-
vascular disease, I would like to address a study by Vistisen et al. (93) in which subgroups 
of cardiovascular disease and all-cause mortality in the Whitehall study were studied. 
They found that there was no optimal cut-off point in fasting glucose to predict cardio-
vascular disease. Furthermore, no association in prediabetes between fasting glucose and 
cardiovascular disease after adjustment for cardiovascular risk factors and demographics 
remained. Prevention of prediabetes lacking risk reduction for CVD can, therefore, be a 
result of mere clustering of risk factors in prediabetes then the risk associated with the 
sole entity itself (93). Remains to be said that there is no additional evidence that a lower 
glucose cut-off improves the effect of prediabetes prevention on cardiovascular morbidity 
and mortality.
In addition, one has to realize that interventions even in high-risk populations are more 
effective in trial-based setting compared to the real-world (103,110–114).
The enormous prevalence estimate of prediabetes in our population and the various 
results in the effectiveness of prevention in prediabetes in a variety of endpoints make us 
question whether lowering the glucose cut-off value, as has been done in ADA-definition, 
would be beneficial in determining prevention policy. We would merely recommend 
research on preventive interventions in type 2 diabetes at population level or health care 
system instead of a screen-and-treat policy (112,115). Until then, we follow Dutch guide-
lines and propose WHO-defined glucose cut-off values for prediabetes screening. Our and 
other results on prediabetes still calls for extensive research and long-term economic 
evaluations of each preventive effort to determine which suits the obesity epidemic best.
PART IV: RISK FACTORS AND COMPLICATIONS IN TYPE 2 DIABETES
The pathogenesis of type 2 diabetes is heterogeneous and contains both genetic and 
environmental factors. Apart from well-known risk factors such as family history (116), 
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ethnicity (117), obesity (117,118) and impaired glucose tolerance (72), there is a constant 
search for new associated risk factors and risk alleles. We aim to contribute to this search 
by performing the DIAGENE-study (chapter 6), a study on prevalence and risk associations 
of vascular complications in both primary care and outpatient setting of patients with type 
2 diabetes. Furthermore, we have performed a candidate-gene study on polymorphisms in 
proline transporter SLC6A20 and susceptibility to Type 2 diabetes (chapter 7). Finally, we 
have investigated whether ADAMTS13 activity is independently associated with incident 
prediabetes and type 2 diabetes (Chapter 8).
The DiaGene Study; the prevalence of macro- and microvascular disease (Chapter 6)
Despite the preventive treatment of cardiovascular risk factors in patients with type 2 dia-
betes (25,26,119–124) a substantial portion of patients with type 2 diabetes will develop 
vascular complications (76,125–127). By collecting the DiaGene cohort our aim was not 
only to analyze the layout of diabetes care in the Netherlands but also to assess the bur-
den of vascular disease in the diabetes population and elucidate potential new metabolic, 
genetic and environmental risk factors. Furthermore, we aimed to confirm the association 
of well-known genetic risk variants with type 2 diabetes in our population.
One major characteristic of Dutch diabetes care is the subdivision between primary 
and outpatient hospital care (128,129). Due to national referral agreements, there were 
noticeable differences between the patients in the primary care setting and outpatient 
clinic, in the DiaGene Study. The complicated nature of diabetes in the outpatient clinic 
was reflected by a younger age of onset, longer duration of diabetes, higher HbA1c, more 
insulin treatment, a greater proportion of low eGFR and significantly more prevalent mi-
crovascular and macrovascular complications. However, both lipids and blood pressure 
were significantly lower and thus better treated compared to primary care. The prevalence 
estimates of both microvascular and macrovascular complications are comparable to 
other diabetes populations in the Netherlands, UK and France. As for our genetic analyses, 
we have confirmed the prevalence and odds-ratios of well-known T2D-risk variants. These 
had the same direction of association to type 2 diabetes as earlier reported (130–132). We 
use these results as proof of a comparable genetic background of our type 2 diabetes pop-
ulation compared to other genetic studies. Up to his point, our study is mainly exploratory 
and confirmatory. However, the DiaGene study already proved its value by participating 
in a large meta-analysis of the DIAGRAM-consortium in which new type 2 diabetes-risk 
alleles where discovered (133). Furthermore, we are planning multi-layer omics on top 
of genome-wide association analyses to further elucidate determinants of T2DM and its 
complications. The availability of prospective data improves the quality of our analyses, 
and will a focus during the forthcoming years. Recently, our group has published on glycan 
patterns and their association with type 2 diabetes (134,135).
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SLC6A20; incident type 2 diabetes (Chapter 7)
SCL6A20 is a member of the solute carrier family 6 (SLC6) which has 20 members (136). 
From a biological perspective in type 2 diabetes, SLC6A20 is interesting since it is a proline 
transporter and therefore, an essential component in the proline metabolism (136). Since 
proline is synthesized from dietary glutamate, which is one of the major gluconeogenic 
precursors in the kidney (137) and small intestines (138) it might influence type 2 diabetes 
risk. In a previous study, performed by Patterson et al. in non-human primates (139), 
SLC6A20 had reduced activity in the kidneys of primates and mice with type 2 diabetes. 
In humans, the relation of SLC6A20 with type 2 diabetes remains unclear. Therefore, we 
studied genetic variance in the SLC6A20 gene in relation to type 2 diabetes in a prospective 
population-based study as discovery population and an additional multi-ethnic replica-
tion cohort. In this study, we found the A allele of rs1306384 in the SLC6A20 gene to have a 
highly significant association with type 2 diabetes. We were the first to describe this poly-
morphism in relation to type 2 diabetes. Since the era of genome-wide association studies 
and meta-analyses of genome-wide association studies, focusing on one particular part in 
the genome in a relatively small number of participants might appear as outdated. Given 
the timeframe, however, we have selected a locus within a high potential causal pathway 
for type 2 diabetes. Furthermore, we have replicated our results in a meta-analysis of 
two different multi-ethnic populations and corrected for multiple testing. In a large-scale 
genome-wide meta-analysis on genome-wide association studies in type 2 diabetes by 
morris in 2012 (131), the variant has not been related to diabetes risk, despite the highly 
significant P-value in our meta-analysis. This could be an effect of age. In an age-stratified 
analysis that we performed in our population, we found a stronger association of the SNP 
with diabetes in the old compared to the young persons of the population. The large meta-
analysis of Morris includes almost 150,000 individuals but of different age categories, and 
this could be the reason that the SNP did not reach significance.
In other words, the genetic variance of SLC6A20 can manifest itself at high age through 
interaction with ageing or being part of a degenerative process. The latter could be an 
effect of epigenetic factors being more present at high age. Therefore, we concluded that 
our results are not generalizable to younger populations.
ADAMTS13 activity; associated risk of diabetes and prediabetes (Chapter 8)
ADAMTS13 (A Disintegrin And Metalloprotease with a ThromboSpondin type 1 motif 
member 13) was discovered in 2001 and is best known for its function in cleaving von Wil-
lebrand factor (VWF) multimers (140,141) . Relatively low ADAMTS13 activity is associated 
with an increased risk of vascular disease (142–145) and vascular complications in T2D 
(146,147) and elevated levels of VWF have been associated with type 2 diabetes (142–145). 
We, therefore, hypothesized that ADAMTS13 levels are inversely associated with the risk of 
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diabetes. We based our hypothesis on the biological interaction of VWF and ADAMTS13 in 
thrombosis potentially exacerbating small vessel disease, which could contribute to the 
development of diabetes (148–151).
Our results, however, contradict the hypothesis mentioned above. In our prospective 
population-based study, ADAMTS13 activity was associated with an increased risk of 
incident diabetes and prediabetes after adjustment for known risk factors. Since we are 
the first to find evidence to suggest a causal role for ADAMTS13 in type 2 diabetes, we have 
to put our results in perspective. In earlier work, we had already found 5% higher levels 
of ADAMTS13 activity in participants with prevalent diabetes compared to participants 
without diabetes (145,152). Previous cross-sectional studies found no difference (147) or 
lower levels of ADAMTS13 activity in a small study on type 1 diabetes (153). An interesting 
observation from the latter study was a positive correlation between HbA1c-levels and 
ADAMTS13 activity. The authors proposed that it reflects high levels of metabolic stress 
with an increase of hepatic production and release of ADAMTS13. Indeed, ADAMTS13 is 
primarily synthesized (154) in the liver and in cases of acute liver injury or liver failure a 
dramatic decrease in circulating levels of ADAMTS13 takes place (155). The upregulation 
of ADAMTS13 activity was previously observed in mice models of diabetes (156) and rat 
models of cholestasis and steatohepatitis (157). However, the aforementioned results sug-
gest reverse causation in the association of ADAMTS13 with incident diabetes.
In our population-based setting, however, we find reverse causation to be unlikely since 
ADAMTS13 is associated to both incident prediabetes and diabetes in a prospective setting 
and this association is robust to adjustment for fasting glucose and fasting insulin. The 
underlying mechanism of the association of ADAMTS13 with incident diabetes remains 
to be explored. Since the association we found is opposite to what we expected based on 
its known function as a cleaving protease, we hypothesize the association to be mediated 
through alternative functionalities of ADAMTS13 or through pathways that respond to AD-
AMTS13, one of which is regulation of inflammation (158,159). A study by Chauhan found a 
role for ADAMTS13 in down-regulation of inflammation in skin and vein samples in mouse 
models (160). Alternative functionalities have been described for ADAMTS13 in the degra-
dation of extracellular matrix (159), regulating the permeability between brain and blood 
(161) and having pro- or anti-angiogenic effects through regulation of VEGF activity (162). 
In research done by Gandhi et al., ADAMTS13 was found to reduce early atherosclerosis 
in ApoE -/- mice (163,164) and plays a role in the remodeling of brain tissue after cerebral 
ischemia (165–167). De Meyer found ADAMTS13 to reduce inflammatory responses after 
myocardial infarction (168). In a study by Wolters et al. low ADAMTS13 activity was associ-
ated with risk of dementia during a follow-up period of 15 years(169). One other associa-
tion was found in ADAMTS13 -/- mice in which diabetes was induced. These mice suffered 
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from premature death that was non-thrombotic and thus possibly through an alternative 
pathway (170). Hence, there is plenty of evidence that suggests additional pathways to be 
affected by ADAMTS13 beyond its role in thrombotic thrombocytopenic purpura.
Therefore, we believe that further research is necessary to replicate our findings and to 
elucidate the underlying causal pathways. Finding the causality between ADAMTS13 and 
diabetes would be important for biological understanding in itself but also to find possible 
new therapeutic targets. Furthermore, ADAMTS13 appears to include a risk portion that 
is not yet covered by current risk factors in diabetes. By establishing ADAMTS13 as a risk 
factor and adding it to the current set of risk factors, diabetes risk prediction can be im-
proved. So being said, ADAMTS13 could be a potential biomarker in the setting of diabetes.
9.2 METHODOLOGICAL TOPICS
There are some methodological issues in this thesis that need to be addressed to evaluate 
the results of my research properly.
STUDY POPULATIONS
The DiaGene study
The DiaGene study is a multi-centre, extensively phenotyped type 2 diabetes cohort study 
with concurrent inclusion of diabetes-free individuals. The population was included in all 
four medical centers in the city of Eindhoven with the intention to invite all patients with 
type 2 diabetes. Eventually, we included 1886 patients from an estimated total of 10000 
patients with type 2 diabetes in the Eindhoven region. We cannot measure or calculate the 
representability of our study sample. The selection of patients was not related to exposure 
or outcome. However, the possibility of a form of selection bias needs to be considered. 
In a population-based study, there is a chance of the so-called ‘healthy volunteer effect’ 
or ‘healthy worker effect’ that causes an underestimation of disease risk estimations since 
there is a selection towards healthy participants that have lower risks compared to the 
‘real’ population (171). However, the prevalence estimates of vascular complications 
in the DiaGene in comparison to other populations of type 2 diabetes do not lead us to 
believe there has been a strong effect of healthy volunteer selection bias in our study.
Conversely, individuals that experience a disease or could be more likely to participate in 
a study on that specific disease. However, as the DiaGene study has a prospective design 
for vascular complications, participants are considered not to take their decision based on 
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future events to happen, thus making participation selection based upon this argument 
less likely (172).
There are some limitations concerning data in the DiaGene study. First, although we have 
retrieved biometrical data at the time of inclusion, the majority of laboratory measure-
ments are collected within 6 months prior or after the moment of inclusion. For some 
measurements, this interval lies within a year.
Finally, we did have to rely on meticulous record-keeping in medical files for data on micro-
and macrovascular events. For macrovascular events in primary care, self-reported data 
were used, which we validated with data from hospital-based participants. We found an 
actual underestimation for myocardial infarction based on self-reported data compared 
to hospital discharge data. This is a phenomenon that has been described before (173). 
Although we acknowledge all the aforementioned, the quality of data is inherent to the 
cohort study set-up and will be comparable to other studies that have the same design. 
Furthermore, we have had two independent investigators to collect the data and reach 
consensus on discrepancies so that we have optimized data-reliability.
The Rotterdam Study
The Rotterdam Study is a large prospective population-based study with long-term 
follow-up and high-quality data on incident prediabetes and type 2 diabetes using general 
practitioner’s records, electronic linkage with pharmacy dispensing records, hospital dis-
charge letters and glucose measurements from each participant’s study centre visit (174). 
Furthermore, through the active follow-up system, there is a comprehensive assessment 
of metabolic syndrome, incident diabetes, cardiovascular disease and mortality. Although 
there may be certain healthy-volunteer effect studies that require active participation, the 
chances of selection bias are low since it is a random selection of the population, and 
having a high participation rate (174). The study population is mainly European-Caucasian 
and has a relatively high age since the original study was set up to investigate diseases 
of the elderly. Results drawn from studies performed in the Rotterdam Study population 
should, therefore, be applied with caution to the European population, which is changing 
dynamically. One should be even more careful to apply our results to other ethnic popula-
tions.
Genetic association
In the era of genome-wide analyses, there is discussion and criticism on the specific 
candidate-gene approaches, as is described in chapter 7. One of the main issues is the 
lack of power in studies that perform candidate-gene analysis. The other point of criticism 
is the external validity in the sense of replication.
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In the SLC6A20-study, we chose to analyze a polymorphism in a biologically plausible 
pathway and replicated it in a multi-ethnic population. By doing so, we increased power 
and addressed the issue of replication.
Although we have made a substantial effort to address issues related to candidate-gene 
studies, we acknowledge the limited power of candidate-gene studies and realize that in 
the context of multigenetic and multifactorial disease the study design belongs for large 
part to the past. At the time of writing, even after genome-wide association studies with 
increasing sample sizes and meta-analyses have discovered 128 distinct signals at 113 
loci independently associated with type 2 diabetes (130,132,175,176), only 5-20% of the 
overall predisposition of type 2 diabetes is explained (175,177). Among others, there is a 
major contribution of genomics to the understanding of T2D disease risk. The incomplete 
overlap between the loci identified with glycemic traits and T2D showed that the risk 
of T2D is not entirely driven by the effects on glucose levels in healthy individuals. Even 
more, most T2D loci have primary roles in ß-cell function and less in insulin resistance 
(178). Eventually, this caused a paradigm shift in the understanding of the disease patho-
physiology from primarily insulin resistance to ß-cell dysfunction. There are global efforts 
to perform sequencing studies with increasing sample size in search of less common or 
rare variants that explain heritability of type 2 diabetes (130,175). Other omic layers, like 
epigenomics may give further insight into the genetic architecture and the etiology of type 
2 diabetes (176).
Lifetime risk approach
Lifetime risk estimation is a proven method to provide patients, physicians and policymak-
ers with a risk estimate that is comprehensive but easy to interpret, thereby promoting 
efficient risk communication. For this reason, absolute risks are preferred over relative 
risks in providing effective risk communication to patients (88); and lifetime risk estimates 
are preferred over 10-year absolute risks in the patient-physician communication relation.
In chapter 4 and 5, we discuss the lifetime risk estimate of diabetes in the Netherlands. We 
have used a modified survival analysis in which there is a separate event when someone is 
death without ever having developed diabetes. This method has been applied in previous 
studies (179,180). Since the method accounts for the competing risk of death, it does not 
overestimate the remaining lifetime risk of diabetes in comparison to the Kaplan-Meier 
estimate. We calculate and mention lifetime risk for diabetes, however, only calculated the 
lifetime risk for diabetes at the age of 45. So one can, therefore, claim that we did not have 
a true estimate of diabetes risk. However, given the fact that the cumulative incidence 
before the age of 45 is low (181), the clinically relevant incidence resides in particular at 
young middle-age.
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9.3 CLINICAL IMPLICATIONS
One of the primary goals of this thesis was to investigate the clinical applicability of the 
metabolic syndrome. Although we are not the only one to have addressed this issue, we 
now know that the metabolic syndrome does not add additional value in risk association 
to the diagnosis of its separate components when evaluating cardiometabolic endpoints. 
In other words, one does not treat a patient differently when someone is ‘diagnosed’ with 
metabolic syndrome, since each component has its own most effective treatment strategy. 
Furthermore, we readdress the variability in diagnosing the metabolic syndrome, which 
is reflected by the specific metabolic syndrome populations that emerge when applying 
AHA-NHLBI definition versus the EGIR-definition.
This thesis addresses the gigantic scale of type 2 diabetes in The Netherlands. One in three 
will develop diabetes; one in eleven will use insulin in their lifetime. By doing so, we have 
delivered a very profound and clear signal to preventive organizations in the Netherlands, 
both commercially and government-based. This is one of the most serious health issues 
we have ever faced. Furthermore, these clear estimates will have their effects in the doc-
tor’s office since the delivery of absolute lifetime risks will improve patient adherence and 
compliance to therapy.
We deliver another clear message in diabetes prevention by providing lifetime risks of 
diabetes in individuals having prediabetes. By showing an immense prevalence of ADA-
defined prediabetes in our population and limited lifetime risk of diabetes, we question 
the feasibility of ADA-defined prediabetes in a screen-and-treat policy.
By giving a comprehensive description of the prevalence and complications of type 2 dia-
betes in the Netherlands and the different lines of care, I believe to have re-addressed the 
importance of diabetes research in the Netherlands. A substantial residual risk remains 
to be reduced through both pharmacological and lifestyle interventions. Furthermore, 
the DiaGene study has created a foundation for future omic studies such as our recent 
glycomic research that has been published by Lemmers et al. and Dotz et al. (134,135). 
Such omic layers are providing us with new pathophysiological insights, that can be used 
for preventive and therapeutic strategies. Also some of these omic layers may harbor valu-
able biomarkers to allow for early intervention to prevent disease or improve the outcome.
Last but not least, our work has created at least new hypothesis-generating results with re-
spect to risk factors for type 2 diabetes. Although I am well aware that these risk factors are 
not directly clinically applicable at this moment, it is valuable to have mentioned them in 
this section. Hopefully, my optimism will stimulate the further clinical testing of variance 
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in proline metabolism in relation with the pathophysiology of type 2 diabetes. Further-
more, although we know ADAMTS13 for its cleaving function in von Willebrand multimers, 
there have been numerous new functions of ADAMTS13 published. My unexpected result 
that ADAMTS13 increased the risk of diabetes, offers a focus on the yet unknown possible 
functions of ADAMTS13 in future human research.
9.4 DIRECTIONS FOR FUTURE RESEARCH
Metabolic syndrome
Although the metabolic syndrome has lost its value as a separate clinical entity to be 
diagnosed in general patient populations, it may still have pathophysiological value for 
the underlying mechanism to be discovered. The way obesity and insulin resistance are 
related to hypertension, dyslipidemia and hyperglycemia remains to be explored and if so, 
offers possible therapeutic targets.
Genetic studies on type 2 diabetes
There has been a lot of genetic research in type 2 diabetes. From linkage studies, to 
candidate-gene approach, and even genome-wide association studies, whole-genome se-
quencing studies with increasing sample sizes. A total of 128 signals at 113 loci have been 
independently associated with type 2 diabetes.(130,175,178). Although increasingly more 
variants have been identified, the impact on clinical-decision-making has been modest. 
At the moment the disease-risk associated with genetic testing is still outperformed by 
risk factors that are more readily available and already incorporated in clinical assess-
ment (182,183). Also, genetic risk counseling showed no significant effect on self-reported 
motivation or adherence in prevention programs for individuals having a high-risk for type 
2 diabetes mellitus (184). Due to incomplete overlap of risk loci, glycemic traits and T2D 
on the one hand and primary roles in ß-cell function for most T2D loci on the other hand, 
genomic studies did cause a shift in disease pathophysiology insights from primary insulin 
resistance to ß-cell dysfunction (178). This shows that the field of genomics, together with 
other omic layers, is able to unravel new genes and biological mechanisms that ultimately 
can be a target for therapy. So, although not directly useful in clinical prediction, genomics 
can potentially play a major role in personalized precision medicine. I therefore advocate 
to increase collaboration between study groups to maximize population sizes in order to 
find more genetics variants. Furthermore, I would recommend adding omic layers such 
as glycomics, proteomics and microbiomics since this can increase the level of findings 
of biologically higher complexity. These efforts will eventually lead us to a better under-
standing of type 2 diabetes.
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General discussion
Studies on risk factors for type 2 diabetes
There is a long and complicated history of risk factor studies in type 2 diabetes. Although 
we have investigated risk factors on an epidemiological level, I believe future research in 
type 2 diabetes should mainly focus on a fundamental level. This should focus on alterna-
tive functionalities of ADAMTS13 and the way it is related to type 2 diabetes. Is it purely 
a factor in endothelial dysfunction or does it have additional functionalities in vascular 
remodelling that can be of importance in the disease-pathophysiology of disease?
Studies on prevention of type 2 diabetes
We have made it even more clear that type 2 diabetes is of cardinal importance in future 
health care. New prevention strategies are needed to control this growing epidemic. The 
prevention strategies focusing on specific risk factors can be considered to some extent 
as personalized medicine. The question is whether specific risk factors are needed to 
determine your treatment, given the general beneficial effects of lifestyle management 
on cardiovascular and diabetes risk. Therefore, apart from screen and treat strategies, we 
advocate a population-based approach directed at both the individuals and the environ-
ment. By integrating our medical research in governmental policy on obesity and type 
2 diabetes prevention, one does not patronize but effectively prevent the disease from 
happening.
9.5 CONCLUDING REMARKS
The current thesis presents a variety of research on prevalence, lifetime risk, and conven-
tional and genetic risk factors of type 2 diabetes and metabolic syndrome. In this chapter, I 
discussed the results, methodological issues and proposed future directions for research. 
Although aware of my humble position in nature’s inscrutability, I believe the contents of 
this thesis will help fighting today’s metabolic threats.
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A global pandemic of obesity-associated diseases such as type 2 diabetes, hypertension 
and dyslipidemia is emerging due to ageing, increased food-consumption and sedentary 
behavior. Research on this topic is of vital importance for more insight into the magnitude 
of the problem, associated risk factors and potential therapeutic targets to reduce disease 
burden.
Part I of the thesis starts with a general introduction on type 2 diabetes, obesity and 
metabolic syndrome. Chapter 1 furthermore contains an overview of risk factors for type 
2 diabetes and its complications. It concludes with a section on lifetime risk estimation 
and the role of prediabetes in prevention of type 2 diabetes. Subsequently, the aims and 
scopes of this thesis are discussed in chapter 2.
In part II of the thesis, we studied the clinical value of the metabolic syndrome. Chapter 
3 contains a study on prevalence of metabolic syndrome according to different defini-
tions and risk of cardiometabolic endpoints in a community-dwelling population. We 
performed this study because controversy remained on whether a diagnosis of metabolic 
syndrome has added value on top of its individual components. Furthermore, various 
definitions of metabolic syndrome exist and our aim was to provide insight into the ef-
fect of different definitions on prevalence estimates and disease risk association. In our 
population, we conclude that metabolic syndrome is a highly prevalent condition with 
variability depending on which definition of metabolic syndrome is applied. Metabolic 
syndrome was associated with incident type 2 diabetes mellitus, coronary heart disease, 
stroke, cardiovascular mortality and all-cause mortality. However, all significant associa-
tions disappeared after correcting metabolic syndrome for its individual components. We 
conclude that metabolic syndrome does not have additional value on top of individual 
components for clinical practice.
Lifetime risk of type 2 diabetes and prediabetes is the subject of part III of this thesis. They 
provide an estimation of the cumulative risk of developing a disease during an individual’s 
remaining lifespan. In chapter 4, we studied lifetime risk of type 2 diabetes in the Rot-
terdam Study. Through the data-analysis in a prospective population-based cohort setting 
with long-term follow-up and extensive data on both parameters of glucose metabolism 
and pharmacology, we here provided a unique setting for estimation of the burden of el-
evated blood glucose levels in the context of overall survival. The estimates of lifetime risk 
are easy to interpret for both experts and lays and will thereby facilitate communication. 
We found that the lifetime risk at age 45 to develop prediabetes is one in two and that 75% 
of study subjects that developed prediabetes progress to diabetes during their lifetime. 
A staggering one-in-three of the population at age 45 will develop diabetes throughout 
their lifetime. Of these, 50% will become insulin-dependent. We conclude that our results 
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demonstrate the immense burden of impaired glucose metabolism on our society and 
underline the importance of effective prevention strategies. The aspect of prevention is 
discussed in chapter 5. Here, we compare lifetime risk to progress to diabetes between 
the definition of prediabetes according to the World Health Organization (WHO) and the 
American Diabetes Association (ADA), the latter having a lower glucose cut-off value, in 
both women and men. We found that ADA-criteria for prediabetes diagnosed up to half of 
the population as prediabetes, more than doubling the prevalence estimates of predia-
betes generated by WHO-criteria in each age category. At age 45, approximately half the 
individuals diagnosed with prediabetes according to ADA-definition and approximately 
two-thirds of WHO-defined prediabetes will eventually develop diabetes. Women with 
prediabetes had higher lifetime risk to progress to diabetes compared to men probably 
due to their worse metabolic state at baseline and this lifetime risk was substantially lower 
in women and men with ADA prediabetes as compared to WHO prediabetes. Therefore 
we conclude that ADA criteria result in the addition of relatively low risk individuals to 
the prediabetes diagnosis. More research is needed into the optimal sex- and age-specific 
prediabetes cutoff for the most efficient and cost-effective preventive strategies.
Part IV of this thesis handles with risk factors for type 2 diabetes and its complications on 
both epidemiological, biochemical and genetical level. Chapter 6 gives a description of 
the DiaGene study, which is a multicenter T2DM cohort study collected in the Netherlands 
in both primary and secondary care. The main purpose of the DiaGene Study is to study 
genetic, biochemical and environmental determinants of T2DM and its complications. In 
total, 1886 patients with type 2 diabetes and 854 controls were included. From their data, 
we concluded that considerable rates of macrovascular and microvascular complications 
are present in the Dutch diabetes population despite treatment. These prevalence rates are 
comparable to other type 2 diabetes populations. Apart from prevalence of complications, 
we describe 11 well-known type 2 diabetes genetic risk variants (in TCF7L2, PPARG-P12A, 
KCNJ11, FTO, IGF2BP2, DUSP9, CENTD2, THADA, HHEX, CDKAL1, KCNQ1) and observe 
similar associations compared to literature. Since we have genetic and biochemical data 
combined with an extensively phenotyped population, this study is well-suited to further 
elucidate pathophysiological disease mechanisms. One genetic association in type 2 dia-
betes is further discussed in chapter 7, where we have assessed the influence of genetic 
variance in the proline transporter SLC6A20 by performing a candidate-gene study. Since 
SLC6A20 is an essential component of proline metabolism and therefore can influence 
glucose homeostasis, we hypothesized that variants in the SLC6A20 gene influence type 
2 diabetes risk in our population. Our study resulted in several findings. At first, the minor 
alleles of rs13062383, rs10461016 and rs2286489 increased the risk of Type 2 diabetes in 
the discovery cohort. However, in an Asian replication population and subsequent meta-
analysis, a highly significant association of rs13062383 with Type 2 diabetes remained. 
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Therefore, we concluded that rs13062383 in SLC6A20 increased the susceptibility to type 
2 diabetes in populations with different genetic backgrounds. In chapter 8, we report our 
study on the association of ADAMTS13-activity and VWF-antigen with incident diabetes. 
ADAMTS13 is a protease that breaks down von Willebrand factor (VWF) multimers into 
smaller, less active particles. VWF has been associated with an increased risk of incident 
type 2 diabetes mellitus. In our large prospective population-based study, ADAMTS13 
activity was associated with an increased risk of incident diabetes and prediabetes 
after adjustment for known risk factors and VWF antigen. Therefore we concluded that 
ADAMTS13 activity appears to be an independent risk factor for incident prediabetes and 
type 2 diabetes. Since the association cannot be explained through its known function, an 
alternative hypothesis is an additional proteolytic functionality of ADAMTS13 beyond VWF 
cleavage.
Finally, part IV of the thesis contains the general discussion in chapter 9. Herein, I discuss 
the results in the context of present-day literature, methodological issues and proposed 
future directions for research. Summarizing the conclusions of this thesis are 1) the meta-
bolic syndrome does not add additional value in risk association to the diagnosis of its 
separate components when evaluating cardiometabolic endpoints. 2) The scale of type 2 
diabetes in The Netherlands is gigantic. One in three will develop diabetes, one in eleven 
will use insulin in their lifetime. 3) There is an immense prevalence of ADA-defined predia-
betes in our population and limited lifetime risk of diabetes. Further research is needed 
on the feasibility of ADA-defined prediabetes in a screen-and-treat policy. 4) SLC6A20 is a 
genetic risk variant associated with type 2 diabetes and ADAMTS13 is an independent risk 
factor for incident type 2 diabetes and prediabetes.
The scientific field of obesity-associated diseases is dynamic and contains many chal-
lenges that need to be solved. Through this thesis, we contribute to the improvement of 
identification, prevention and treatment of type 2 diabetes and associated diseases.
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Er is een wereldwijde epidemie van ziektes die geassocieerd zijn met obesitas zoals diabe-
tes mellitus type 2, hypertensie en dyslipidemie. Dit komt onder andere door vergrijzing, 
voedingsgewoonten en een inactieve leefstijl. Onderzoek naar dit onderwerp is van 
levensbelang want we hebben inzicht nodig in de exacte grootte van het probleem, de risi-
cofactoren die geassocieerd zijn met de verschillende ziektes en mogelijke therapeutische 
opties om de ziektelast te verminderen.
Deel 1 van dit proefschrift start met een algemene introductie over diabetes type 2, obe-
sitas en het metabool syndroom met ook een overzicht van risicofactoren voor diabetes 
type 2 en de complicaties van deze ziekte. Hoofdstuk 1 eindigt met uitleg over epidemiolo-
gische levenslange risicoberekeningen en de rol van het vaststellen van prediabetes bij de 
preventie van diabetes type 2. Naast een algemene introductie wordt in hoofdstuk 2 het 
doel van dit proefschrift uiteengezet.
In deel 2 van dit proefschrift hebben we de klinische waarde van het metabool syndroom 
bestudeerd. Hoofdstuk 3 beschrijft hoe vaak het metabool syndroom voorkomt en hoe 
dit varieert afhankelijk van welke definitie men kiest. Tevens kijken we naar het verband 
tussen metabool syndroom en het risico op cardiometabole ziektes in de algemene 
bevolking. We hebben deze studie verricht omdat er controverse bestond over of het 
metabool syndroom toegevoegde waarde heeft bovenop de losse componenten waaruit 
het syndroom bestaat. Daarnaast zijn er verschillende definities van het metabool syn-
droom, waarbij ons doel was meer inzicht te verkrijgen in het effect dat het toepassen van 
de verschillende definities heeft op de prevalentiecijfers en risico associatie. Op basis van 
onze resultaten concluderen we dat het metabool syndroom in onze populatie een hoge 
prevalentie kent met hoge variabiliteit afhankelijk van verschillende afkapwaardes van de 
definities. Het metabool syndroom was in onze studie geassocieerd met de incidentie van 
diabetes type 2, coronaire hartziekten, cerebrovasculaire aandoeningen, cardiovasculaire 
mortaliteit en mortaliteit door alle oorzaken. Echter verdwijnen al deze associaties nadat 
we het metabool syndroom corrigeren voor de individuele componenten waaruit het is 
opgebouwd. We concluderen dan ook dat het metabool syndroom geen toegevoegde 
waarde heeft bovenop de componenten waaruit het is opgebouwd voor voorspelling van 
cardiometabole ziektes in de klinische praktijk.
Het levenslange risico op het krijgen van diabetes type 2 en prediabetes staat centraal in 
deel III van dit proefschrift. Deze levenslange risicoberekening geeft een schatting van het 
cumulatieve risico dat een persoon loopt om een ziekte in zijn of haar leven te krijgen. 
In hoofdstuk 4 hebben we het levenslange risico op diabetes type 2 in de Rotterdam 
Studie onderzocht. Door deze specifieke analyse toe te passen in een prospectief cohort 
van de algehele populatie met een lange follow-up en uitgebreide gegevens over glucose 
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metabolisme en medicatiegebruik, hebben we een unieke en kwalitatief hoogwaardige 
schatting kunnen geven van hoe vaak stoornissen van het glucose metabolisme voorko-
men We hebben gevonden dat er op een leeftijd van 45 jaar, een levenslang risico van 50% 
is om prediabetes te ontwikkelen en dat 75% van de personen die prediabetes hebben, 
ook diabetes ontwikkelen in hun leven. Uiteindelijk ontwikkelt 1 op 3 personen met een 
leeftijd van 45 jaar, diabetes tijdens de rest van hun leven. Van deze diabetici zal de helft 
insulineafhankelijk worden. Door onze berekeningen van levenslang risico zorgen we voor 
makkelijk te interpreteren risicoschattingen voor zowel zorgverleners als leken. Hiermee 
bevorderen we de kwaliteit van risico-communicatie in de spreekkamer. Daarnaast heb-
ben we met onze studie de grootte van het probleem in Nederland duidelijk gemaakt en 
pleiten we voor onderzoek naar effectievere preventieve strategieën.
Het preventieve aspect wordt verder besproken in hoofdstuk 5. Hier vergelijken we het 
levenslange risico op progressie naar diabetes type 2 tussen twee definities van prediabe-
tes in zowel vrouwen als mannen. Dit zijn de definities van de World Health Organization 
(WHO) en de American Diabetes Association (ADA), van welke de laatste een lagere glucose 
afkapwaarde heeft. Uit onze resultaten bleek dat de ADA-definitie de helft van de popula-
tie diagnosticeert als prediabeet en dat in elke leeftijdscategorie de prevalentiecijfers het 
dubbele waren van de WHO-definitie. Op een leeftijd van 45 jaar zal ongeveer de helft van 
de individuen met een ADA-prediabetes diagnose uiteindelijk diabetes ontwikkelen ten 
opzichte van tweederde van de individuen met een WHO-prediabetes diagnose. Vrouwen 
met prediabetes hebben een hoger levenslang risico om diabetes te ontwikkelen in ver-
gelijking met mannen, hetgeen waarschijnlijk het gevolg is van hun slechtere metabole 
toestand bij het begin van de studie follow-up. Dit levenslang risico op het ontwikkelen 
van diabetes was lager bij zowel vrouwen en mannen met ADA prediabetes in vergelijking 
met WHO-prediabetes. Hieruit concluderen we dat een ADA-definitie resulteert in het se-
lecteren van individuen met een lager risico op het ontwikkelen van diabetes, waarbij het 
de vraag is of bij al deze personen preventieve interventies effectief, noodzakelijk en kos-
teneffectief zullen zijn. We stellen dan ook voor dat er nader onderzoek moet plaatsvinden 
naar de optimale afkapwaarde met aandacht voor zowel leeftijd als geslacht binnen de 
prediabetes definitie waarmee de meest effectieve en efficiënte selectie van hoog-risico 
patiënten kan worden gemaakt
Deel IV van dit proefschrift gaat over epidemiologische, biochemische en genetische risi-
cofactoren voor het krijgen van diabetes type 2 en de complicaties die met diabetes type 2 
gepaard gaan. Hoofdstuk 6 geeft een beschrijving van de DiaGene studie, een multicenter 
diabetes type 2 cohort studie uit de eerste en tweede lijn in Nederland. Het belangrijkste 
doel van de studie is het analyseren van genetische, biochemische en omgevingsfactoren 
die het ontstaan van diabetes type 2 en haar complicaties beïnvloeden. Uit de data die 
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we verkregen, concludeerden we dat er ondanks behandeling een aanzienlijk aantal 
macro- en microvasculaire complicaties voorkomt in de diabetespopulatie in Nederland. 
De prevalentiecijfers zijn vergelijkbaar met andere studiepopulaties van diabetes type 
2. Los van de prevalentie van complicaties, beschrijven we 11 bekende genetische risico 
varianten (TCF7L2, PPARG-P12A, KCNJ11, FTO, IGF2BP2, DUSP9, CENTD2, THADA, HHEX, 
CDKAL1, KCNQ1) en zien we dezelfde associaties als eerder beschreven is in de literatuur. 
We concluderen dat onze studie, waarin we genetische en biochemische data combineren 
met een uitgebreid gefenotypeerde populatie, geschikt is om verder onderzoek te doen 
naar pathofysiologische mechanismen van diabetes type 2.
Een nieuwe genetische associatie bij diabetes type 2 wordt besproken in hoofdstuk 7, 
waarin we de invloed van genetische variatie binnen de proline transporter SLC6A20 on-
derzoeken door het verrichten van een kandidaat-gen studie. Omdat SLC6A20 een essen-
tieel onderdeel is van proline metabolisme en glucose homeostase beïnvloedt, was onze 
hypothese dat varianten in het SLC6A20 gen het risico op het krijgen van diabetes type 2 
beïnvloedt. Onze studie heeft ons verschillende bevindingen opgeleverd. Allereerst zagen 
we dat de minor allelen rs13062383, rs10461016 en rs2286489 het risico op het krijgen 
van diabetes type 2 verhogen. Daarnaast zagen we dat in een Aziatische replicatie studie 
en meta-analyse alleen de associatie van rs13062383 hoogst significant bleef. Zodoende 
concludeerden we dat rs13062383 in SLC6A20 het risico op het krijgen van diabetes type 2 
in populaties met verschillende genetische achtergrond verhoogt.
In hoofdstuk 8 beschrijven we een studie die de associatie onderzocht van ADAMTS13-
activiteit en von-Willebrand factor (VWF)-antigen met incidente diabetes type 2. We 
hebben dit onderzocht omdat ADAMTS13 een protease is dat vWF-multimeren verwerkt 
tot kleinere, minder actieve onderdelen. VWF is in het verleden al geassocieerd met 
een verhoogd risico op het krijgen van diabetes type 2. In onze studie bleek ADAMTS13-
activiteit geassocieerd te zijn met een verhoogd risico op het krijgen van zowel diabetes 
als prediabetes na correctie voor bekende risicofactoren en VWF-antigeen. We hebben 
hierdoor geconcludeerd dat ADAMTS13-activiteit een onafhankelijke risicofactor voor het 
krijgen van prediabetes en diabetes type 2.
Tot slot bevat deel IV van dit proefschrift de algemene discussie in hoofdstuk 9. Hierin 
bediscussieer ik de resultaten van de onderzoeken in de context van de huidige literatuur, 
maar ook methodologische kwesties en voorstellen voor toekomstig onderzoek. Ik heb 
enkele conclusies van dit proefschrift te benoemen: 1) het metabool syndroom heeft 
geen toegevoegde waarde ten opzichte van de componenten waaruit het is opgebouwd 
bij risicopredictie van cardiovasculaire en metabole ziekte. 2) de schaal waarop diabetes 
type 2 in Nederland voorkomt is gigantisch; 1 op de drie ontwikkelt diabetes, 1 op 11 
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zal insulineafhankelijk worden in zijn of haar leven. 3) Door het toepassen van de ADA-
definitie ontstaat er een enorme prevalentie van prediabetes met een relatief gelimiteerd 
levenslang risico op het krijgen van diabetes. We betwijfelen hiermee de haalbaarheid 
van ADA-prediabetes in een screen-en-behandelstrategie. 4) SLC6A20 is een genetische 
variant welke geassocieerd is met diabetes type 2, evenals ADAMTS13-activiteit, hetgeen 
ook geassocieerd is met prediabetes. Het wetenschappelijk onderzoek bij ziektes geas-
socieerd met obesitas is zeer dynamisch en kent veel uitdagingen die nog moeten worden 
opgelost. Met deze thesis, dragen we bij aan een verbetering van identificatie, preventie 
en behandeling van diabetes type 2 en geassocieerde ziektes.
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Terwijl ik dit opschrijf besef ik me terdege dat mijn proefschrift af is. Uiteindelijk is het een 
zeer leerzame en enerverende periode geweest waarin ik veel heb geleerd en waarvoor ik 
een aantal mensen graag zou willen bedanken.
Allereerst wil ik mijn promotor prof. dr. E.J.G. Sijbrands bedanken. Beste Eric, bedankt 
voor je bevlogen adviezen en commentaren. Door jouw onophoudelijke en aanstekelijke 
enthousiasme met ontzettend creatieve en originele inbreng heb ik altijd weten door 
te zetten. Naast discussies over het werk, hebben we ook veel gediscussieerd over die 
belangrijkste bijzaak in het leven, waarvoor dank. Bedankt voor alles wat je in mijn pro-
motietijd voor mij hebt gedaan.
Many thanks go out to my second promotor Prof Dr. O.H. Franco. Dear Oscar, during our 
sessions you always provided me with new insights and positive energy. Thank you very 
much for your most valuable comments, hands-on advice and most of all the opportunity 
to work in such an inspiring research group.
Mijn eerste copromotor, Dr. M. van Hoek, zou ik graag willen bedanken. Beste Mandy, 
bedankt voor je engelengeduld met mij. Ondanks dat het proefschrift telkens op zich liet 
wachten door weer een klinisch drukke periode of een moeizame rebuttal waarin het 
allemaal even op zich liet wachten, bleef je altijd geduldig, enthousiast en vooral zeer des-
kundig. Bedankt voor jouw scherpe commentaren, gezellige nuchtere humor en kordate 
begeleiding. Dank!
Mijn tweede copromotor, Dr. A.G. Lieverse, zou ik hierbij ook graag willen bedanken. 
Beste Louis, dankzij jou ben ik bij het onderzoek terechtgekomen. Via een route in het 
prachtige Máxima Medisch Centrum met Prof. Dr. H.R. Haak, kwam ik als semi-arts bij jullie 
terecht. Daar ben ik geraakt door het vak interne geneeskunde. Dankzij jou heb ik een start 
in zowel wetenschap als kliniek gehad. Jouw begeleiding was laagdrempelig, prettig en 
buitengewoon deskundig. Bedankt hiervoor.
Ik wil graag de leden van de leescommissie bedanken voor hun kritische beoordeling van 
het manuscript:
Prof. Dr. C. Stettler, dear Christoph, I am honoured that you have read my manuscript, gave 
your most valuable comments and were willing to be part of this committee. Thank you 
very much.
Prof Dr. E.F.C. van Rossum, beste Liesbeth, hartelijk dank voor het plaatsnemen in de 
commissie. Ik vind het gewoon fantastisch om een zo positieve, vooruitstrevende en in-
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spirerende autoriteit op het gebied van obesitas in de commissie te mogen hebben. Dank 
hiervoor.
Prof. Dr. H.R. Haak, beste Harm, door jou wilde ik internist worden. De kundigheid en stand-
vastigheid die jij immer tentoonspreidt en waarvan ik getuige heb mogen zijn, bewonder 
ik. Jij wist je tot in de periferie van mijn opleiding in Rotterdam te bekommeren om het wel 
en wee van mijn leercurve en welzijn hetgeen je siert en kenmerkt als internist, opleider 
en mens. Dat jij bovendien op natuurlijke en prettige wijze respect en autoriteit afdwingt 
maar bovenal voor mij een sleutelfiguur bent en blijft waaraan ik mijn functioneren spie-
gel, geeft mij aan je te danken voor de hulp en begeleiding. Het is enorm gewaardeerd.
Graag wil ik ook bedanken Prof. Dr. P.W.B. Nanayakkara en Prof. Dr. B. Bravenboer voor het 
plaatsnemen in de promotiecommissie.
Prof. Dr. P.W.B. Nanayakkara, beste Prabath, jouw aanstekelijke enthousiasme en scherpe 
ideeën geven mij veel energie en inspireren bovenal! Je bent een geweldig acuut internist 
en ik vind het een eer dat jij plaats hebt willen nemen in de commissie.
Prof. Dr. B. Bravenboer, beste Bert, bedankt voor jouw advies en commentaar. Van het 
begin van mijn onderzoeksperiode waarin jij hebt geholpen bij de inclusie van patiënten 
en latere kritische revisies van de manuscripten. Het is een eer dat je in de commissie 
plaats hebt willen nemen.
Graag wil ik alle co-auteurs bedanken voor hun bijdrage aan de manuscripten beschreven 
in dit proefschrift: Dr. A. Dehghan, Dr. M. Kavousi, Dr. M.J.G. Leening, Prof. Dr. B.H.Ch. Stric-
ker, Dr. J.G. Langendonk, Dr. R.F.H. Lemmers, Dr. R.J. Erdtsieck, Dr. A. Lucas, Dr. M.T. Mulder, 
Prof. Dr. M.A. Ikram, Prof. Dr. A. Hofman, Prof Dr. M.P.M. de Maat, Prof Dr. F.W.G. Leebeek. 
Beste Maarten, door jouw uitermate deskundige commentaren en adviezen is de kwaliteit 
van de manuscripten verbeterd. Strik eromheen en dank! Beste Janneke, bedankt voor 
jouw bijstand, hulp en advies. Roosmarijn, lieve collega! Ik heb altijd genoten van onze 
overlegjes, koffiebabbels en fietsanalyses. Ronald, bedankt voor jouw waardevolle hulp 
bij de inclusie van patiënten. Dear Maryam, thank you for your help, advise and valuable 
comments. Abbas, thank you very much for your patience, comments and guidance. You 
have helped me a lot throughout the process of this thesis and I am very thankful for that. 
Het gehele onderzoek was niet mogelijk geweest indien er geen deelnemers bereid 
waren om hun medewerking te verlenen. Daarom zou ik graag alle deelnemers aan de 
DiaGene studie en Rotterdam studie willen bedanken. Zeker zou ik ook alle internisten, 
verpleegkundigen en laboranten bedanken die hebben meegewerkt aan de inzameling 
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en verwerking van gegevens binnen de DiaGene studie en Rotterdam studie. En mijn dank 
aan Leonie, Jeanette, Antoon, Edith en Hanny voor hun geweldige hulp! 
Dan ga ik ook zeker mijn paranimfen Frederik Bouw en Rick van de Langenberg bedanken.
Freddy, we hebben een mooie tijd in Rotterdam achter de rug. Je bent vanaf het begin af 
aan een goede vriend geweest waarbij ik altijd enorme steun aan je heb gehad. Ik herinner 
me de geweldige bakkie’s, etentjes, party’s en German roadtrips met een gouden randje. 
Je gaat met jouw lieve Kirsten, Didrik en Olivier zeker een geweldige toekomst tegemoet!
Face, wat mooi dat je mijn paranimf bent! Door alle jaren heen waarin we veel hebben 
meegemaakt, hebben we elkaar gevonden en opnieuw uitgevonden. Zo blij voor je dat je 
je plek hebt gevonden in Utrecht met je lieve vrouw Celien en jullie prachtige dochtertje 
Sara. Ik waardeer je steun door dik en dun en geniet altijd van je verhalen, commentaren 
en grollen! JWZ Bro! X
Graag zou ik ook mijn mede auteurs willen bedanken. Dr. Paul S. de Vries en Dr. S. Lig-
thart. Paul, bedankt voor de samenwerking bij ons onderzoek naar ADAMTS13. Het was 
een groot genoegen om met je te kunnen overleggen en sparren maar bovenal te mogen 
genieten van je oneindige vriendelijkheid en redelijkheid. Wat een prachtige stap naar de 
VS en bewonderenswaardig hoe je daar je leven met je vrouw Lysed hebt opgebouwd. 
Bedankt voor alles!
Symen, ongelofelijk bedankt voor je hulp. Naast een geweldige collega ben je een vriend 
geworden, hebben we de nodige wetenschappelijke, politieke maar ook onzinnige discus-
sies gehad. Samen zijn we naar de ADA-congressen in Boston en New Orleans geweest 
hetgeen geweldig was. Ook hebben we samengewerkt in het Amphia waarbij ik je heb 
leren kennen als een extreem kundig arts. Ik geniet van je kennis, kunde, bevlogenheid, 
enthousiasme en gevoel voor humor. Ik hoop dat we nog vele jaren samen kunnen werken.
Bd-289 master mannen, bedankt voor jullie steun en toeverlaat, rempeng balletjes, 
raketlanceringen, en ziekenhuispasbeschilderingen. Sjaam, bedankt voor je ontspannen 
aanwezigheid in ons kantoortje. De Rempeng was awesome, big up yourself! Stijn, je bent 
een dedicated cardioloog die keihard werkt maar zeker ook weet te genieten. Alles wat jij 
doet, doe je dedicated. Ik heb genoten van de fietsles die je me regelmatig hebt gegeven! 
Luit, ik heb genoten van je gestrekte been altijd en overal. Jouw onnavolgbare scherpte 
stemt altijd tot nadenken in positieve zin. Daarnaast ben je een hartelijke gast en hoop ik 
dat we elkaar nog lang mogen zien in de toekomst. Bedankt!
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Tijdens deze periode heb ik het genoegen gehad om samen te werken met meerdere op-
leiders in de opleiding interne geneeskunde. Allereerst wil ik mijn opleiders in het Erasmus 
MC bedanken. Prof. Dr. J.L.C.M. van Saase, Dr. J. Alsma en Prof. Dr. S.C.E. Klein Nagelvoort-
Schuit. Beste Jan, Zowel als opleider, supervisor en als mens heb ik altijd enorm van je 
kunnen genieten. De rust, afweging, deskundigheid die je uitstraalt heeft een uitermate 
positief effect op eenieder die jouw begeleiding mag genieten. Bedankt daarvoor. Beste 
Jelmer, de opleiding acute interne geneeskunde heeft een geweldig mooie tijd mogen zijn 
en daarvoor wil ik je heel graag bedanken. Beste Stephanie, jouw pragmatische, kordate 
en vakinhoudelijk sublieme begeleiding heeft mij enorm geholpen in het bereiken van 
mijn doelen tijdens de opleiding. Dank daarvoor.
Dank opleider Dr. P.J. Wismans. Pieter, je bent een geweldige internist zowel op medisch-
inhoudelijk vlak en als mens. Jij hebt gezorgd dat we als Havencrew een soort familie zijn 
geworden. Ik bewonder je omnivore kennisbehoefte alsmede de passie die je hebt voor je 
patiënten, assistenten en personeel! Bedankt voor je warmte en vriendschap.
Uiteraard ook mijn dank aan Dr. H. Boom. Beste Henk, ik heb een prachtige tijd gehad in 
het Reinier de Graaf Gasthuis. Jouw bezielende leiding waarbij je niet bang bent om het 
beestje bij de naam te noemen, respecteer ik enorm. Tijdens mijn tijd in het Reinier en 
zeker ook tijdens de dialysestage, heb ik enorm veel geleerd en daarvoor zou ik je heel 
graag willen bedanken.
Daarnaast wil ik ook graag mijn laatste perifere opleiders bedanken. Allereerst Dr. G. 
Buunk. Beste Gerba, jouw aanwezigheid geeft rust in het ziekenhuis en dat is het beste 
compliment dat je een acuut internist kan geven. Naast de kans die je me hebt gegeven om 
fellow acute en later als internist in het Amphia te mogen werken, wil ik je bedanken voor 
de steun die je me hebt gegeven. Jouw nuchterheid en kalmte gaven mij rust op momen-
ten dat ik het heel goed kon gebruiken. Dr. J.W.J. van Esser. Beste Joost, Ik bewonder je 
als mens en opleider omdat je zowel vakinhoudelijk als op menselijk vlak mijns inziens op 
de top presteert. Met jouw sociale capaciteit kun jij eenieder direct op zijn of haar gemak 
stellen en weet jij wat er speelt om daar op een fijne manier op in te spelen. Ik heb naast 
je vakinhoudelijke begeleiding ook enorm genoten van onze gesprekken over de wereld-
geschiedenis en het mooie Zuiden. Ik hoop dat het je goed gaat inde toekomst en dat ons 
contact nog lang blijft bestaan.
Graag zou ik ook mijn huidige opleider op de intensive care, Dr. D.C.J.J. Bergmans, willen be-
danken voor de prettige ontvangst en uitermate interessante tijd waarvan ik tot nu toe heb 
mogen genieten tijdens mijn fellowship in het MUMC+ in Maastricht. Ook alle intensivisten, 
fellows, arts-assistenten en verpleegkundigen IC bedankt voor de nu al prachtige tijd!
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Graag zou ik ook de mannen van de OHD Silenus in Maastricht willen bedanken. Zij heb-
ben me een mooie studietijd bezorgd en vriendschappen voor het leven. Bransen, wat 
mooi dat we elkaar weer gaan ontmoeten in Maastricht! Flipside! Enschot, mooie tijden 
beleefd en er zullen nog mooie tijden komen! Timmie, hoe vaak ik wel niet heb gezegd 
dat het ging gebeuren. Dank voor je inspirerende vriendschap! Mosmuller, bedankt voor 
alles, ook al spreken we elkaar niet vaak, het is altijd goed! Thomas en Wouter, jullie zijn 
mijn kunstzinnige en creatieve helden! Jack’ur body! Rubber, Kees, Lukees, Poire, Marco, 
Masih, Casper, Pierre, Camel, Ruben en nog alle andere helden.
De super 14. Ik ben enorm dankbaar dat ik lid ben van dit illustere middelbare school 
genootschap. Dick, goudeerlijke vent, Werchter-koning, jouw visie op bepaalde zaken is 
interessant en blijft mij in positieve zin verbazen. Worm, bedankt voor je chakrale inspi-
ratie en creativiteit. De wenteling van het vocabulaire neemt bij jou immer een prachtige 
curve. Nick, Nix jij ouwe geluksvogel dwingt dit af door alles en iedereen goed en serieus 
te behandelen. Onze vakanties koester ik enorm! Vinnie, gouden Balatonbeer. Je bent een 
lieve gast met een hart van platina. Ik leer je steeds beter kennen en dat vind ik geweldig, 
held! G, Gerry Flexible, je bent een koning van het eerste uur, een spreker die vlijmscherp 
in de ziel van de mens kan kijken. Je werk kan niet beter bij je passen, ik geniet van jou! 
Tjerry P, ik vind ons contact waardevol en onze gesprekken vaak weergaloos! Het ga je 
goed! Ringrose, ouwe kameel. Je bent een rots in de branding, een rustpunt. Ik waardeer 
je vriendschap en adviezen en bewonder je passie voor de geestelijke gezondheidszorg. 
Joris, Ekson, jij was mijn eerste maat op de middelbare school en ik geniet tot op de dag 
van vandaag heel erg van je vriendschap. Je bent een geweldig huisarts en ook nog in een 
prachtige stad :). Bedankt daarvoor! Maarten, aap, jouw gedrevenheid in de advocatuur 
is bewonderenswaardig en je vriendschap onnavolgbaar. Je hebt zoveel haar op je borst 
als hartelijkheid, heel veel dus! Bedankt! Paulus, Duif, je chaos is heerlijk en geeft aan dat 
je vooral kijkt naar de grote lijn. Ik geniet daarvan, evenals onze vriendschap en liefde 
voor auto’s. Zin om met jou te klussen aan ons klassieke rallybeest. Fr@, Freddy B, vriend 
van de familie van Herpt-Hobijn, ouwe bankklever. Ik houd enorm van onze vriendschap. 
Onze gezamenlijke passie voor afzien, trainen en kapotgaan is geweldig. Op nog vele jaren 
samen trainen, lullen en af en toe een borreltje! Emil, Enderto, pad, bedankt voor jouw 
creatieve inbreng, je vriendschap en je smeuïg soepele en onnavolgbare teksten. Ik blijf 
het zeggen: Jij bent en wordt een groot journalist! Bedankt maat! Rolof HP, vriend voor het 
leven, creatieve en kundige geest. Bedankt voor jouw steun en toeverlaat en hit-linkjes. 
De Franse technokelder komt er heus! Manolo, tekstverslindende leesmachine, held en 
geweldige vriend! De boekenclub, Inheemse stamtalen en Karel V mogen wat mij betreft 
nog heel vaak en lang gebeuren. Bedankt dat jij er bent!
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Mannen van het HS; Jan, Joost en Rick (Face, red). Een prachtige studententijd hebben we 
mogen voortzetten in een mooi leven als man, vader en uiteraard HS-mattie. Jan/Jean: een 
jachtvliegtuig dat gewapend met onophoudelijke energie, chirurgische vakkundigheid, 
een overontwikkelde emotionele radar en een bak aan intelligentie iedere donkere wolk 
weer opklaart. Bedankt voor jouw vriendschap, je bent een gouden gast met een gouden 
toekomst samen met Michelle en Jantje! Joost/Josh/Kolossos: de mate waarin jij zonder 
angst of aannames nieuwe avonturen instapt is bewonderenswaardig. Naast jouw sociale 
capaciteit en vingervlugge handigheid beschik je over een beukharde processor. We delen 
onze liefde voor Sacha Baron Cohen en reaguren ons een ongeluk waarvoor dank. Ik hoop 
dat we nog veel avonturen mogen beleven samen! Alle geluk en liefde voor jou, Lot, Vins 
en Mels! Face, ontzettende vent die je bent. Vanaf het moment dat je mijn treinmaatje was, 
ben je een geweldige maat. Ik hou enorm van je nuchtere commentaar en prettige advie-
zen. Zelf het Midden-Oosten kun je met een vlijmscherpe gortdroge analyse verhelderen. 
Dat we nog maar lang mogen genieten van onze vrouwkes, kinders, weekendjes en fessa’s.
Natuurlijk wil ik ook mijn familie bedanken. Zonder jullie steun had ik dit nooit kunnen 
doen. Ome Janus en tante Hilly, ik wil jullie heel graag bedanken voor jullie gezelligheid en 
lieve ondersteuning. Paul, lieve schoonvader, bedankt voor jouw adviezen, hulp en altijd 
aanwezige steun bij het soms wat chaotische huishouden en klussen en je gezellige praat, 
bedankt! Lieve Irma, het proefschrift kwam te laat voor jou. Het was zo fijn geweest als jij 
met ons deze mijlpaal had kunnen beleven. Jouw liefde, zorg en motivatie zijn voor mij een 
inspiratie. Ik zal altijd goed voor je dochter en kleinzoon zorgen! Mijn lieve pa en ma, jullie 
zijn er altijd voor ons als kinderen geweest. Jullie hebben ons altijd gesteund in hetgeen 
we wilden gaan doen. Ik hou enorm van jullie en hoop dat jullie nog lang mogen genieten 
van jullie leven met die enorme meute aan kleinkinderen. Rens, Linda, Mara, Leon en Bj-
orn, bedankt voor jullie steun, koffie en sushimomenten. Jullie hebben een prachtig gezin 
en een heerlijke standplaats in Nederwetten, groei groot en geniet ervan! Bram en Vera, 
Roos, Sarah, Julie en David! Bedankt voor jullie steun, amusement en heerlijke chaos. Het 
is altijd weer genieten als we bij jullie over de vloer komen of vice versa, jullie stralen een 
bak inspiratie en energie uit!en dat is ongelofelijk belangrijk voor mij en ons! Lieve familie 
van Herpt- van Liempt-Nouwens-Tankink, ik hou van jullie!
Tenslotte wil ik lieve Mandy bedanken, mijn lieve kippie. Sinds ons introductielesje in het 
Reiniertje is mijn wereld door jou in positieve zin compleet veranderd. Na het afgelopen 
zware jaar waarin jouw lieve moeder Irma is overleden, gaan we er met onze lieve zoon 
Niek tegenaan om in de komende jaren weer veel plezier te beleven. We zijn verhuisd naar 
Maastricht en hebben alweer mooie plannen liggen. Ik weet zeker dat er een prachtige 
tijd staat te komen en heb enorm veel zin om die met jou en Niek te gaan beleven. Ik hou 
enorm veel van je.
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Thijs van Herpt was born on July 19th 1984 in Helmond. After graduating Cum Laude for 
his gymnasium on Pleincollege Eckart in Eindhoven, he studied medicine at Maastricht 
University. The last year of his internship he completed under supervision of Prof. Dr. H.R. 
Haak in Máxima medical center in Eindhoven where he started as part-time resident not in 
training and researcher after which he moved to Rotterdam in 2011 to perform full-time re-
search at the departments of vascular internal medicine and epidemiology of the Erasmus 
MC. In 2013, he started his training to become an internist in the Havenziekenhuis with Dr. 
P.J. Wismans in Rotterdam. After this period in Rotterdam, he continued his training in the 
Reinier de Graaf Gasthuis Delft (Dr. H. Boom and Dr. E.F. Posthuma) and returned to Eras-
mus MC in 2016 under supervision of Dr. S.C.E. Klein Nagelvoort-Schuit. In 2017, he was 
enrolled in the sub specialism of Acute Internal Medicine under supervision of Dr. J. Alsma. 
During and after his last year of training, he worked as a senior resident and internist in 
Amphia hospital in Breda. From March 2020 onward, he is enrolled in a fellowship training 
program Intensive Care in Maastricht University Medical Center under supervision of Dr. 
D.C.J.J. Bergmans. Thijs has a wife and a son, called Mandy and Niek. In his spare time, he 
hikes, runs marathons or cycles across the Dutch, Flemish and French countryside.
Thijs van Herpt werd geboren op 19 juli 1984 te Helmond. Na het Cum Laude behalen 
van zijn gymnasiumdiploma aan het Pleincollege Eckart in Eindhoven begon hij aan de 
studie geneeskunde aan de Universiteit Maastricht. Hij doorliep zijn coassistentschappen 
waarvan hij in het laatste jaar zijn artsexamen in 2008 volbracht in het Máxima Medisch 
Centrum Eindhoven onder de hoede van Prof. Dr. H.R. Haak. Hier kwam hij ook te werken 
als parttime arts-assistent en parttime arts-onderzoeker. In 2011 verhuisde hij naar Rot-
terdam om fulltime onderzoek te doen bij de afdelingen vasculaire geneeskunde en epi-
demiologie van het Erasmus MC waarna hij in 2013 begon met de opleiding tot internist. In 
eerste instantie onder de bezielende leiding van Dr. P.J. Wismans in het Havenziekenhuis 
te Rotterdam. Vervolgens heeft hij in 2014 de opleiding voortgezet in het Reinier de Graaf 
Gasthuis te Delft (opleider Dr. H. Boom en Dr. E.F.M. Posthuma) om in september 2016 
weer terug te keren naar het Erasmus MC (opleider Dr. S.C.E. Klein Nagelvoort-Schuit). Hij 
heeft zich vanaf 1 mei 2017 gespecialiseerd in het aandachtsgebied Acute Geneeskunde 
(opleider J. Alsma). Vanaf 1 juli 2019 was hij werkzaam als Internist Acute Geneeskunde 
in het Amphia ziekenhuis in Breda waarna hij vanaf 1 maart 2020 een fellowship Intensive 
Care volgt in het Maastricht Universitair Medisch Centrum onder begeleiding van Dr. 
D.C.J.J. Bergmans. Hij heeft een vrouw en zoon, genaamd Mandy en Niek. In zijn vrije 
tijd wandelt hij, loopt hij marathons of fietst hij door het Nederlands, Vlaams en Franse 
landschap.

PhD Portfolio

PhD Portfolio 229
Naam Thijs van Herpt
Department Internal Medicine
Research school  Cardiovascular Research School Erasmus University Rotterdam 
(COEUR)
Promotor Prof. dr. E.J.G. Sijbrands, Prof.Dr. O.H. Franco
Copromotor Dr M. van Hoek, Dr. A.G. Lieverse
PhD-period  2008-2020
PhD training Year ECTS
General academic skills
Evidence Based Medicine 2010  0.3
Biomedical English Writing and Communication 2015  3.0
Research skills
COEUR
- Lectures: 11 2009-2013  1.1
- Vascular Clinical Epidemiology 2010  0.7
- Molecular biology in atherosclerosis and cardiovascular research 2014  1.5
NIHES
- Introduction to Data-analysis (ESP03) 2010  1.0
- Principles of Research in Medicine (ESP01) 2010  0.7
- Case-Control studies (ESP40) 2011  0.7
- Regression analyses (ESP09) 2011  1.9
- Repeated Measurements (CE08) 2011  1.4
Molmed Courses
- SNP’s and human disease 2009  2.0
- SNP course 2010  2.0
- Biomedical research techniques 2011  1.5
Other
- MMC Evidence Based Medicine  2010  0.2
- MMC Statistics and SPSS 2009  0.2
Symposia and conferences
Wetenschapsdagen Interne Geneeskunde, Antwerpen* 2010-2012  1.2
American Diabetes Association 75th scientific session, Boston * 2015  1.5
American Diabetes Association 76th scientific session, New Orleans * 2016  1.2
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Internal Medicine research symposia, Rotterdam* 2016  0.6
* Poster presentation
Presentations and teaching
Presentations at the Internal Medicine Departments of EMC   2.1
Poster and oral presentations at symposia   1.6
Teaching    5.1
Total   30.6


